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Paediatric infectious respiratory diseases
Infectious diseases still form a significant burden of disease in children. In 2013, WHO 
reported that approximately 50% of deaths of children under the age of five were due to 
infectious causes (1). Especially acute respiratory tract infections (ARTIs) are a frequent 
cause of morbidity and mortality (2,3). ARTIs can be caused by a multitude of pathogens 
including bacteria, viruses and fungi. Recently Jain et al. showed in a large study in the USA 
that in the pneumocci vaccination era viruses are the most frequent cause of radiologically 
confirmed pneumonia (4). Indeed ARTIs may be caused by well-known seasonal viruses 
such as respiratory syncytial virus (RSV) and influenza virus, but may also result from 
infection with a large number of other viruses as well as from infection with emerging and 
re-emerging viruses. The latter also may be associated with severe disease and therefore 
remains a significant threat to children (5–7). An important example is avian influenza 
virus (H5N1) which was initially identified in a 3-year-old boy in Hong Kong who was 
admitted to hospital and subsequently died from a combination of influenza pneumonia, 
acute respiratory distress syndrome, multi-organ failure, and disseminated intravascular 
coagulation (8). H5N1 has since continued to be a serious cause of concern for adults and 
children resulting in 850 cases of which 449 patients died so far (53%) (9).
Another major threat, which has dramatically increased over the past decades, is the 
re-emergence of dengue virus (DENV) infection. A recent study estimated that 390 
million dengue virus infections per year in adults and children are likely to occur (10). 
An estimated 500 000 patients with severe dengue infection require hospitalization, 
many of which are children (11). These examples illustrate that infectious diseases are 
definitely not a phenomenon of the past and will continue to pose a threat to human and 
in particular also child health. The focus of this thesis is on the impact and management 
of paediatric respiratory virus infections and of newly discovered, emerging, and re-
emerging viruses in children.
Acute respiratory tract infections (ARTIs) in children
WHO reports that children under the age of five can suffer from up to six viral ARTIs each 
year (12–14). for children less than one year of age, ARTIs are the most common reason 
for emergency department visits because of breathing difficulties (15–18). Based on 
their clinical presentation ARTIs are differentiated into upper respiratory tract infections 
(URTI) and lower respiratory tract infections (lRTI). This division is arbitrarily chosen 
as being above and under the laryngo-tracheal transition in the human respiratory 
tract (Figure 1). URTI include: common cold, acute otitis media, viral pharyngitis, and 
viral laryngotracheitis. lRTI include: acute bronchitis, bronchiolitis, viral pneumonia, 
and acute respiratory distress syndrome, all of which can progress into a severe acute 
respiratory tract infection (SARI) or are referred to as such.
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Causative viral agents of ARTIs
Respiratory viruses are transmitted through aerosols, respiratory droplets, via indirect 
contact with infected secretions, or through contact with contaminated environmental 
surfaces (21). Most common causative agents for respiratory tract infections in children 
are: RSV, human metapneumovirus (HMPV), influenza viruses, human rhinovirus (HRV), 
human bocavirus (HBoV) and parainfluenza viruses type 1-4 (22–24). Other viruses 
associated with ARTI include adenovirus (ADV), and human coronaviruses OC43 (HCoV-
OC43), Nl63 (HCoV-Nl63) and 229E (HCoV-229E) (25) (Figure 2). Some of these viruses 
were only discovered in the past two decades, such as HMPV in 2001 and HBoV in 2005 
(14,26). Viruses that are difficult to isolate in vitro such as HBoV, have been discovered 
by recently developed virus discovery technologies, such as random amplification and 
next-generation sequencing (NGS). With the advent of these new molecular methods an 
ever increasing number of new animal and human viruses, including respiratory viruses 
has been discovered (for review see (27–34)).
Figure 1. Anatomy respiratory tract (courtesy of J.Y. Siegers).
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The epidemiology of respiratory viruses varies considerably. In temperate climate zones, 
RSV infections and influenza are known to cause seasonal outbreaks that may start from 
October onward until March at the northern hemisphere, and in our summer months 
at the southern hemisphere (7,35). These infections affect individuals of all ages, but 
the major disease burden is found in high-risk individuals and those at the extremes of 
the age spectrum (18,35,36). The seasonality of the other respiratory viruses has been 
studied to a lesser extent, although these also have defined incidence patterns with 
usually more infections during fall, winter, or spring (37).
Underlying disorders and risk factors for ARTI in children
The respiratory disease burden of viral infections in children with underlying high-risk 
conditions is high (2,4). In addition to risk factors such as neuromuscular disorders, 
immune deficiencies, and cardiopulmonary disease several factors have been identified 
to contribute to the burden of disease caused by respiratory viruses in children. 
Underlying medical conditions such as pre-term birth (children born before 37 weeks 
of gestation), asthma/reactive airway disease, lung abnormalities such as congenital 
hernia diaphragmatica, congenital heart disease, neurological disorders, skeletal 
malformations (scoliosis), and chromosomal disorders (including Down syndrome), 
have been documented to lead to an increased risk for hospitalization due to ARTI 
(38,39).
Diagnostics of seasonal virus infections
Accurate aetiological diagnosis of respiratory virus infections may be important in the 
hospital setting as for some of these viruses specific interventions are available. It can 
also help determine whether a viral or bacterial agent is the cause of disease, which 
may influence decisions about clinical management, like starting specific, symptomatic 
or antibiotic treatment, and patient or hospital management, like patient isolation and 
Figure 2. Commonly detected respiratory viruses in children adapted from Jain et al. NEJM 2015 
(4), Self et al. JID 2015 (19), Esposito et al. Influenza and other respiratory viruses 2013 (20).
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tailored hygienic measures. Aetiological diagnosis alone on the basis of clinical symptoms 
and signs which often include rhinorrhea, nasal congestion, fever, and coughing at 
different levels of severity, is virtually impossible due to their limited specificity for the 
individual virus infections. Therefore laboratory based diagnostic assays are needed 
to confirm suspicions on clinical and epidemiological grounds and to come to a final 
aetiologal diagnosis (40,41).
Over the last decades new virus diagnostic methods have been developed using real-
time reverse transcriptase polymerase chain reactions (RT-PCR), which have gradually 
replaced more classical and laborious techniques to have become the current gold 
standard for virus detection in patients including children with ARTI (40). RT-PCR has 
been shown to have higher sensitivity and specificity in diagnosing viruses than virus 
isolation, direct immunofluorescence (D-If), and other antigen detection tests. RT-PCR 
based virological diagnostics are however not routinely performed in all hospitals, as with 
the currently available technology, these still require a molecular diagnostic laboratory 
with specialized personnel and equipment (42). Instead, commercially available rapid 
antigen detection tests (RADTs) are used in predominantly primary and secondary care 
settings as these are still easier and cheaper to perform and less time-consuming (43–45). 
Although molecular and antigen detection methods are rapidly improving and therefore 
aetiological data become more accessible, clinical presentation and epidemiological 
data remain a major factor in clinical decision-making.
Intervention strategies: prevention and treatment of seasonal virus infections
Treatment of ARTIs is still primarily and largely based on supportive care, i.e. hydration 
and oxygenation, as specific antiviral therapy is not yet available for most respiratory 
viruses. However, prevention and treatment options are available for RSV and influenza 
viruses. Preventive passive immunization with the RSV specific humanized monoclonal 
antibody palivizumab (Synagis®) is predominantly used in pre-term born children at 
risk of developing severe infection and has now been practised successfully for several 
years (35,46–49). Still, it is important to realize that complete protection is not possible 
and monthly injection of palivizumab is necessary (35,46,50). Unfortunately, decades 
of attempts to develop a RSV vaccine have not resulted in a safe and effective vaccine. 
Problems encountered in the early days of RSV vaccine development in the early 1960s 
came from studies, in which whole inactivated virus vaccinated children, upon later 
exposure to the virus, developed more severe (and occasionally even fatal) disease, than 
placebo vaccinated children (51). Since the underlying mechanisms of this unexpected 
phenomenon were poorly understood, these findings caused a major setback to the RSV 
vaccine field. Over the past decade however, at least a dozen promising vaccine candidates 
and therapeutic agents have been developed, which are currently in different stages of 
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clinical development (46,52). Their eventual introduction would indeed have the potential 
to change paediatric clinical practice in the respiratory field considerably (46,52).
for specific treatment of influenza virus infections there are currently two classes of anti-
virals commercially available: neuraminidase inhibitors (Oseltamivir, Zanamivir, and in 
some countries also Peramivir and Laninamivir) and M2-channel blockers (Amantadine 
and Rimantadine) (53,54). Neuraminidase inhibitors prevent the release of virions from 
infected (host) cells and can be used both prophylactically and for treatment of acute 
influenza. It is important that treatment is started as soon as possible, and if possible 
within 48 hours after onset of disease (55). M2-channel blockers target the M2 protein 
of influenza A virus. Unfortunately, due to rapid development of viral resistance and 
often prominent side effects, the clinical use of M2-channel blockers is currently no 
longer advised (56).
Preventive vaccination offers the most cost-effective and successful protection from 
seasonal influenza. Based on predicted annual differences in the antigenic make-up 
of seasonal influenza viruses, vaccine strains represented in the annual vaccination 
strategies need to be subject to updating every season (57). Current influenza vaccines 
are developed to induce immune responses against two types of seasonal Influenza 
A virus (H1N1 and H3N2), and one or two lineages of Influenza B virus (Victoria or 
Yamagata) (58).
for other respiratory viruses no vaccines or specific treatment are available. However, 
promising developments have recently taken place. for instance a cross-neutralizing 
antibody showed protection against several human and animal paramyxoviruses 
(RSV, HMPV, pneumonia virus of mice and bovine RSV) which may form the basis for 
prophylaxis of human RSV and HMPV infections (59). This monoclonal antibody also 
identified a new candidate antigenic site that could be included in a vaccine (pre 
f-fusion protein). In addition, ongoing studies testing HMPV candidate vaccines recently 
revealed a promising strategy towards a live-attenuated vaccine (59,60). Overall, apart 
from symptomatic treatment based on supportive care, there are still limited treatment 
options for respiratory virus infections in children (47).
Emerging and re-emerging virus infections
Although in the seventies of the last century it was assumed by several policymakers and 
scientists, that most bacterial and viral infections were under control in the industrialized 
world with the use of vaccines, antibiotics and antivirals, the unprecedented pace of 
emergence of previously unknown or re-emerging virus infections in the past decades 
proved otherwise (61). Emerging and re-emerging infectious diseases are caused 
by newly discovered pathogens and by pathogens that have recently become more 
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widespread. Most of these infections are of viral and eventually all of zoonotic origin, 
like influenza viruses, severe acute respiratory syndrome coronavirus (SARS-CoV), 
Middle-East respiratory syndrome coronavirus (MERS-CoV), Ebola virus, Dengue virus 
and Zika virus (62–71). Taking advantage of the complex relationships between human 
and animal species, also known as the human-animal interface, these viruses manage 
to cross-species barriers (61,62,70,71). People become infected via direct contact 
with infected animals or via other intermediate hosts such as birds, rodents, bats or 
arthropods (61,62,70,71). 
Previously unknown or believed to be contained viruses have caused new outbreaks. For 
example, the severe disease caused by SARS-CoV, rapidly became a pandemic threat. 
SARS was first identified in China and subsequently new cases were found in other 
countries and continents (72). An unprecedented well coordinated and collaborative 
response by scientists from all over the world led to the rapid identification of SARS-CoV 
as the causative agent and by a quick and well-coordinated public health response, an 
emerging pandemic was stopped in its wake for the first time in human history (73–76). 
More recently, another coronavirus has spilled over from the animal world, again causing 
severe and often fatal ARTI in humans. It was named after the region where the first case 
was described in 2012: MERS-CoV (31). Currently, 1714 laboratory-confirmed cases have 
been described in 26 countries and approximately 36% of the reported cases with MERS 
died (77). The route of transmission is not fully proven, but dromedary camels are most 
likely to be a major reservoir host for MERS-CoV and an animal source of infections in 
humans (66,78). Predominantly nosocomial human-to-human transmission of MERS-
CoV has been reported upon close contact (79). Among recent study reports on MERS 
vaccine development is that on a Modified Vaccinia virus Ankara (MVA) based MERS-CoV 
vaccine, which was able to induce protective immunity resulting in reduction of excreted 
infectious MERS-CoV in dromedary camels (80). This MVA-based vaccine will now also 
be tested for protection of humans at risk, such as people with camel contacts and 
healthcare workers. These newly discovered coronaviruses, SARS-CoV and MERS-CoV, 
mainly affected adult or elderly patients (72,81). Smits et al. described, with the use of an 
animal model for SARS, that older macaques developed a more severe pro-inflammatory 
response resulting in more extensive lung damage compared to younger macaques 
(82). However, the other recently discovered coronaviruses: HCoV-Nl63, HCoV-HKU1, 
but also the longer known HCoV-229E and HCoV-OC43 are known to usually cause mild 
disease in paediatric patients (6,25,83,84). The severity of the disease caused in children 
depends on several factors. for influenza viruses this has been studied in more detail. 
Maternal antibodies may be an important first line of defence that however lasts for 
the first months to a year only (85). In the absence of such antibodies the still immature 
immune system in the first months has to deal with the infection (86). Thereafter a more 
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mature immune system may have to deal with these infections for the first time, which 
in the absence of memory responses will be more severe than in adults (87).
Recent geographical extensions of areas where arthropod-borne viruses such as DENV, 
West-Nile virus, Chikungunya virus and Zika virus occur, has created major public 
health concerns (11,88–90). for none of these virus infections, vaccines are available 
and treatment options are limited and largely symptomatic (88–93). Currently, vector 
control and use of repellents with e.g. DEET (N,N-di-ethyl-meta-tolueenamide) are 
among the limited prevention methods (88–90,93). Children, pregnant women and 
immune-compromised patients form high-risk groups that may develop severe disease 
upon infection with these viruses (88–90,93). It is interesting to note that some of these 
viruses such as Chikungunya virus and West Nile virus, do not seem to cause as many 
major clinical symptoms in children compared to adults (94–96). In contrast for Zika virus 
infection pregnant women and more specifically their unborn babies currently form 
a high-risk group, as this infection has been associated with an unexplained increase 
of microcephaly in newborn babies from mothers infected with Zika virus in the first 
trimester of their pregnancy (90,97). The WHO has defined priority studies on the 
understanding of Zika virus disease (90,98,99). for several decades however, the most 
problematic paediatric re-emerging viral infection has been DENV.
Dengue virus, a re-emerging infectious disease
DENV circulates in tropical and subtropical areas around the world and is transmitted 
by the bite of infected mosquitoes of the Aedes species. There are four different DENV 
serotypes (1-4), which may co-circulate in endemic areas (100). Outbreaks occur mostly 
during the rainy season due to the increased number of mosquitoes (101). DENV affects 
humans of all age groups, although in some parts of the world it is mainly a paediatric 
public health problem (11,102). Severe DENV infections mostly affect children in South-
East Asia, which may present with dengue shock syndrome, while in the Americas, adults 
are more likely to develop severe disease (103,104). However, recent epidemics in the 
Americas have shown an increased number of paediatric patients with severe and fatal 
DENV infections (105,106). DENV infections present with different clinical manifestations. 
A large number of infected people will not show clear clinical symptoms, while others 
develop dengue haemorrhagic fever or dengue shock syndrome, which may be fatal (10). 
Clinical manifestations of severe dengue are characterized by systemic capillary leakage, 
thrombocytopaenia and hypovolaemic shock (100,107). Factors that may predispose 
for severe dengue are: age, previous exposure to a heterologous DENV subtype, and 
underlying medical conditions such as chronic aenemia, diabetes mellitus, hypertension, 
congestive heart failure, other cardiovascular diseases, chronic obstructive pulmonary 
disease, asthma, renal disease, and multiple co-morbidities (108).
Processed on: 20-6-2016
503421-L-bw-Moesker
General introduction and outline of the thesis 17
1
Until now treatment options for DENV are limited as no specific antiviral treatment is 
available and treatment is based on supportive care and intense monitoring of patients. 
Recently, the first dengue vaccine, Dengvaxia (CYD-TDV) by Sanofi Pasteur, was registered 
in several countries for use in individuals between 9-45 years of age living in endemic 
areas (11,106,109). Soon recommendations of the Strategic Advisory Group of Experts 
(SAGE) will follow concerning immunization with this new dengue vaccine. Moreover, 
clinical trials with other candidate vaccines are still on-going and more research is 
needed for vaccination of children under the age of nine (110,111). 
AIM AND OUTlINE Of THIS THESIS
This thesis primarily aims to study the impact of newly discovered respiratory viruses 
in children as well as the role of emerging and re-emerging viruses in the development 
of severe disease. In addition the performance of currently used viral diagnostic and 
prevention methods for acute virus infections in children are addressed.
After presenting an introduction to the field of acute paediatric virus infections in 
children in Chapter 1, the capacity of viruses as sole causative agents to cause severe 
acute respiratory tract infections (SARIs) in children is evaluated in Chapters 2 and 
Chapter 3. In Chapter 4 the potential role of underlying sickle cell anaemia in the 
development of severe dengue is addressed by identifying and studying two juvenile 
cases with this combination of predisposition and infection. In Chapter 5 the diagnostic 
performance of commercial rapid antigen detection tests for RSV and influenza in a 
tertiary care paediatric hospital is evaluated, with RT-PCR as gold standard and other 
currently used diagnostic assays as comparators. Subsequently in Chapter 6 a candidate 
H5 influenza vaccine based upon the MVA vector system, is tested for safety and breadth 
of immunogenicity in healthy young adult volunteers. Finally Chapter 7 presents a 
summarizing discussion of the thesis.
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ABSTRACT
In 2005 human bocavirus (HBoV) was discovered in respiratory tract samples of children. 
The role of HBoV as single causative agent for respiratory tract infections remains unclear. 
Detection of HBoV in children with respiratory disease is frequently in combination 
with other viruses or bacteria. We set up an algorithm to study whether HBoV alone 
can cause severe acute respiratory tract infection (SARI) in children. The algorithm 
was developed to exclude cases with no other likely cause than HBoV for the need for 
paediatric intensive care unit (PICU) admission with SARI. We searched for other viruses 
by next-generation sequencing (NGS) in these cases and studied their HBoV viral loads. 
To benchmark our algorithm, the same was applied to respiratory syncytial virus (RSV) 
positive patients.
from our total group of 990 patients who tested positive for a respiratory virus by 
means of RT-PCR, HBoV and RSV were detected in 178 and 366 children admitted to our 
hospital. forty-nine HBoV positive patients and 72 RSV positive patients were admitted 
to the PICU.
We found seven single HBoV infected cases with SARI admitted to PICU (7/49, 14%). 
They had no other detectable virus by NGS. They had much higher HBoV loads than 
other patients positive for HBoV. We identified fourteen RSV infected SARI patients with 
a single RSV infection (14/72, 19%). We conclude that our study provides strong support 
that HBoV can cause SARI in children in the absence of viral and bacterial co-infections.
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INTRODUCTION
In the past decade, many unknown viruses have been identified using novel molecular 
pathogen discovery techniques (112). After detection, it is not always clear if these newly 
discovered viruses are able to cause disease. for some viruses it remains difficult to rule 
out simultaneous infections in the patient with other known or yet unknown pathogens. 
Human bocavirus (HBoV) is a clear example of such a newly discovered virus.
HBoV was discovered in 2005 in respiratory tract samples from children suffering 
acute respiratory tract infections (113). Currently, four genotypes have been described 
(HBoV 1-4) (114). Based on seroprevalence studies, HBoV specific antibodies in adults 
ranges from 64 to 95%, indicating the high number of HBoV encounters (115). HBoV 
infection in children has been associated with respiratory tract infections (HBoV1-2) and 
gastrointestinal disease (HBoV 2-4) (114). HBoV infection results often in a mild self-
limiting respiratory tract infection and may even be asymptomatic (114,116). Many 
children shed HBoV in the respiratory tract for prolonged periods, making interpretation 
of a positive test result in a patient difficult (117). Nonetheless, a few case reports describe 
HBoV as cause of severe acute respiratory tract infection (SARI) in children requiring 
intensive care. Although the role of other pathogens was addressed, co-infections were 
not excluded in a structured method (114,118–125). Altogether, this has resulted in the 
on-going debate whether HBoV as single causative agent can cause disease.
To address this issue, we set up an algorithm to exclude cases with no other likely cause 
than HBoV for the need for intensive care. We searched for overlooked viruses by next-
generation sequencing (NGS) in these cases and studied their HBoV viral loads. To 
benchmark this method, the same algorithm was applied to patients with respiratory 
syncytial virus (RSV) infection. As RSV is generally considered to be a well-established 
paediatric pathogen that can cause SARI in children (126–128).
METHODS AND MATERIAlS
Patient and sample selection
We conducted a retrospective cohort study during 5 consecutive years from April 2007 
through March 2012. We selected paediatric patients (<18 years) admitted to the 
Paediatric Intensive Care Unit (PICU) of Erasmus MC-Sophia, which is a tertiary paediatric 
referral centre. This is the sole PICU for a region with a general population of ~4 million 
and an annual birth cohort of ~47,000 children (129).
We selected respiratory tract samples of these patients that tested positive with real-
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time reverse transcriptase polymerase chain reactions (RT-PCRs) for respiratory viral 
diagnostics. We used the electronic laboratory information management system of the 
Viroscience Department to obtain all test results. Samples included nasal washings, 
sputum, throat swabs and broncho-alveolar lavages, which were obtained during routine 
clinical practice. We only used the first available sample of each patient. A viral pathogen 
was defined if a cycle threshold value (Ct-value) < 40 was detected for adenoviruses, 
coronaviruses (OC43, 229E and Nl63), HBoV 1-4, human metapneumovirus, influenza 
A and B viruses, parainfluenza viruses 1-4, RSV and/or rhinoviruses (42). The Ct-value 
represents the number of cycles required for the fluorescent signal to cross the threshold 
(exceeds background level) and is inversely related to viral load.
Algorithm
All HBoV RT-PCR positive cases, with or without co-infections, were originally included. 
Next four selection steps were applied: first, we selected all PICU admitted patients, 
as these patients are critically ill and key for testing our hypothesis. Second, patients 
with a viral co-detection upon RT-PCR were excluded. Third, selected clinical data were 
extracted from electronic medical files of the patients. Only patients with SARI as reason 
for admission were included (see Table 1 and supporting Table 2). Fourth, absence of 
bacterial co-infections was considered likely if C-reactive protein (CRP) levels were ≤ 40 
mg/l upon admission and bacterial cultures tested negative, such as sputum, blood or 
cerebrospinal fluid cultures. We defined a sputum culture negative if ≤ 10 bacteria per 
ocular field were present in gram staining, if no respiratory pathogenic bacteria were 
cultured, and/or when commensal bacterial growth was ≤ 2/4. Sputa containing < 10 
epithelial cells per ocular field (10x10 magnification) were considered quality sputa. 
Sputa containing ≥ 10 epithelial cells per ocular field were only considered quality sputa if 
the leucocyte-to-epithelial cell ratio was ≥ 10 and > 6 bacteria with the same morphology 
were present. Absence of a sputum culture was not a reason for exclusion, as sputum is 
not easily obtained from children. A reason for exclusion was if other bacterial cultures 
tested positive, such as a cerebrospinal fluid cultures or blood cultures.
Lastly, selected samples were tested for Mycoplasma pneumoniae using RT-PCR and 
only negative samples were used for NGS. Confirmatory serology detecting antibodies 
against HBoV or RSV was not performed, as serum samples were not collected routinely 
from these patients.
Three investigators independently reviewed the previously described selection steps 
and disagreement was resolved by consensus (fM, JVK and Pf).
Processed on: 20-6-2016
503421-L-bw-Moesker
Human bocavirus infection as a cause of severe acute respiratory tract infection 23
2
Next-generation sequencing
After applying the algorithm, samples were analysed for the presence of known and 
unknown viruses. We used a viral metagenomics procedure as previously described, 
which includes random RNA and DNA amplification in combination with NGS (454 life 
Sciences®, Branford, Connecticut, USA)(130,131). In brief, the amplicons of random RNA 
and DNA amplification were pooled and purified, after which rapid library preparation, 
emulsion PCR and NGS were performed. Iterative exhaustive assembly of sequences was 
applied according to our virus discovery pipeline written in the python programming 
language (Python 2.7). An absolute minimum of two reads was required for a distinct hit 
to be reported. Hits positive for endogenous retroviruses or anelloviruses were excluded 
from analysis. Presence of genome material for bovine viruses was discarded because 
of bovine reagents used. Sequences were deposited in GenBank and given accession 
numbers (see supplemental data).
Phylogenetic analysis of HBoV
We performed phylogenetic analyses to study whether a specific HBoV subtype could 
be linked to a more virulent HBoV infection resulting in PICU admission. We used the 
VP1/VP2 genes for sequence analysis, after which a phylogenetic tree was reconstructed. 
Samples tested were HBoV RT-PCR positive selected cases for NGS and selected controls. 
Controls were samples of patients with Ct-value < 30, which is the minimum requirement 
to sequence HBoV in this method. These control samples were obtained from children 
whether or not admitted to PICU, without SARI and with co-infections. Two samples 
were obtained from children born in hospital and admitted for more than 90 days and 
were called nosocomially infected controls. All samples were amplified and sequenced as 
described previously (132). Phylogenetic analyses were conducted with MEGA version 5.
HBoV Ct-values in respiratory tract samples
To study the role of HBoV Ct-values in patients with SARI, we compared median Ct-values 
in three groups of patients. Groups were defined as; all hospitalized HBoV patients, all 
PICU admitted patients with HBoV and viral co-detection and selected PICU admitted 
patients with a single HBoV infection.
Validation Method using RSV infections
To validate our algorithm we applied the exact same selection steps to RSV positive 
samples of patients admitted to PICU. We chose RSV for validation because it’s role in 
children with SARI is well-established compared to other pathogens and we therefore 
expected that RSV related SARI admissions would remain to be identifiable after using 
our algorithm (126–128).
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Statistical analysis
Data were analysed using SPSS version 20.0 (IBM, SPSS, Chicago, Il, USA) and GraphPad 
Prism version 6. for continuous data, medians, interquartile range (IQR), lower IQR and 
upper IQR (lIQR and UIQR) were calculated. for the assessment of HBoV viral loads, 
median Ct-values were compared using the Mann-Whitney U test. A p-value <0.05 was 
taken as threshold of statistical significance.
Ethical considerations
The Medical Ethical Committee of the Erasmus MC approved this study (MEC 2013-221). 
Informed consent was waived because this is a retrospective cohort study. Data were 
stored anonymously and cannot be retraced to individual patients.
RESULTS
Patient and sample inclusion
In total 990 paediatric patients with a median age of 0.82 years (IQR 3.13), were identified 
for whom respiratory viral diagnostics were performed. Of those, 178 patients (18%) 
were HBoV RT-PCR positive. PICU admission was necessary for 49 HBoV cases (28%), 
of which 20/49 were positive for HBoV alone (41%) and 29/49 were positive for HBoV 
and other viruses (59%) (see supporting Table 3). Subsequently, clinical charts were 
reviewed and only patients admitted to PICU because of SARI were selected (11/20, 
55%). Next, samples of patients with CRP levels ≤ 40 mg/l upon admission were included 
(8/11, 73%). lastly, cases with negative blood, liquor and sputum cultures (if available) 
and negative RT-PCR test results for M. pneumoniae were selected. Sputa were obtained 
from intubated children. A total of 7/8 cases (88%) were considered with a single HBoV 
infection resulting in SARI and their samples were tested with NGS (see Figure 1).
Next-generation sequencing of HBoV cases
The seven identified respiratory tract samples were subjected to NGS and near full-
length genomes were obtained in most samples (see supporting Table 4). No other viral 
pathogens besides HBoV were detected with NGS in 7 cases selected with our algorithm 
(2.8-44.3 % of total number of analysed reads).
Clinical data from children with HBoV
The median age of the seven children with HBoV was 24 months (min 4.4 – max 31.4, lIQR 
15.7 – UIQR 28) and four patients were female (4/7, 57%). One patient was four-months-
old upon admission and was born prematurely with a gestational age of 27 weeks and 
was previously diagnosed with broncho-pulmonary dysplasia. Due to the small sample 
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size we referred from further comparative statistical testing. The length of symptoms 
before PICU admission was 1-7 days. Upon PICU admission CRP levels with a median of 
8 mg/l (min 1 – max 36, lIQR 5 – UIQR 28) were tested within a median PICU stay of 
2.5 hours (min 0 – max 6 hours). for 6/7 children follow-up CRP levels were obtained. In 
two cases there was an increase in CRP, none of these CRP-levels were ≥ 80 mg/l (see 
Table 2). for patient 2, CRP levels increased after initiation of ECMO (from 18 to 58 mg/l 
respectively). Of the other patient negative bacterial sputum samples were obtained in 
the absence of antibiotics at day 1 of PICU stay. Three of the seven patients (43%) with 
a single HBoV infection had no pre-existing medical history. All seven patients received 
antibiotics during admission and required supplemental oxygen. Mechanical ventilation 
was performed in five patients (71%) and extracorporeal membrane oxygenation (ECMO) 
treatment was needed in one patient (14%). All patients survived. The median duration 
of PICU admission was 4 days (IQR 2-7 days) (see Table 1).
Phylogenetic analysis of HBoV
To study whether a specific subtype of HBoV was associated with severe disease, 
phylogenetic analysis were performed. The VP1/VP2 region of HBoV was successfully 
amplified in all 7 selected cases (100%) and 40 controls (87%) (see supporting Figure 4).
Figure 1. flowchart for patient selection of HBoV RT-PCR positive patients admitted to the Erasmus 
MC-Sophia from 2007 -2012
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Table 1. Baseline characteristics of selected HBoV and RSV RT-PCR positive PICU admitted patients 
at the Erasmus MC-Sophia from 2007-2012
Characteristics
HBoV positive PICU 
cases (n = 7)
RSV positive PICU cases
(n = 17)
Age 
Months†
Years† 
24 (4-31, 14.3-31.3)
2 (0.3-2.62, 1.19-2.60)
2 (0-39, 0-7.5)
0.18 (0.02-3.26, 0.06-0.68)
Female 4 (57) 5 (29)
Male 3 (43) 12 (71)
Reason for admission
Respiratory failure
ECMO indication due to respiratory failure
Bronchiolitis / PSA
ALTE with ARTI
3 (43)
1 (14)
3 (43)
-
16 (94)
-
-
1 (6)
Clinical diagnosis at admittance
URTI
LRTI
BHR / PSA
ARDS
Severe atelectasis with ARTI
Bronchiolitis
-
1 (14)
4 (57)
1 (14)
1 (14)
-
1 (6)
1 (6)
-
-
-
15 (88)
Medical history
None
Pulmonary disease
GSA < 37 weeks
GSA < 37 weeks and pulmonary disease
Cardiac disease
Congenital anatomical malformations
Macrosome or dysmature
3 (43)
3 (43)
-
1 (14)
-
-
-
6 (35)
2 (12)
2 (12)
-
1 (6)
4 (24)
2 (12)
Laboratory testing 
CRP (mg/L) †
WBC count  (x 109 /L) †
8 (1-36, 5-28)
13.6 (8.1-27, 9.3-20)
8 (2-22, 4-11.5)
13.5 (8.7-33, 10.5-15)
Sputum obtained and start antibiotics 
≤ 12 hours before sputum obtained
> 12 hours after sputum obtained
Sputum not obtained
1 (14)
4 (57)
2 (28)
3 (17)
4 (24)
10 (59)
Respiratory support
Supplemental
Invasive
ECMO
1 (14)
5 (72)
1 (14)
7 (41)
10 (59)
-
PICU admission duration
Days (median, min-max) 4 (2-7) 4 (2-29)
Survival 7 (100) 17 (100)
Viral metagenomics
HBoV as sole viral pathogen detected
RSV as sole viral pathogen detected
7 (100)
-
-
14(82) ‡
* Values are no. % cases. AlTE; acute life threating event, ARDS; acute respiratory distress 
syndrome, BHR; bronchial hyperreactivity, CRP; C-reactive protein, ECMO; extracorporeal 
membrane oxygenation, GSA; gestational age, HBoV; human bocavirus, lRTI; lower respiratory 
tract infection, PSA; paediatric status asthmaticus, PICU; paediatric intensive care unit, RSV; 
respiratory syncytial virus, URTI; upper respiratory tract infection, WBC; white blood cells. 
† median, min-max, lIQR-UIQR. ‡ One sample could not be processed, one tested negative for 
viruses, one tested positive for rhinovirus.
Processed on: 20-6-2016
503421-L-bw-Moesker
Human bocavirus infection as a cause of severe acute respiratory tract infection 27
2
Blast and phylogenetic analyses showed that all HBoV strains of cases and controls were 
closely related to a total of two reference genotypes corresponding to HBoV genotype 1 
(Stockholm: ST1 and ST2)(132).
HBoV Ct-values in respiratory tract samples
We compared the median HBoV Ct-values to study whether a low Ct-value resulted in 
severe disease and if viral co-detection resulted in higher Ct-values. We found significantly 
lower Ct-values in the seven-selected HBoV positive cases (median Ct-value 15.6, lIQR 
11.6 –UIQR 16.3) compared to all HBoV positive patients admitted to hospital (median 
Ct-value 33.9, lIQR 11.3-UIQR 36.8)  (p < 0.0001) (see Figure 2).
furthermore, HBoV Ct-values were significantly lower compared to 29 PICU patients with 
HBoV and viral co-detection (median Ct-value 28.6, lIQR 13.6 – UIQR 35.45) (p=0.001) 
(see Figure 2).
Validation Method using RSV infections
Of the 990 paediatric patients, 366 tested RSV RT-PCR positive (37%). PICU admission 
was required in 72/366 of RSV cases (20%). After applying our selection steps, 17/24 RSV 
RT-PCR positive samples were tested with NGS (71%). Of these, 15/17 samples yielded 
Figure 2. Comparison between median Ct-values of HBoV RT-PCR positive respiratory tract 
samples of paediatric patient admitted to the Erasmus MC-Sophia from 2007-2012; all hospital 
admitted paediatric patients versus Paediatric Intensive Care Unit (PICU) admitted patients with 
HBoV and viral co-detection versus PICU admitted patients with a single HBoV infection. Horizontal 
bars represent group medians
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results (88%). One sample could not be processed; another had a limited number of 
reads. In all samples RSV was detected (0.01-31.7 % of total number of analysed reads). 
In addition, in one sample a rhinovirus was co-detected (1.17 % reads; see figure 3 and 
supporting Table 5). Overall, in 14/72 SARI PICU patients RSV was found to be the sole 
pathogen (19%).
DISCUSSION
We here present a study on the relation between a recently discovered viral pathogen - 
HBoV - and SARI in children. We analysed HBoV RT-PCR positive samples from paediatric 
patients in whom viral and bacterial co-infections were considered unlikely after a 
rigid selection process. Pivotal to our approach is the addition of NGS to the clinical 
and conventional laboratory data. Based on the algorithm and NGS, we showed that a 
single HBoV infection caused SARI in seven patients requiring PICU admission. Which 
is in concordance with case reports on severely ill children with HBoV infection (118–
Figure 3. flowchart for patient selection of RSV RT-PCR positive patients admitted to the Erasmus 
MC-Sophia from 2007 -2012
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125). Although, in these reports viral and bacterial co-infections were described, they 
were not structurally assessed and NGS was not performed to detect overlooked viruses 
(118–125).
By adding NGS to our selection method, we bypassed the limitation of testing with RT-
PCR alone, which relies on the use of selected primers for suspected pathogens. NGS 
allows detection of variant viruses that would otherwise escape detection (133,134). It is 
specifically designed to detect viruses and is optimized to decrease the number of other 
nucleid acids from i.e. host and bacteria. We showed previously that the sensitivity of 
detection with this method is approaching that of RT-PCRs in respiratory specimens (33). 
The routine clinical use of NGS alone is still in development, but it may well be that it will 
replace RT-PCR in the future (134).
In addition to the NGS findings, we also studied the difference between median HBoV Ct-
values of selected cases and other patients with HBoV detection. We found a significantly 
lower median Ct-value in the selected cases than that of patients also admitted to PICU, 
but with viral co-detection. This may indicate that a single recent HBoV infection is 
associated with a higher viral load than in combination with other viruses as suggested 
previously by other studies (124,135,136). Based on the age of the patients and the low 
Ct-values we assume that the severe HBoV infection was a consequence of a primary 
infection (124). furthermore, we compared the median Ct-values of selected cases with 
patients not admitted to PICU with HBoV and found that the Ct-values of the selected 
cases were also significantly lower suggesting a direct relation between disease severity 
and viral load as reported by others (121,124,136). Interestingly, others have also found 
a relation between Ct-values gender and underlying disease. Unfortunately our samples 
size was too small to confirm or refute these findings (124).
In order to benchmark our algorithm used to exclude patients with viral and bacterial 
co-infections, we also applied it to patients with RSV infection. We only found 14 cases 
with RSV as single causative agent for SARI. Considering the incidence of RSV-associated 
hospitalizations, this is lower than expected (128). We were able to benchmark our 
algorithm, although it seems to be very stringent and results in an underestimation of 
the true HBoV epidemiology. It is therefore of note that we did not set out to estimate 
the true burden of disease of HBoV, but to establish whether HBoV by itself can cause 
severe acute respiratory tract infections. Our study is subject to several limitations. It 
may be argued that the retrospective nature of this study and its inherent limitations 
may have resulted in a sample bias. Blood samples for HBoV serology or PCR were not 
obtained, because these are not routinely tested at our hospital. Furthermore, not all 
bacteriology samples were obtained, as more invasive procedures should have been 
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carried out to fully rule out the role of bacteria in lower respiratory tract infections. 
These are currently not routinely practiced in critically ill children for ethical and technical 
reasons. As an alternative we set strict CRP levels to our inclusion criteria. Based on 
previously published data we set a lower cut-off for bacterial co-infections (40 mg/L) 
than the usually applied 80 mg/l, to minimize the contribution of bacterial infections to 
the observed disease. In addition, during non-structured follow-up none of the patients 
showed an increase in CRP levels > 80 mg/l. Still, in two cases a moderate increase was 
observed and it should be noted that despite these low CRP levels, bacterial involvement 
cannot be fully ruled out based on CRP levels alone (137–139). Other biomarkers such as 
pro-calcitonin and interleukins could have been used to differentiate between bacterial 
and viral infections, but these were not carried out in our hospital (139,140).
Based on our findings we conclude that a single HBoV infection can cause SARI in children 
in the absence of viral and bacterial co-infection.
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SUPPORTING INfORMATION
Table 2. Overview non-structured follow-up CRP levels obtained during PICU-stay
PICU stay (days) 1 1.5 2 2.5 3 3.5 4
Patient 1 CRP levels (mg/l) 5 - - - - - -
Patient 2 CRP levels 36 18 55 58 41 - -
Patient 3 CRP levels 8 - 4 - - - -
Patient 4 CRP levels 11 9 - 5 - - -
Patient 5 CRP levels 28 - 79 - 66 - 10
Patient 6 CRP levels 7 - 1 - - - -
Patient 7 CRP levels 1 - 5 - 6 - 4
- represents missing data
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Supporting Table 2. Reasons for admission because of a Severe Acute Respiratory tract Infection 
(SARI) or not because of SARI
Reasons for admission defined as SARI Reason for admission not defined as SARI
Respiratory failure with possible need for 
mechanical ventilation
Neurologis disorders
Ischaemia
Extracorporeal membrane oxygenation 
(ECMO) indication due to respiratory failure
Erythema multiforme and shock
Nosocomial infection
Bronchiolitis / Paediatric status astmaticus Gastro-intestinal disease
Acute life threatening event (ALTE) with ARTI Cardiac disease
Acute respiratory distress syndrome (ARDS) Congenital malformations
Admission data missing
Supporting Table 3. HBoV RT-PCR positive and viral co-detection with RT-PCR of PICU admitted 
patients from 2007 till 2012
Pathogen detected with RT-PCR HBoV and one other virus
n = 24 (%)
Rhinovirus 9 (38)
Adenovirus 4 (17)
RSV 4 (17)
Human coronavirus NL 63 3 (13)
Human coronavirus OC43 1 (4)
Parainfluenza virus type 3 1 (4)
Influenza A 2 (8)
Pathogen detected with RT-PCR HBoV and ≥ 2 viruses
n = 5
Parainfluenza virus type 1 + rhinovirus 2
Parainfluenza virus type 2 + human coronavirus Nl63 1
Adenovirus + human coronavirus Nl63 1
Adenovirus + RSV 1
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Supporting Table 4. Viral metagenomics results of selected HBoV cases
Sample number 
HBoV
Total number of 
analysed reads
No. HBoV reads
% HBoV reads / total 
analysed reads
1 6823 1382 20.26
2 30736 2634 8.57
3 17305 7670 44.32
4 27437 1570 5.72
5 6903 2057 29.80
6 10471 2681 25.60
7 15848 444 2.8
Supporting Table 5. Viral metagenomics results of selected RSV cases
Sample 
number
RSV
Total number of 
analysed reads
No. RSV 
reads
No. 
Rhinovirus 
reads
% RSV reads / 
total analysed 
reads
% Rhinovirus 
reads / total 
analysed reads
1 6736 1641 - 24.36
2 11417 1898 - 16.62
3 14207 74 167 0.5 1.17
4 13463 4 - 0.03
5 7942 652 - 8.2
6 6937 2197 - 31.7
7 10350 2568 - 24.8
8 12390 602 - 4.85
9 13846 3321 - 24
10 16271 22 - 0.14
11 584 0 - 0
12 12161 2284 - 18.8
13 0* n/a - n/a
14 17636 2 - 0.01
15 17190 1429 - 8.3
16 16061 293 - 1.8 1.2
17 9661 2007 - 20.8 0.3
* Sample could not be processed.
Processed on: 20-6-2016
503421-L-bw-Moesker
Human bocavirus infection as a cause of severe acute respiratory tract infection 33
2
Supporting information gene bank numbers phylogenetic tree
BankIt1747547 k2007001255 KM257816
BankIt1747547 k2007001443 KM257817
BankIt1747547 K2007001535 KM257818
BankIt1747547 k2007001654 KM257819
BankIt1747547 K2007001674 KM257820
BankIt1747547 K2007001679 KM257821
BankIt1747547 K2007001732 KM257822
BankIt1747547 K2007001919 KM257823
BankIt1747547 K2007002149 KM257824
BankIt1747547 K2007002237 KM257825
BankIt1747547 K2007002841 KM257826
BankIt1747547 K2007002845 KM257827
BankIt1747547 K2007002941 KM257828
BankIt1747547 K2008000633 KM257829
BankIt1747547 K2008000789 KM257830
BankIt1747547 K2008000848 KM257831
BankIt1747547 K2008001151 KM257832
BankIt1747547 K2008002153 KM257833
BankIt1747547 K2008003556 KM257834
BankIt1747547 K2008003588 KM257835
BankIt1747547 K2009000061 KM257836
BankIt1747547 K2009000096 KM257837
BankIt1747547 K2009000114 KM257838
BankIt1747547 K2009000155 KM257839
BankIt1747547 K2009000980 KM257840
BankIt1747547 K2009001410 KM257841
BankIt1747547 K2009002317 KM257842
BankIt1747547 K2009002589 KM257843
BankIt1747547 K2009008335 KM257844
BankIt1747547 K2010000191 KM257845
BankIt1747547 K2010000628 KM257846
BankIt1747547 K2010001030 KM257847
BankIt1747547 K2010001188 KM257848
BankIt1747547 K2010001467 KM257849
BankIt1747547 K2010001581 KM257850
BankIt1747547 K2010001713 KM257851
BankIt1747547 K2010002032 KM257852
BankIt1747547 K2010003139 KM257853
BankIt1747547 K2010003215 KM257854
BankIt1747547 K2010003563 KM257855
BankIt1747547 K2011000161 KM257856
BankIt1747547 K2011000613 KM257857
BankIt1747547 K2011002002 KM257858
BankIt1747547 K2011002635 KM257859
BankIt1747547 K2012000382 KM257860
BankIt1747547 K2012001042 KM257861
BankIt1747547 K2012000293 KM257862
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Supporting Figure 4
Figure 4. Phylogenetic analysis of the partial VP1/VP2 nucleotide sequences of HBoV RT-PCR positive 
samples of patients admitted to the Erasmus MC-Sophia from 2007 until 2012. Phylogenetic tree 
was constructed with MEGA 5 software using the neighbor-joining method. Bootstrap values are 
shown at the branch nodes. Prototype strain ST1 and ST2 were also included (page 23).
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ABSTRACT
Background: Respiratory syncytial virus (RSV) and influenza A viruses are known to cause 
severe acute respiratory tract infections (SARIs) in children. for other viruses like human 
rhinoviruses (HRVs) this is less well established. Viral or bacterial co-infections are often 
considered essential for severe manifestations of these virus infections.
Objective: The study aims at identifying viruses that may cause SARI in children in 
the absence of viral and bacterial co-infections, at identifying disease characteristics 
associated with these single virus infections, and at identifying a possible correlation 
between viral loads and disease severities.
Study design: Between April 2007 and March 2012, we identified children (<18 year) 
with or without a medical history, admitted to our paediatric intensive care unit (PICU) 
with SARI or to the medium care (MC) with an acute respiratory tract infection (ARTI) 
(controls). Data were extracted from the clinical and laboratory databases of our 
tertiary care paediatric hospital. Patient specimens were tested for fifteen respiratory 
viruses with real-time reverse transcriptase PCR assays and we selected patients with 
a single virus infection only. Typical bacterial co-infections were considered unlikely to 
have contributed to the PICU or MC admission based on C-reactive protein-levels or 
bacteriological test results if performed.
results: We identified 44 patients admitted to PICU with SARI and 40 patients admitted 
to MC with ARTI. Twelve viruses were associated with SARI, ten of which were also 
associated with ARTI in the absence of typical bacterial and viral co-infections, with RSV 
and HRV being the most frequent causes. Viral loads were not different between PICU-
SARI patients and MC-ARTI patients.
conclusion: Both SARI and ARTI may be caused by single viral pathogens in previously 
healthy children as well as in children with a medical history. No relationship between 
viral load and disease severity was identified.
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INTRODUCTION
Worldwide acute respiratory tract infections (ARTIs) are among the most important 
causes of morbidity and mortality in children (3,141). While most ARTIs result in 
relatively mild and self-limiting disease, sometimes disease progresses to severe acute 
respiratory tract infections (SARIs). SARIs are characterized by respiratory failure and 
are an indication for admission to a paediatric intensive care unit (PICU) because of the 
need of respiratory support. Some viruses such as respiratory syncytial virus (RSV) and 
influenza viruses have been shown to be the single cause of SARI, but for other viruses 
like human rhinoviruses (HRVs) and human coronavirus-NL63 (HCoV-NL63) this is under 
debate (84,142,143). It may be that these viruses cause minimal or mild disease only, but 
in combination with bacterial co-infections, viral co-infections or alternatively, underlying 
high-risk conditions infection may result into SARI (144–146). This hypothesis follows 
observations of detection of viruses in the nasopharynx of children in absence of clinical 
signs and symptoms (19,116,147,148). Another explanation for the variable association 
between infection and severe disease could be the extent of infection, as reflected by 
viral loads. High viral loads may be associated with increased host cell damage and a more 
profound immune response, but this relationship has not been confirmed consistently 
(126,149,150). To address the possible causative role of virus infections in SARIs, we 
performed a retrospective study in our hospital, which has implemented routine testing 
for fifteen respiratory viruses over the study period.
MATERIAlS AND METHODS
Patient and sample selection
We conducted a retrospective study analysing data of paediatric patients (age <18 years) 
with or without a medical history that were admitted to Erasmus MC-Sophia from April 
2007 through March 2012. Erasmus MC-Sophia is a tertiary paediatric referral centre. 
Clinical and virological data were extracted from the clinical and laboratory databases. 
We collected all qualitative and quantitative diagnostic virological data obtained with 
real-time reverse transcriptase PCR (RT-PCR) on respiratory tract samples (nasal washing, 
sputum, throat swab, nose swab, or bronchoalveolar lavage specimen (BAl)) of patients 
admitted to PICU or medium care (MC). Nasal washings were obtained by infusing 
1-2 ml NaCl intranasally. Samples were obtained on clinical indication. Only samples 
obtained upon admission or within 72 hours after admission were included. Patients 
could be included more than once if re-admitted with SARI or ARTI, and a sample was 
obtained > 35 days after the first discharge and tested positive for a different virus. for 
further analysis these patients (SARI: n=1; ARTI: n=1) were considered new patients. The 
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following clinical data was obtained: age, gender, reason for admission, clinical diagnosis, 
underlying medical condition, specimen used for RT-PCR, C-reactive protein (CRP)-levels, 
bacteriological test results, types of respiratory support, length of PICU stay and hospital 
stay, and final outcome. Based on this clinical data, we subsequently grouped patients 
with SARI or ARTI as primary reason for PICU or MC admission respectively.
Patients were also categorized according to presence or absence of known risk factors for 
SARI: pulmonary disease, pre-term birth (born before 37 weeks of gestation), anatomical 
malformations, syndromal disorders, cardiovascular disease, oncology, immunology, 
neuro-muscular impairment and other disorders including scoliosis.
Study groups
We defined SARI as a severe acute respiratory tract infection with the potential need for 
invasive respiratory support and therefore requiring PICU admission. We defined ARTI as 
acute respiratory tract infection without the need for intensive care admission and we 
used this group as a control to study severe disease caused by a single virus infection. In 
the present study we specifically focused on samples obtained from patients admitted to 
PICU or MC with SARI or ARTI, caused by a single virus infection in the absence of typical 
bacterial and viral co-infections (PICU-SARI patients and MC-ARTI patients respectively). 
We further defined respiratory support into supplemental oxygen need (nasal cannula), 
non-invasive respiratory support (non-rebreathing mask and optiflow), invasive 
respiratory support with endotracheal intubation (nasopharyngeal tube, trachea tube, 
trachea-cannula) and extracorporeal membrane oxygenation (ECMO).
The laboratory diagnostic work-up was RT-PCR testing for fifteen respiratory viruses: 
adenoviruses (ADV), HCoV-Nl63, HCoV-OC43 and HCoV-229E, human bocavirus (HBoV), 
human metapneumovirus (HMPV), influenza A and B viruses, parainfluenza viruses 1-4 
(PIV), RSV type A and B and HRV (42). Samples with a cycle threshold (Ct)-value < 40 
were considered positive. Of note Ct-values are inversely correlated to viral load, and 
only provide semi-quantitative results. for the purpose of this study we combined RSV 
type A and B results and we excluded patient samples obtained during an emergency 
department visit, out-patient-clinic visit or from patients admitted to the neonatal 
intensive care unit. Positive viral test results were traced back to patients admitted to 
PICU or MC. We compared all patients with a single virus detected and admitted to PICU 
with patients admitted to PICU with SARI (PICU-SARI patients), and all patients admitted 
to MC with patients with ARTI admitted to MC (MC-ARTI patients).
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Exclusion of typical bacterial co-infections
We excluded samples from patients with evidence of typical bacterial co-infections upon 
admission and within 24 hours after admission when: CRP-levels were > 40 mg/l or 
tested first time > 24 hours after admission and/or in case of positive bacteriological 
test results. We defined a sputum positive for bacterial infection when > 10 bacteria 
per ocular field (/Of) were present in gram staining performed on the sputum (direct 
examination), respiratory pathogenic bacteria were cultured, and/or commensal bacteria 
were cultured with growth of > 2 on a scale of 4. The quality of sputum was optimal 
for testing when it contained < 10 epithelial cells/Of (10 x 10 magnification). Sputum 
samples containing ≥ 10 epithelial cells/Of observed by direct examination, were only 
considered sputum of good quality when the leucocyte-to-epithelial cell ratio was ≥ 
10/Of. Absence of sputum for bacteriological testing was not a reason for exclusion, 
as sputum could not be obtained from all children. Furthermore, we analysed other 
bacterial cultures if performed and a positive culture of cerebrospinal fluid, blood or 
BAl were defined as bacterial co-infection and thus a reason for exclusion from further 
analysis. Routine testing for atypical bacterial infections caused by Chlamydophila 
pneumoniae, Mycoplasma pneumoniae or Bordetella pertussis was not performed.
Three investigators (fM, JVK and Pf) independently reviewed the combined laboratory 
and clinical data from all PICU patients, based on the previously defined selection 
criteria, to decide on inclusion. Disagreement was resolved by consensus.
Statistical analyses
Data were analysed using SPSS version 20.0 (IBM, SPSS, Chicago, Il, USA) and GraphPad 
Prism version 6. for continuous data, medians, interquartile ranges (IQR), lower IQR 
(lIQR) and upper IQR (UIQR) were calculated. To analyse categorical data we used 
fisher’s-exact tests or Chi-square tests depending on the sample size. We calculated the 
number of viruses present in the study groups. To study the relation between disease 
severity and viral load, we compared the Ct-values in nasal washings in our study groups 
with Mann-Whitney U tests. We only included groups with more than six children based 
on the following power analysis: n= 2*(2.8*SD/Mean)^2, with an estimated mean of 25 
and SD of 15 based on the number of patients needed to show a difference in Ct-values.
ethics
This study was approved by the Medical Ethical Committee of the Erasmus MC, 
Rotterdam the Netherlands (MEC 2013-221). Informed consent was waived because 
this was a retrospective case-chart study. Data were stored anonymously and cannot be 
retraced to individual patients.
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RESULTS
PICU-SARI patient characteristics
The selection of PICU-SARI patients is outlined in Figure 1A and details of excluded 
patients are listed in S1 Table. An overview of the epidemiological data is shown in S1 
Figure. We identified 44 PICU-SARI patients with a median age of 9.6 months (lIQR 2 
-UIQR 25, min 0.46 - max 152) and an equal gender distribution (males: 22/44, 50%) 
(Table 1). One patient was admitted twice because of SARI, with RSV or HRV as single 
causative agent detected, and with an admission interval of 23.5 months. Thirty-four 
patients had an underlying medical condition (34/44, 77%). The remaining ten patients 
were healthy until admission (10/44, 23%) (Table 1). The most common underlying 
medical condition was pre-term birth (10/34, 29%). Reasons for admission were: 
obstructive upper respiratory tract infection (URTI) (9/44, 20%), lower respiratory tract 
infection (lRTI) (15/44, 34%) and severe wheezing with respiratory distress (18/44, 
41%). One patient was admitted with an apparent life-threatening event (AlTE (n=1)) 
with SARI and one patient with SARI related respiratory fatigue due to muscular disease 
(n=1) (2/44, 5%). Respiratory support consisted of supplemental oxygen (9/44, 20%), 
non–invasive respiratory support including non-rebreathing mask and optiflow was 
given in eight patients (8/44, 18%), whereas 27 patients required invasive respiratory 
support (27/44, 61%). for one patient additional ECMO was applied due to insufficient 
oxygenation (1/44, 2%). RSV was more frequently detected in boys (9/13, 69%), most 
patients were admitted with bronchiolitis (10/13, 77%), six had no underlying medical 
condition (6/13, 46%), and eight required invasive respiratory support (8/13, 62%). 
HRV was detected in six girls (6/11, 55%), most patients were admitted with lRTI (4/11, 
36%) or wheezing (4/11, 36%), all patients had an underlying medical condition, and 
seven patients required invasive respiratory support (7/11, 64%). Overall, the median 
PICU-stay was 3 days (min 0-max 39), after which patients were either transferred from 
PICU to MC (n=14, 32%, after which n=8 (57%) were transferred to another hospital 
or discharged n=6 (43%)), transferred from PICU to another hospitals (n=22, 50%) or 
were discharged after PICU admission (n=8, 18%). Admission duration in other hospitals 
could not be analysed, as data was not available. The overall hospital stay for patients 
admitted to both PICU and MC was 7 days (min 3-max 30). Two patients died during PICU 
admission because of cardiorespiratory failure. One of these was a previously healthy 
child admitted for cardiorespiratory arrest upon influenza A virus infection, the other 
was a patient with spinal muscular atrophy (SMA) type-2, who developed respiratory 
failure due to PIV-3.
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MC-ARTI patient characteristics
The selection of MC-ARTI patients is outlined in Figure 1B and details of excluded patients 
are listed in S2 Table. After using our predefined selection criteria 40 patients admitted 
to the MC with ARTI were identified. The median age of the MC-ARTI patients was 14 
months (lIQR 7.6 -UIQR 30, min 0.7-max 199) with more males than females (22/40, 
55%) (Table 1). One patient was admitted twice because of ARTI, with RSV or HMPV as 
single causative agent detected, and with an admission interval of 1.4 months.
Figure 1A. Flowchart patient selection for patients admitted to the paediatric intensive care unit 
(PICU) with severe acute respiratory tract infections (SARIs) with one respiratory virus, in the absence 
of viral co-infections and typical bacterial co-infections in children admitted to Erasmus MC-Sophia 
between 2007 and 2012.
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Table 1. Baseline characteristics of children admitted to the paediatric intensive care unit (PICU) 
with severe acute respiratory tract infections (SARIs) or medium care (MC) with acute respiratory 
tract infections (ARTIs) associated with a single virus infection in the absence of viral co-infections 
and typical bacterial co-infections at Erasmus MC-Sophia from 2007-2012.
PICU-SARI patients  
n = 44 (%)
MC-ARTI patients  
n = 40 (%)
p-values
Age    
Months 9.6 (1.8-24.7, 0.46-152)a 14.15 (7.6-30.1, 0.7-199)a 0.0447
Years 0.8 (0.15-2.1, 0.04-12.7)a 1.18 (0.63-2.5, 0.06-16.6)a 0.0442
Male 22 (50) 22 (55) 0.66
Reason for Admission    
Upper respiratory  
tract infections 
9 (21) 9 (22.5)
 
Lower respiratory  
tract infections
15 (34) 18 (45)  
Wheezing and oxygen need 18 (41) 11 (27.5)  
Others 2 (4)* 2 (5)**  
Medical history    
None 10 (23) 6 (15) 0.4 (F)
Pulmonary disease 
(including cystic fibrosis)
6 (14) 5 (12.5) ns
Pre-term birth (gestational 
age < 37 weeks)
10 (23) 4 (10) 0.15 (F)
Anatomical malformations 
and syndromal
8 (18) 5 (12.5) 0.55 (F)
Cardiovascular 1 (2) 4 (10) 0.19 (F)
Oncology and immunology - 2 (5) -
Neuro-muscular, SGA and 
others
9 (21) 14 (35) 0.15 (F)
Specimens    
Nasal washing 34 (77) 39 (98) 0.006 (C)
Sputum 8 (18) -  
Throat swab 2 (5) -  
Nasal swab - 1 (2)  
Respiratory support    
Supplemental 9 (20) 30 (75)  
Non-invasive 8 (18) 5 (12.5)  
Invasive 27 (61) -  
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Thirty-four patients had an underlying medical condition (34/40, 85%) including: 
pulmonary disease (5/34, 15%), a history of pre-term birth (4/34, 12%), and anatomical 
malformations and syndromal disorders (5/34, 15%) (Table 1). Reasons for admission 
were: URTI (9/40, 22.5%), lRTI (18/40, 45%) and wheezing (11/40, 27.5%). RSV was most 
frequently detected in boys (7/13, 54%), most patients were admitted with bronchiolitis 
(7/13, 54%), ten patients had underlying medical conditions (10/13, 77%), and all RSV 
infected patients’ required supplemental or non-invasive respiratory support (12/13, 92% 
and 1/13, 8%). HRV was mostly detected in girls (7/12, 58%), the most common reason 
for admission was lRTI (7/12, 58%), ten patients had underlying medical conditions 
(10/12, 83%), and nine required supplemental oxygen (9/12, 75%), one received non-
invasive respiratory support (1/12, 8%), and two HRV infected patients did not require 
respiratory support (2/12, 17%). In addition, one patient was admitted because of an 
exacerbation of cystic fibrosis with HRV as single pathogen detected (1/12, 8%) and one 
patient was admitted with an AlTE and ARTI with also a single HRV infection (1/12, 8%). 
The median hospitalisation stay of MC-ARTI patients was 5 days (1-21 days). In the MC-
ARTI group one patient suffering from SMA-type 1 died with an HRV-infection.
Comparison of PICU-SARI patients with MC-ARTI patients
The median age of PICU-SARI patients was lower than for MC-ARTI patients (9.6 vs 14 
months respectively; p=0.045). Specimens tested were mainly nasal washings in both 
groups (77% and 98%, p=0.006). In addition, CRP-levels were similar between both 
groups with a median of 6 and 7.5 mg/l respectively (p>0.05). As expected the number 
of bacterial sputum samples obtained was higher in PICU-SARI patients than in MC-
ARTI patients (19/44; 43% vs 8/40; 20%, p=0.035). Overall, we found 23 patients with 
a single virus and a bacterial co-infection admitted to the PICU with SARI (S3 Table). 
Extracorporeal oxygenation 1 (including invasive) -  
None - 5 (12.5)  
Length of stay   
PICU stay days 3 (0-39)b 0 0.0002
Hospital stay 0 5 (1-21)b  
Survival 42 (96) 39 (98) 0.61 (C)
a median, lower interquartile range – upper interquartile range, minimum-maximum; b median, 
minimum-maximum; 
* apparent life-threatening event and respiratory fatigue due to muscular disease; 
** exacerbation of cystic fibrosis and apparent life-threatening event; f = fisher-exact-test C = 
Chi-square test.
Table 1. Continued
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Most bacterial co-infections were found in patients with RSV (8/23, 35%) and HRV (7/23, 
30%) infections. Eleven patients admitted to the MC with ARTI had a proven bacterial 
co-infection (S4 Table), and PIV-3 was most frequently co-detected (3/11, 27%). Due to 
the limited number of proven bacterial co-infections, no associations between detected 
respiratory virus and bacterial infection could be evaluated. Twenty-three percent of 
PICU-SARI patients were previously healthy until admission compared to 15% of the MC-
ARTI patients (10/44, 23% vs. 6/40, 15%, p=0.4) (Table 1).
Figure 1B. Flowchart patient selection for patients admitted to medium care (MC) with acute 
respiratory tract infections (ARTI) with one respiratory virus, in the absence of viral co-infections 
and typical bacterial co-infections in children admitted to Erasmus MC-Sophia between 2007 and 
2012.
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Detection and distribution of respiratory viruses
Overall in the non selected PICU and MC patients HRV was very often detected and in a 
lower percentage in samples obtained from PICU patients (31%) than in samples of MC 
patients (42%) (p=0.002), whereas RSV (24% versus 15%, p=0.002) and ADV (10% versus 
5%, p=0.007) were more often detected in samples obtained from PICU patients (Table 
2). However, after applying our selection criteria for SARI and ARTI with a single virus 
only, these differences could no longer be found. Indeed RSV and HRV were represented 
roughly equally and predominated above all other viruses in both PICU-SARI patients 
and MC-ARTI patients (RSV: 13/44, 30% and 13/40, 33%, HRV: 11/44, 25% and 12/40, 
30%). Besides HRV and RSV nine of the other viruses tested for were associated with 
SARI and seven of these viruses were also associated with ARTI (except for ADV and 
HCoV-Nl63). Of the ten previously healthy PICU-SARI patients six were infected with RSV 
(6/10, 60%), three with HBoV (3/10, 30%), and one was infected with influenza A virus 
(1/10, 10%). Of the six previously healthy MC-ARTI patients, three patients were RSV 
infected (3/6, 50%), HRV was detected in two patients (2/6, 33%) and one patient tested 
positive for PIV-1 (1/6, 17%).
Ct-values of viral pathogens in respiratory tract samples of PICU-SARI patients 
compared to MC-ARTI patients
In an attempt to relate viral load to disease severity in PICU-SARI and MC-ARTI patients, 
we compared the total combined Ct-values in nasal washings, which revealed that 
the median Ct-values were not different between both groups (Ct values 22.2 vs 25.1 
respectively; p=0.191, Figure 2). There was a difference between Ct-values of PICU-SARI 
patients compared to PICU-non-SARI patients (p=0.005). This was not found for MC-ARTI 
patients compared to MC-non-ARTI patients (p=0.0994). We also compared Ct-values 
of PICU-SARI patients to MC-ARTI patients with and without a medical history and we 
found no differences between the respective groups (p=0.289 and p=0.917, data not 
shown). furthermore we compared PICU-SARI patients with invasive respiratory support 
with PICU-SARI patients and MC-ARTI patients with supplemental and non-invasive 
respiratory support and we found no difference between these two groups (p=0.0977, 
data not shown). Due to limited numbers we were not able to compare Ct-values for all 
individual viruses identified in this study, but based on our power calculation for both 
RSV and HRV infected patients, sufficient samples were available to compare Ct-values. 
No difference could be found in Ct-values between PICU-SARI patients and MC-ARTI 
patients with median Ct-values for RSV of 20.6 vs 21.4 (p=0.94) and HRV with 28.3 vs 
26.4 (p=0.44) respectively (Figure 4A and 4B).
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DISCUSSION
In the present paper we have shown that in our tertiary care centre both SARI and 
ARTI may be caused by single viral pathogens, with RSV and HRV being the most 
frequent causes. In addition, nine others of the fifteen respiratory viruses tested for 
were identified as single agents that may be associated with SARI in previously healthy 
children as well as in children with a medical history. Except for ADV and HCoV-NL63, the 
remaining seven viruses were also associated with ARTI in previously healthy children 
as well as in children with a medical history. Our data does not support a relationship 
between viral load as reflected by surrogate marker Ct-values on the one hand and 
disease severity reflected by MC or PICU admission on the other. This is counter-intuitive 
and indeed various studies have indicated that higher viral loads are related to more 
severe disease as well as locally increased cytokine production (126,136,145,150–158). 
Other studies failed to replicate this finding (116,159–162). Our findings may have been 
Figure 3. Cycle threshold (Ct) values of all single virus positive samples tested in nasal washings of 
patients admitted to the paediatric intensive care unit (PICU) with severe acute respiratory tract 
infections (SARIs) (PICU-SARI patients), all PICU admitted patients, patients admitted to medium 
care (MC) with acute respiratory tract infections (ARTIs) and all MC admitted patients between 
2007 and 2012 (Note: Ct-values were not available for all samples, *with statistical significant 
difference).
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influenced by the selection of hospitalized and seriously ill children. Although Ct-values 
as presented in our study do not represent an absolute quantitation of viral loads, we 
did use these semi-quantitative values as a surrogate marker for viral load in our patient 
samples, as is not unusual in this type of studies (126,154). Moreover, viral load may be 
one of many factors that could be associated with disease severity. In this respect the 
Figure 4A and 4B. Cycle threshold (Ct) values of positive samples for respiratory syncytial virus 
(RSV) (A) and human rhinovirus (HRV) (B) tested in nasal washings and compared between patients 
admitted to the paediatric intensive care unit (PICU) with severe acute respiratory tract infection 
(SARI) (PICU-SARI patients), all PICU admitted patients, patients admitted to medium care (MC) with 
acute respiratory tract infections (ARTIs) (MC-ARTI patients) and all MC admitted patients (Note: 
Ct-values were not available for all samples).
Figure 4A
Figure 4B
Processed on: 20-6-2016
503421-L-bw-Moesker
Viruses as sole causative agents of severe acute respiratory tract infections in children 51
3
role of a deleterious or counter-productive immune response may be a factor related to 
disease severity. This has been subject of several studies into the pathogenesis of viral 
respiratory disease and a better understanding may lead to novel targets for treatment 
of critically ill patients (47,163–170).
In accordance with several other studies, RSV and HRV were the most frequently detected 
respiratory pathogens throughout the study (4,47,128,142). RSV is a well-established 
respiratory virus known to cause severe disease by itself, especially in younger children 
(4,47,128). For HRV this role as single pathogenic agent has been less well established as 
it is frequently detected in combination with other respiratory viruses, and has therefore 
frequently been considered an innocent bystander. We described eleven critically ill 
patients with HRV as single pathogen detected, supporting other studies that have 
described HRV as an agent that may cause more or less severe disease (142,171,172). 
less common respiratory viruses such as HCoV and PIV 1-4 were detected, but additional 
analyses were not performed due to a lack of power.
Previous studies have demonstrated a higher susceptibility to several respiratory viruses 
in children with certain risk factors such as pre-term birth and broncho-pulmonary 
dysplasia (4,39). Indeed pre-term birth was also a marked factor related to hospitalization 
in our study. In agreement with other studies, RSV proved to be the most common 
pathogen detected in previously healthy children requiring PICU admission (4,127,128). 
It is interesting to note that HBoV and influenza A virus were also found in previously 
healthy PICU-SARI children. Previously we showed that also HBoV can cause SARI in 
paediatric patients (158). Two of our PICU-SARI patients died, which is comparable to 
previously published frequencies (3,4).
Our selection for a single virus only with an unlikely typical bacterial infection is largely 
dependent on CRP-levels, which are frequently tested in clinical settings and used to 
help differentiate between viral and bacterial infections (137,173). We are aware that 
the low CRP-levels (≤ 40 mg/l) tested within 24 hours after admission used in our study, 
may underestimate the occurrence of a bacterial infection or bacterial super-infection. 
Indeed we cannot fully exclude that some of our patients may have had secondary or 
pre-existing bacterial infections during hospitalization. We can also not fully exclude the 
presence of atypical bacteria such as M. pneumoniae, C. pneumoniae or B. pertussis as 
these were not routinely tested for. Still, considering the very low CRP used to include 
our patients, we feel that major bacterial involvement was unlikely at the time of hospital 
admittance (174).
Although this is a retrospective study from one tertiary care centre only, and bacterial 
cultures could not be performed for all patients for obvious reasons, we identified 44 
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PICU-SARI patients and 40 MC-ARTI patients infected with one single virus only from a 
total of 3269 patient samples over a 5-year period. The data generated shed new light on 
the aetiological role of several respiratory viruses: both SARI and ARTI can be caused by 
several single viral pathogens in the absence of viral and typical bacterial co-infections.
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S3 Table. Bacterial co-infections in single respiratory virus positive patients admitted to the 
paediatric intensive care unit (PICU) with severe acute respiratory tract infection (SARI) at Erasmus 
MC-Sophia over a 5-year period (2007-2012).
Virus detected
Ct-
value
Sputum 
sample 
obtained 
<48 hours 
after 
admission
Sputum test 
result
Bloodculture 
sample 
obtained <48 
hours after 
admission
Blood-
culture test 
result
Other samples 
tested for 
bacteria
Respiratory syncytial virus 26 Yes negative Yes negative
NASW^: PCR 
M. pneumoniae
Respiratory syncytial virus 20  Yes
H. influenzae, 
S. pneumoniae, 
S. aureus
Yes negative
 
Respiratory syncytial virus 27 Yes
H. influenzae, 
S. aureus No   
Respiratory syncytial virus 22 Yes M. catarrhalis No   
Respiratory syncytial virus 19 Yes E. coli Yes negative  
Influenza A virus 27 Yes
> 10 bacteria per 
ocular field in 
gram stain
No  
 
Influenza A virus 35 No (336) negative yes S. aureus BAL**: S. aureus
Rhinovirus 18 Yes E. coli No   
Rhinovirus 24 Yes S. pneumoniae Yes S. pneumoniae  
Rhinovirus 22 Yes
P. auruginosa, 
Corynebacterium 
sp.
No  
 
Parainfluenza virus type 3 33 Yes S. pneumoniae, 
M. catarrhalis
No negative  
Human bocavirus 39 Yes
K. pneumoniae,  
E.coli Yes negative  
Adenovirus 21 Yes P. auruginosa No   
Human metapneumovirus 20 Yes S. aureus No   
Respiratory syncytial virus 24 Yes
P. auruginosa, 
S. pyogenes
No   
Respiratory syncytial virus 23 Yes H. influenzae Yes negative  
Respiratory syncytial virus 22 Yes P. auruginosa No   
Rhinovirus 23 Yes
S. pneumoniae, 
S. aureus Yes negative  
Rhinovirus 29 Yes
P. aeruginosa, 
M. catarrhalis
No   
Adenovirus 32 Yes P. aeruginosa No   
Human metapneumovirus 21 No (72) negative Yes
Coagulase 
negative 
S. aureus  
Rhinovirus 19 Yes M. catarrhalis  No  
Rhinovirus 29 Yes S. aureus  No  
Processed on: 20-6-2016
503421-L-bw-Moesker
56 PLOS ONE
S4 Table. Bacterial co-infections in single respiratory virus positive patients admitted to medium 
care (MC) with acute respiratory tract infection (ARTI) at Erasmus MC-Sophia over a 5-year period 
(2007-2012).
Virus detected
Ct-
value
Sputum 
sample 
obtained <48 
hours after 
admission
Sputum test 
result
Bloodculture 
sample 
obtained 
< 48 hours 
after 
admission
Bloodcul-
ture test 
result
other 
samples 
tested for 
bacteria
Parainfluenza virus type 3 37 Yes P. aeruginosa No   
Rhinovirus 30 Yes P. aeruginosa No   
Parainfluenza virus type 3 N.A.* Yes
S. pneumoniae, 
H. influenzae
No   
Parainfluenza virus type 3 25 Yes
S. aureus, 
E. coli
No   
Human coronavirus OC43 28 Yes
Aspergillus sp., 
S. maltophilia, 
P. auruginosa
No   
Human coronavirus OC43 24 Yes
M. catarrhalis, 
H. influenzae, 
E.coli
No   
Respiratory syncytial virus 29 Yes S. aureus No   
Rhinovirus 33 Yes M. catarrhalis Yes negative  
Influenza A virus 32 Yes H. influenzae No  
Throatswab: 
C. albicans
Parainfluenza virus type 4 22 Yes P. auruginosa No   
Human metapneumovirus 37 Yes P. auruginosa No   
*N.A., not available
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Presentation of Cases
Case 1. A 10-year-old girl presented to our clinic with a history of four days fever, malaise 
and a generalized tonic-clonic convulsion. She had been diagnosed with SCD type HbSC 
before. At presentation she was alert, felt nauseous and complained of headache and 
painful eyes. Temperature was 38.0°C, heart rate (HR) 135/min, blood pressure (BP) 94/62 
mmHg, respiratory rate (RR) 20/min; liver and spleen were 1 cm palpable, abdominal 
tenderness was present in the right upper quadrant. No further abnormalities were 
reported on physical examination. Initial lab results revealed a moderate increase of CRP, 
anemia with thrombocytopenia, increased liver enzymes, and decreased albumin and 
hematocrit (Ht) (Table S1). On day two, during defervescence she became hypotensive 
and was treated with further hyperhydration and inotropic agents. Blood products were 
transfused to correct anemia and thrombocytopenia. Acute hemorrhage, hemolysis 
and splenic sequestration were considered, but could not be confirmed with abdominal 
ultrasound. However, pleural effusion and ascites were seen. On day three she lost 
vision. A brain CT-scan revealed no abnormalities. lumbar puncture was deferred and 
antibiotic treatment was adjusted to cover possible meningitis. Hereafter she developed 
acute respiratory distress syndrome (ARDS) requiring mechanical ventilation. Dengue 
serology was positive for IgM (titer: 3.26) and IgG (titer: 3.26) and RT-PCR showed dengue 
serotype 2 (DENV-2). Her clinical situation deteriorated with an increased hemorrhagic 
tendency, and blood, clotting products, and clotting factors were administered. In time 
multi organ dysfunction syndrome (MODS) developed and deteriorated. Blood cultures 
remained negative for bacteria, but Candida was cultured and antifungals were initiated. 
Despite these efforts the patient died 28 days after admission.
Case 2. A 19-year-old female presented to our clinic with a history of fever, headache, 
retro-orbital pain, and muscle ache for two days, hematemesis and epistaxis starting on 
the day of admission. She had arrived a few weeks earlier in Curaçao where she was born 
and raised till the age of 7. Her medical history revealed SCA. On examination she was 
alert, with a body temperature of 37°C, BP 120/80 mm Hg, HR 100/min and RR 15-20 / 
min. She had abdominal tenderness in the right upper quadrant. No other abnormalities 
on physical examination were found. Initial lab results revealed moderate increase of 
CRP, anemia with thrombocytopenia and increased liver enzymes. NS1-antigen tested 
positive and dengue serology was negative for IgM (titer 0.41) and positive for IgG 
(5.71), RT-PCR showed DENV-2. Shortly after admittance she became hypotensive, 
with distension of her abdomen and was admitted to the intensive care unit. Profuse 
abdominal bleeding was suspected with marked decrease of hemoglobin, low platelets, 
severe disrupted coagulation parameters and intra- and retro-abdominal free fluid with 
fibrin strands on ultrasound. She was intubated on a seizure. Although in the course of 
time shock and bleeding stabilized, she continued to develop MODS. In addition, both 
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pupils became less reactive to light until fully non reactive. CT-brain imaging could not be 
performed. On day 4 she died upon cardiac arrest.
Case Discussion
Dengue and Curaçao
During the past decades dengue has been reported to occur in Curaçao. Until now fatal 
cases were never documented. However the 2010-2011 outbreak with 1822 serologically 
confirmed cases was associated with four deaths (personal communication). Two of 
these four patients, were previously diagnosed with sickle cell disease (SCD) (combined 
heterozygosity for the abnormal hemoglobin S and normal Hb C; HbSC) and sickle 
cell anemia (SCA homozygosity for abnormal hemoglobin S; HbSS). Although chronic 
diseases such as SCD are considered to be a risk factor for the development of severe 
dengue, few cases of children or adolescents have been reported (175).
Short Literature Review
We gave a detailed description of two fatal dengue cases with underlying SCD that 
occurred in Curaçao where SCD is not uncommon (176). These cases indicate that 
SCD may predispose for severe manifestations of dengue infection. In the Americas 
all four serotypes of DENV circulate as well as in Asia where fatal dengue is frequently 
Table 1. Summary of literature review
Author, year of 
publication
Country Number 
of
Patients
Gender/
age
(years)
SCD type Dengue 
virus 
serotype
Outcome
Present case 1 Curaçao 1 F/10 HbSC DENV-2 Died
Present case 2 Curaçao 1 F/19 HbSS DENV-2 Died
Limonta et al., 2009 Cuba 2 M/34
M/25
HbSC
HbSA
DENV-3 (s)
DENV-3 (s)
Died
Died
Andrianarisoa et al., 
2007 
Madagascar ND ND ND ND ND
Ware et al., 1999 Jamaica 1 F/19 HbSS ND Died
Teruel-Lopez et al., 
1991** 
Venezuela ND ND ND ND ND
Bravo et al., 1987 Cuba 4
4
Adults
Children
HbSS
HbSS
DENV-2 (ND)
DENV-2 (ND)
Died
Died
Gentilini et al.,
1964 *
Haiti ND ND ND ND ND
M, male; F, female; *, no abstract available; ND, no data available; DENV, dengue virus 
serotype; (s), secondary; HbSC, heterozygote sickle cell disease; HbSS, homozygote sickle cell 
anemia; HbAS, sickle cell trait.** review describing Bravo et al article.
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reported. Hitherto no cases have been found in Asia in SCD patients, probably due to 
the relatively low prevalence of SCD (177). furthermore reports describing patients with 
this combination of diseases are scarce, little detailed and restricted to a few fatal cases 
and apart form the study from Cuba concern adult patients only (see Table 1) (178–184).
Presented Cases and Treatment Difficulties
The clinical findings of the two cases described here are difficult to interpret because 
of the apparent complementary vascular endothelial damage in SCD, SCA and severe 
dengue infection. Interesting are the essential similarities between these cases: shock, 
plasma leakage, hemorrhage and MODS (175). The onset of vaso-occlusion with SCD 
and SCA is often to be triggered by inflammation, as is the case in a dengue infection 
(185). A dengue review reports that severe bleeding seldom happens in children (186). 
Still our cases proved otherwise in this distinct risk group. An additional challenge was 
that treatment is basically different for both diseases. In SCD and SCA it is preferred to 
have a low Ht to reduce the risk of vaso-occlusion whereas anemia as a result of dengue 
may necessitate transfusion. The WHO reports an increase of Ht as a sign of plasma 
leakage and a decrease may be due to hemorrhage. Both cases show a continuing 
decrease of Ht, associated with hemorrhage, but plasma leakage was predominating 
as well suggesting not to use this marker in patients with SCD and SCA. Iatrogenic 
interstitial fluid overload in patients with SCD, SCA and dengue infection because of pre-
existing vascular endothelial damage is not an imaginary hazard. Whether the clinical 
manifestations would have occurred due to a secondary dengue infection only, despite 
SCD or SCA remains a matter for debate.
This report is based on two clinical cases of SCD, SCA and severe dengue during the 2010-
2011 epidemic in Curaçao. There is little information on how to treat these patients. 
In populations with a high prevalence of SCD, SCA and dengue activity clinicians should 
be aware of the possible pitfalls in clinical management.
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ABSTRACT
Background: Rapid antigen detection tests (RADTs) are increasingly used to detect 
influenza viruses and respiratory syncytial virus (RSV). However, their sensitivity and 
specificity are a matter of debate, challenging their clinical usefulness.
Objectives: Comparing diagnostic performances of BinaxNow Influenza AB® (BNI) and 
BinaxNow RSV® (BNR), to those of real-time reverse transcriptase PCR (RT-PCR), virus 
isolation and direct immunofluorescence (D-If) in paediatric patients.
Study design: Between November 2005 and September 2013, 521 nasal washings from 
symptomatic children (age <5 years) attending our tertiary care centre were tested, with 
a combination of the respective assays using RT-PCR as gold standard.
results: Sensitivity, specificity, positive predictive value (PPV) and negative predictive 
value (NPV) of BNI were 69% (confidence interval [CI] [51-83]), 96% [94-97], 55% [39-70] 
and 98% [96-99] respectively. Of eleven false-negative samples, RT-PCR Ct-values were 
higher than all RT-PCR positive test results (27 vs 22, p=0.012). Of twenty false-positive 
samples, none were culture positive and two tested positive in D-If.
Sensitivity, specificity, PPV and NPV for BNR were 79% [73-85], 98% [96-99], 97% [93-99] 
and 88% [84-91]. Of the 42 false-negative samples the median Ct-value was higher than 
that of all RT-PCR positive samples (31 vs 23, p<0.0001). five false-positive samples were 
detected. Three of these tested positive for RSV in virus isolation and D-If.
conclusions: RADTs have a high specificity with BNR being superior to BNI. However, 
their relative low sensitivity limits their usefulness for clinical decision making in a 
tertiary care paediatric hospital.
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BACKGROUND
Influenza viruses and respiratory syncytial viruses (RSV) cause acute respiratory tract 
infections (ARTIs) in children, being a leading cause of hospitalization (4,127,187). 
Identification of both viruses is important for disease management, as the presence 
of these infections may require specific treatment (i.e. oseltamivir) and hospital 
containment measures. The current gold standard for detection of these viruses is 
real-time reverse transcriptase PCR (RT-PCR) (40). This is however not performed in all 
hospitals, as it requires a molecular diagnostic laboratory with specialized personnel and 
equipment. Instead, rapid antigen detection tests (RADTs) are used as these assays are 
easier and cheaper to perform and less time-consuming (43–45). The performance of 
these tests depends on factors like time between disease onset and sampling, quality 
and type of specimen and epidemiological parameters (188). Diagnostic value and clinical 
usefulness of RADTs for influenza diagnosis vary greatly (43–45,189–192). This prompted 
us to evaluate the diagnostic performance of the routinely used RADTs (manufactured by 
Alere BinaxNOW®) for these two viruses as used in our tertiary care paediatric hospital.
OBJECTIVES
Comparing diagnostic performances of two RADTs, BinaxNow Influenza AB® (BNI) and 
BinaxNow RSV® (BNR), with those of RT-PCR in samples of paediatric patients attending 
our tertiary care centre with ARTIs for a period of almost eight consecutive years. 
Discrepant data were subsequently compared with those of virus isolation and direct 
immunofluorescence (D-If) assays.
STUDY DESIGN
This study was conducted from November 2005 through September 2013, we identified 
paediatric patients between 0-5 years who attended Erasmus MC-Sophia’s emergency 
department, out-patient-clinic and those who were hospitalized in this period. To 
analyse the performance of the BNI and BNR compared to RT-PCR we selected 521 nasal 
washings of 489 patients with a median age of 4 months (minimum 0.03 - maximum 
58 months, lower interquartile range 1.6 - upper interquartile range 9.8) and 55% 
(268/489) were male. Nasal washings were obtained during routine clinical practice in 
symptomatic children and were tested immediately after sampling by trained laboratory 
personnel using all four diagnostic methods. Multiple samples from the same patient 
were included in our analysis. Therefore patients are referred to as cases. Data regarding 
gender, age and hospital admission were obtained from the electronic patient files.
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ethics
Data collection and analyses were conducted on anonymized samples, which does not 
require further medical ethics review as consented by our Medical ethical board (MEC-
2015-306).
tests
RT-PCR gold standard
All nasal washings were tested for the presence of selected viruses by means of RT-
PCR with primers and probes sets used in the routine setting of our department (42). 
In short, RNA and DNA were extracted using MagnaPurelC (Roche Diagnostics, Almere, 
the Netherlands) and the total nucleic acid isolation kit. The extractions were internally 
controlled by addition of a known concentration of phocine distemper virus (PDV) and 
phocine herpes virus (PHV). Uni-plex RT-PCR was used to detect RSV-A, RSV-B, human 
rhinovirus (HRV), parainfluenza virus (PIV) type 3 (PIV-3), adenovirus (ADV), and human 
bocavirus (HBoV). Duplex reactions were performed combining influenza A virus and 
PDV, influenza B virus and human coronavirus (HCoV) OC43 (HCoVOC43), human 
metapneumovirus (HMPV) and PIV-2, HCoV229E and PIV-4, and HCoVNL63 and PIV-1. A 
cycle threshold value (Ct-value) of <40 was defined positive for any virus. RT-PCRs were 
developed in-house for influenza viruses and RSV-A and validated (42). RSV-B primers 
and probes were used as reported by Dewhurst-Maridor et al. (193).
Rapid antigen detection tests (RADTs)
Alere BinaxNOW® Influenza A and B (BNI) and Alere BinaxNOW® RSV (BNR)  (Scarborough, 
Maine, USA) are commercially available in vitro immunochromatographic assays for the 
qualitative detection with monoclonal antibodies directed against influenza A and B 
virus nucleoproteins and RSV fusion protein antigen, respectively. Nasal washings were 
obtained using standard protocols and rapid antigen testing was performed as described 
by the manufacturer. for our analyses the test results of BNI influenza A and influenza B 
were combined into a single influenza BNI dataset as influenza B was not encountered 
frequently with only four influenza B BNI positive samples, two of which were influenza 
B RT-PCR positive.
Virus isolation assay
Virus isolation assays were always performed in combination with D-If. Madin-Darby 
Canine Kidney (MDCK) cell line (NBl-2) (ATCC® CCL-34™) and the human cell line HEp-2 
(ATCC® CCL-23™) were used to isolate influenza viruses and RSV respectively. Virus cultures 
were regularly checked for cytopathic effect by light microscopy. Immunofluorescence 
with fluorescein isothiocyanate (fITC) labeled monoclonal antibodies was used to 
confirm the presence of influenza virus or RSV (194).
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Direct immunofluorescence (D-IF) assays in clinical specimens
Cells were isolated from nasal washings, dried on microscope slides, and fixed with 
acetone. Subsequently, cells were stained with fITC conjugated monoclonal antibodies 
against influenza A virus, influenza B virus or RSV (IMAGEN™ Influenza A and B and 
IMAGEN™ RSV, Hampshire, United Kingdom). Specimens were incubated with fITC-
conjugated antibodies for 15 minutes at 37 ̊C, subsequently excess reagent was washed 
off with phosphate buffered saline. The stained area was then mounted and viewed by 
fluorescent microscopy.
Comparison between tests
The focus of our study was to compare data obtained with two RADTs, BNI and BNR with 
those obtained by RT-PCR as gold standard. We defined false-negative tests as those 
for which the rapid test was negative and the gold standard RT-PCR positive; a false-
positive test result was defined if the rapid test tested positive and the gold standard RT-
PCR tested negative. We compared the available Ct-values in all respective categories of 
samples and analysed whether there was an association between Ct-values and RADTs 
results and hospitalization. for influenza all Ct-values were available, for RSV Ct-values 
were available for 183/204 (90%) of the performed tests. Missing Ct-values were from 
samples tested in 2005 and 2006 when routine input of Ct-values in our laboratory 
system was not yet performed and digital documentation was not available. finally, 
false-negative and false-positive test results were compared to test results obtained with 
the other virus detection methods: virus isolation and D-If assays.
Statistical analyses
The main outcomes of this study were the sensitivity, specificity, positive predictive 
value (PPV) and negative predictive value (NPV) of the BNI and BNR rapid test results 
compared to RT-PCR during the total study period and during viral season (October 1st 
through March 31st). Ct-values were compared with Mann-Whitney U tests.
RESULTS
Sensitivity and specificity of BNI 
Of 521 nasal washings both influenza RT-PCR and BNI data were available. Most were 
obtained between September and March (supplemental data Figure 1 and Figure 2). Of 
these, 35 cases tested positive with RT-PCR (35/521, 7%, median Ct-value 22 [range] [17–
39]) whereas 44 tested positive in the BNI (44/521, 8%). Of the 35 RT-PCR positive cases 
24 also tested positive in the BNI (24/35, 69%, median Ct-value 21 [17-31]). The eleven RT-
PCR positive (median Ct-value 27 [18-39]) and BNI negative cases were considered false-
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negative cases (11/521, 2%). Of the 486 RT-PCR negative cases, 20 were BNI positive, and 
were therefore considered false-positive cases (20/521, 4%). Considering RT-PCR as the 
gold standard, it may be concluded that the BNI has a relatively low sensitivity of 69% 
(confidence interval (CI): [51-83]) (24/35), a high specificity of 96% [CI: 94-97] (466/486), 
a low PPV of 55% [CI: 39-70] (24/44) and a high NPV of 98%  [CI: 96-99] (466/477) (Table 
1). We also calculated these parameters only with samples obtained in the period from 
October 1st through March 31st, when respiratory viruses are more prevalent in the 
Netherlands. Sensitivity and specificity decreased with 2% and 1% respectively (69% to 
67% and 96% to 95%). PPV and NPV both decreased with 1% from 55% to 54% and 98% 
to 97% respectively.
Sensitivity and specificity of BNR 
Of 514 nasal washings both RSV RT-PCR and BNR data were available. Of these, 204 cases 
were RSV RT-PCR positive (204/514, 40%) with Ct-values available for 183 samples ranging 
from 14-39 (median Ct-value 23) and 167 were BNR positive (167/514, 32%) (Table 
1). Hundred sixty-two samples were RT-PCR positive and BNR positive (162/514, 32%, 
median Ct-value 21 [14-35], no Ct-value available n=15). forty-two cases were considered 
false- negative (42/514, 8%, median Ct-value 31 [22-39], no Ct-value available n=6). Of 
the 310 RT-PCR negative cases, five were BNR positive and considered false-positive cases 
(5/514, 1%). The overall test performance of BNR was relatively high with a sensitivity of 
79% [CI: 73-85] (162/204), specificity of 98% [CI: 96-99] (305/310), PPV of 97% [CI: 93-99] 
(162/167) and NPV of 88% [CI: 84-91] (305/347). We also calculated these parameters 
Table 1. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) 
of rapid antigen detection test BinaxNOW influenza AB® and BinaxNOW RSV® compared to gold 
standard RT-PCR tested in nasal washings of children between 0-5 years at Erasmus MC-Sophia 
from 2005-2013.
Rapid antigen detection tests
Sensitivity (%)
[95% confidence
interval; CI]
n
Specificity (%)
[95% CI]
n
PPV (%)
[95% CI]
n
NPV (%)
[95% CI]
n
BinaxNow Influenza AB® 
vs RT-PCR n=521
68.6 [51-83]
24/35
95.8 [94-97]
466/486
54.5 [39-70]
24/44
97.7 [96-99]
466/477
BinaxNow RSV® 
vs RT-PCR n=514
79.4 [73-85]
162/204
98.4 [96-99]
305/310
97 [93-99]
162/167
88 [84-91]
305/347
Samples obtained in respiratory virus season
BinaxNow Influenza AB® 
vs RT-PCR n=436
66.7 [48-82]
22/33
95.3 [93-97]
384/403
53.7 [37-69]
22/41
97.2 [95-99]
384/395
BinaxNow RSV® 
vs RT-PCR n=428
80 [74-85]
160/200
98 [96-100]
224/228
98 [94-99]
160/164
85 [80-89]
224/264
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during the respiratory virus season (October-March) and sensitivity increased with 1% 
(79% to 80%), but the specificity remained the same (98%). PPV increased with 1% (from 
97% to 98%) and NPV decreased with 3% from 88% to 85% respectively.
Discordant samples 
False-negative rapid antigen detection tests
from the eleven false-negative BNI cases, influenza virus was successfully isolated in six 
cases (6/11, 55%, median Ct-value 25 [17-27]), three of which were also influenza D-If 
positive. By means of RT-PCR, virus isolation or D-If 7/11 (63%) samples tested positive for 
another virus, most frequently RSV (n=3) or adenovirus ADV (n=3) (supplemental Table 1a).
BNR results were considered false-negative in 42 cases, in 25 (60%) of those RSV was 
cultured successfully. In these 25 cases the Ct-values ranged from 22-39 with a median 
of 32. In addition, in 20/42 (48%) cases, RSV D-If tested positive (median Ct-value 29 [22-
37]). Co-infections were found in 16/42 (38%) cases and most often HRV (n=7). In four 
cases BNI tested positive for influenza, which could be confirmed for three samples by 
RT-PCR (supplemental Table 1b).
False-positive rapid antigen detection tests
Of the 20 influenza false-positive cases, six tested positive in BNR (6/20, 30%). Moreover, 
six cases tested RSV RT-PCR positive (6/20, 30%) of which five were also BNR positive. In 
eight samples another respiratory virus than influenza virus or RSV was detected with RT-
PCR (8/20, 40%). for two samples the D-If was positive for influenza, in accordance with 
the BNI, but for both virus isolation did not yield influenza virus (supplemental Table 2a).
for BNR only five false-positive cases were found. Three of these were RSV positive in 
virus isolation and D-If (3/5, 60%). One case tested negative in all methods except for 
BNI (supplemental Table 2b). The sensitivity (80%), specificity (99%) and PPV (99%) 
increased if we considered the three RSV positive virus isolations as true-positive cases, 
resulting in only two false-positive cases (2/514, 0,4%).
Test results and hospitalization
Of all 521 patients tested for BNI and BNR 361 patients (361/521, 69%) were hospitalized. 
Hospitalization rates were 16/24 (67%) and 115/162 (71%) for true-positive BNI and BNR 
cases respectively. false-negative test results did not seem to have a major impact on 
hospitalization with hospitalization rates of 7/11 (64% vs 69%, p=1) and 25/42 (60% vs 
71%, p=0.1912) for BNI and BNR test results respectively (Table 2).
Comparing the Ct-values of the respective categories, BNI and BNR cases that were 
false-negative displayed overall higher Ct-values (p=0.012 vs p<0.0001) (Figure 1A and 
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Figure 1B). However, no differences were found in Ct-values of hospitalized and non-
hospitalized patients within the respective case groups (p>0.5 for both BNI and BNR) 
(Figure 2A and Figure 2B). The BNI test result did not differentiate for severe disease 
with three of the false-negative cases admitted to the paediatric intensive care unit 
(PICU), but also three false-positive cases. for BNR six patients were admitted to the 
PICU (6/42, 14%) despite a false-negative test result. None of the five BNR false-positive 
tested patients were admitted to the PICU (0/5).
DISCUSSION
The present study evaluated the diagnostic performance of BNI and BNR RADTs in a large 
number of symptomatic paediatric patients between 0-5 years attending our tertiary 
care paediatric hospital during almost eight consecutive years. By testing fresh nasal 
washings with RT-PCR, we found a relatively low sensitivity and PPV for BNI. The overall 
test performance of BNR scored higher for all these aspects. Both BNI and BNR false-
negative cases displayed a significantly higher Ct-value compared to all RT-PCR positive 
and true-positive tested cases.
The accuracy of rapid tests is generally less than that of RT-PCR and virus isolation assays. 
However, RADTs are valuable as a point-of-care test for their ease of use, fast results and 
laboratory independence (188). These advantages, and especially the high specificity are 
important for their use as surveillance tools for influenza outbreaks as recommended by 
the World Health Organization (188). Indeed for surveillance purpose a high specificity 
is of importance, which we found to be the case in our study. However, for clinical 
management this is not sufficient. In theory, the decision to start antiviral therapy and to 
refrain from unnecessary further diagnostic testing and antibiotic use may be based on 
RADT (195–197). In addition, rapid test results may result in more effective isolation and 
containment measures (44). for this purpose assay sensitivity is of utmost importance. 
Therefore, we conclude that the relatively low sensitivity of the BNI in our tertiary care 
Table 2. BinaxNow Influenza AB® (BNI) and BinaxNOW RSV® (BNR) test results in relation to 
hospitalization of children between 0-5 years at Erasmus MC-Sophia from 2005-2013.
BNI true-positive (%) false-negative (%) false-positive (%)
Admitted 16/24 (67) 7/11 (64) 16/20 (80)
Not admitted 8/24 (33) 4/11 (36) 2/20 (10)
Unknown - - 2/20 (10)
BNR
Admitted 115/162 (71) 25/42 (60) 5/5 (100)
Not admitted 47/162 (29) 17/42 (40) -
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Figure 1A. Ct-values compared for BinaxNOW influenza AB® (BNI) rapid test positive results and 
rapid test negative results for influenza in children between 0-5 years at Erasmus MC-Sophia from 
2005-2013.
Figure 1B. Ct-values compared for BinaxNOW RSV® (BNR) rapid test positive results and rapid test 
negative results for RSV in children between 0-5 years at Erasmus MC-Sophia from 2005-2013. 
The number between ( ) refers to all RT-PCR positive results, for 21 samples no Ct-values were 
available.
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Figure 2B. Ct-values in relation to BinaxNOW RSV® (BNR) rapid test results and hospitalization of 
children between 0-5 years at Erasmus MC-Sophia from 2005-2013. ns= no statistical significant 
difference.
Figure 2A. Ct-values in relation to BinaxNOW influenza AB® (BNI) rapid test results and 
hospitalization of children between 0-5 years at Erasmus MC-Sophia from 2005-2013. ns= no 
statistical significant difference.
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centre is worrisome. Of note, BNR test performance proved to be better compared to 
the BNI, although false-negative cases were detected. Based on our results we stopped 
using BNI and will use rapid PCR-based tests for detection of influenza virus and RSV.
We considered the clinical implications of a false-negative and false-positive test result 
in relation to hospitalization and found no significant differences between these groups 
and RT-PCR positive and BNI positive tested cases, indicating that the clinical observation 
is still pivotal in admission decision-making as suggested by current guidelines. In the 
present study we were not able to study effects of testing on treatment since antiviral 
medication was not routinely used in our hospital before 2009. Data on isolation and 
containment measures were not available.
Although the retrospective nature of our study has inherent limitations, we were able 
to include more than 500 samples of patients over time. Since, our study spanned a 
considerably longer period of time than previous studies, we were able to test the 
clinical feasibility of RADTs “in a real life” clinical setting and for different circulating 
virus subtypes during eight consecutive seasons. Overall, most studies reported a high 
specificity and high NPV versus a low sensitivity and low PPV for BNI, which is largely in 
agreement with our results (43–45,189–192). We did find a relatively high sensitivity of 
79% and an even higher PPV (97%) for BNR, which is in agreement with data obtained in 
other studies (43,198,199).
During the last decade, RT-PCR has become the gold standard for detecting the presence 
of respiratory viruses (40). The downside of RT-PCR is the relatively long time (6-24 
hours) between sample collection and availability of test results (200). This makes 
current RT-PCR formats less useful for admission decision-making and calls for faster 
methods. Indeed, new rapid point-of-care PCRs are being developed and implemented 
with a shorter turnaround time (201–206). Studies comparing their performances with 
those of RT-PCR would allow us to judge their potential for clinical decision-making.
In conclusion, we evaluated the performance of the RADTs BNI and BNR in a tertiary 
care paediatric hospital setting over eight consecutive years. We showed that sensitivity 
and PPV of BNI were relatively low (69% and 55%), whereas those of BNR were higher 
(79% and 97%) when compared to the respective gold standard RT-PCR. false-negative 
samples consistently displayed high Ct-values, although this did not influence whether 
patients were hospitalized or not. Given the relatively low sensitivity and PPV of the BNI 
we strongly advocate a restricted use of BNI or similar rapid influenza antigen detection 
assays in a tertiary paediatric care setting. In contrast, the higher sensitivity and PPV of 
the BNR rendered this rapid test more useful, albeit still less sensitive than RT-PCR.
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Ethical approval: Data collection and analyses were conducted on anonymized samples, 
which does not require further medical ethics review as consented by our Medical 
ethical board (MEC-2015-306).
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SUPPLEMENTAL DATA
Supplemental Figure 1. Number of all BinaxNOW influenza AB® (BNI) and BinaxNOW RSV® (BNR) 
rapid tests performed and all positive test results for BNI and BNR in children between 0-5 years at 
Erasmus MC-Sophia from 2005 – 2013 in months.
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Supplemental Table 1a BinaxNOW influenza AB® (BNI) false-negative samples (n=11) compared 
to BinaxNOW RSV® (BNR), RT-PCR, virus isolation and direct immunofluorescence (D-If) tested in 
nasal washings obtained from symptomatic children between 0-5 years at Erasmus MC-Sophia 
from 2005-2013. In addition co-infections are reported.
BNI false-negative 
samples
BNR RT-PCR (Ct-value) virus isolation D-IF
1 negative influenza (30)+RSV* (26) negative RSV
2 positive influenza (35) negative RSV
3 positive influenza (36)+HRV* (no Ct) RSV RSV
4 negative influenza (25) influenza negative
5 negative influenza (36)+ADV* (37) negative negative
6 negative influenza (27)+ADV (26) influenza negative
7 negative influenza (26) influenza influenza 
8 negative influenza (39) negative picornavirus
9 negative influenza (18)+ADV (no Ct) influenza influenza 
10 negative influenza (26) influenza negative
11 negative influenza (23) influenza influenza 
* RSV: respiratory syncytial virus; ADV: adenovirus; HRV: human rhinovirus
Supplemental Table 1b BinaxNOW RSV® (BNR) false-negative samples (n=42) compared to 
BinaxNOW influenza AB® (BNI), RT-PCR, virus isolation and direct immunofluorescence (D-If) 
tested in nasal washings obtained from symptomatic children between 0-5 years at Erasmus MC-
Sophia from 2005-2013. In addition co-infections are reported.
BNR false-negative 
samples
BNI RT-PCR (Ct-value) virus isolation D-IF
1 negative RSV* (26)+influenza (30) negative RSV
2 positive RSV (24) negative RSV
3 positive RSV (31)+influenza (19) influenza negative
4 positive RSV (32)+influenza (20) influenza influenza
5 positive RSV (31)+influenza (19) influenza influenza
6 negative RSV (30) negative negative
7 negative RSV (34)+HRV* (29) RSV RSV
8 negative RSV (30) negative RSV
9 negative RSV (35)+HRV (29) RSV RSV
10 negative RSV (33)+ADV* (38) RSV RSV
11 negative RSV (22) RSV RSV
12 negative RSV (no Ct) negative negative
13 negative RSV (34)+ADV (35) RSV RSV
14 negative RSV (no Ct) RSV negative
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15 negative RSV (37)+HRV (no Ct) RSV picornavirus
16 negative RSV (36)+HRV (18) negative picornavirus
17 negative RSV (29) negative negative
18 negative RSV (30) RSV RSV
19 negative RSV (no Ct) RSV RSV
20 negative RSV (35) negative picornavirus
21 negative RSV (25) RSV negative
22 negative RSV (34)+HRV (no Ct)+HBoV (no Ct) negative negative
23 negative RSV (32) negative negative
24 negative RSV (37) RSV RSV
25 negative RSV (23) RSV RSV
26 negative RSV (32)+ADV (36) RSV negative
27 negative RSV (39) RSV negative
28 negative RSV (28) negative negative
29 negative RSV (31) RSV RSV
30 negative RSV (36)+ADV (36) RSV negative
31 negative
RSV (27)+HRV (23)+
HCoV229E* (27)
RSV RSV
32 negative RSV (no Ct) RSV RSV
33 negative RSV (28) RSV RSV
34 negative RSV (29)+HRV (34) RSV picornavirus
35 negative RSV (29) RSV RSV
36 negative RSV (24) negative RSV
37 negative RSV (24) RSV positive negative
38 negative RSV (no Ct) negative negative
39 negative RSV (no Ct) RSV RSV
40 negative RSV (36)+HCoVOC43 (28) RSV negative
41 negative RSV (26) negative RSV
42 negative RSV (34) RSV negative
* RSV: respiratory syncytial virus; ADV: adenovirus; HRV: human rhinovirus; HMPV: human 
metapneumovirus; HBoV: human bocavirus; HCoV: human coronavirus; No Ct: no Ct-value 
available
Supplemental Table 1b Continued
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Supplemental Table 2a BinaxNOW influenza AB® (BNI) false-positive samples (n=20) compared 
to BinaxNOW RSV® (BNR), RT-PCR, virus isolation and direct immunofluorescence (D-If) tested 
in nasal washings obtained from symptomatic children between 0-5 years at Erasmus MC-Sophia 
from 2005-2013. In addition co-infections are reported.
BNI false-positive 
samples
BNR RT-PCR (Ct-value) virus isolation D-IF
1 positive negative negative negative
2 negative RSV* (24) negative RSV
3 positive RSV (18) RSV RSV
4 positive RSV (16) RSV RSV
5 positive RSV (no Ct) RSV RSV
6 positive RSV (21) RSV RSV
7 positive RSV (19) RSV RSV
8 negative negative negative picornavirus
9 negative HRV* (32)+HBoV* (34) negative influenza
10 negative negative negative negative
11 negative HMPV* (38) negative negative
12 negative HRV (no Ct) picornavirus picornavirus
13 negative HMPV (29) negative negative
14 negative negative negative negative
15 negative negative negative influenza
16 negative HCoVNL63* (39) negative negative
17 negative negative negative negative
18 negative HCoVOC43 (27) negative negative
19 negative HCoVOC43 (19) negative negative
20 negative HRV (24)+HCoVNl63 (19) negative negative
* RSV: respiratory syncytial virus; HRV: human rhinovirus; HMPV: human metapneumovirus; 
HBoV: human bocavirus; HCoV: human coronavirus; No Ct: no Ct-value available
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Supplemental Table 2b BinaxNOW RSV® (BNR) false-positive samples (n=5) compared to 
BinaxNOW influenza AB® (BNI), RT-PCR, virus isolation and direct immunofluorescence (D-If) 
tested in nasal washings obtained from symptomatic children between 0-5 years at Erasmus MC-
Sophia from 2005-2013. In addition co-infections are reported.
BNR false-positive 
samples
BNI RT-PCR (Ct-value) virus isolation D-IF
1 positive negative negative negative
2 negative negative RSV* RSV
3 negative negative RSV RSV
4 negative negative RSV RSV
5 negative negative negative negative
* RSV: respiratory syncytial virus
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ABSTRACT
Background: Modified Vaccinia virus Ankara (MVA) is a promising viral vector platform 
for H5N1 influenza vaccine development. Preclinical evaluation of MVA-based H5N1 
vaccines showed their immunogenicity and safety in various animal models, warranting 
clinical evaluation.
Methods: In this randomized double-blind phase I/IIa study young healthy volunteers 
were immunized once or twice with a normal dose (108 plaque forming units (pfu)) or a 
tenfold lower dose of either the MVA-H5-sfMR (vector encoding the hemagglutinin gene 
of influenza A/Vietnam/1194/04 virus (H5N1 subtype) or MVA-f6-sfMR (empty vector) 
vaccine. Healthy volunteers that received the MVA-H5-sfMR vaccine were eligible for 
a boost immunization one year after the first immunization. Primary safety endpoints 
were local and/or systemic reactions. Secondary outcomes were hemagglutination 
inhibition (HI) and virus-neutralization (VN) antibody titers in the sera from the healthy 
volunteers. The trial is registered at the Dutch Trial Register (www.trialregister.nl) (NTR 
registration number: NTR3401).
Findings: 79 of the 80 healthy volunteers that were enrolled completed the study. No 
serious adverse events occurred. The majority of the healthy volunteers experienced one 
or more local and systemic reactions. Healthy volunteers that received the tenfold lower 
dose were prone to develop less systemic reactions. The MVA-H5-sfMR 108 pfu vaccine 
induced significantly higher antibody responses after one and two immunizations. 27 of 
the 39 eligible healthy volunteers were enrolled in the boost immunization study. The 
results indicated that a single shot MVA-H5-sfMR 108 pfu prime immunization resulted in 
higher antibody responses upon boost immunization than two shots with MVA-H5-sfMR 
at a ten-fold lower dose.
Interpretation: This study illustrates that the MVA-based pandemic H5N1 vaccine was 
well-tolerated and immunogenic and underlines that vaccine candidates arising from 
the MVA platform hold great promise for the future.
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INTRODUCTION
Avian influenza viruses are continuously introduced into the human population with 
variable impact for infected individuals and the population at large. first reports of 
human infection with highly pathogenic avian influenza (HPAI) viruses of the H5N1 
subtype date back to 1997 (207). Since their re-occurrence in 2003, H5N1 viruses have 
infected at least 650 humans and 386 of these cases were fatal (9). To facilitate fast-
track vaccine development for these viruses the European Medicines Agency (EMA) 
has developed a pandemic vaccine mock-up dossier for Europe (208). The influenza A 
(H1N1) 2009 pandemic highlighted that in spite of the possibility for fast-track licensing 
of conventional vaccines, the delay between onset of the pandemic and arrival of 
vaccines on the market proved to be unacceptable (209). Consequently the production 
and distribution time of vaccines in the early pandemic period still is an unsolved 
problem that should be taken into account in the development of candidate vaccines 
against future, possibly emerging H5N1 pandemic viruses (210).
The immunogenicity of H5N1 vaccine formulations based on traditional vaccine 
platforms is low compared to that of seasonal influenza vaccines, resulting in the 
need to use multiple-shot immunization regimens or the addition of an adjuvant. The 
limited immunogenicity is not only associated with the relative naivety of the human 
population towards these avian influenza viruses, but also results from an intrinsic 
limited immunogenicity of the H5 hemagglutinin (HA). This phenomenon was identified 
for various avian influenza-virus derived HA’s, like H5, H7, and H9 (211). Couch et al 
have assessed the immunogenicity of various avian influenza vaccines and found that 
the secondary structures of the vaccine antigens may affect their immunogenicity (211). 
It is difficult to ensure consistency of the appropriate morphology when the vaccine 
is produced with traditional methods of virus inactivation and breakdown through 
treatment with detergents. Furthermore, Couch et al illustrated that in comparison with 
seasonal influenza virus HA’s, the conformation of avian influenza HA’s and their uptake 
and processing by immune cells is similar and does not result in limited immunogenicity. 
This indicates that avian influenza vaccine development could profit considerably from 
novel vaccine production platforms such as those based on recombinant proteins, 
virosomes and viral or bacterial vectors (212–215). An additional challenge for H5N1 
vaccine development is the explosive antigenic diversification of avian H5N1 viruses in 
the past decades, which has resulted in the emergence of a plethora of virus clades, 
subclades and lineages (216).
Consequently a future HA-based pandemic H5N1 vaccine should be suitable for fast 
and large-scale production and preferably present HA in its native multimeric form. 
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Viral vectors such as adenoviruses and poxviruses have proven to be potent antigen-
presentation platforms that comply largely with these requirements (217–219). 
Poxviruses and more specifically Modified Vaccinia virus Ankara (MVA) are of special 
interest. The latter is replication-deficient in mammalian cells which is a clear advantage 
from a safety perspective. This will eventually allow for large-scale immunization 
campaigns that may also include the classical high-risk groups for influenza. Preclinical 
evaluation of MVA-based H5N1 vaccines showed their immunogenicity and safety in 
various animal models, warranting clinical evaluation (220–225).
Here we present data from the first-in-man phase I/IIa clinical trial conducted with the 
MVA-HA-based H5N1 vaccine MVA-H5-sfMR assessing its safety and immunogenicity. 
This is the first ever demonstration that a MVA-based H5N1 candidate vaccine is safe and 
immunogenic in humans.
MATERIAlS & METHODS
Study Design
The phase 1/2a study was randomized and double-blind performed in a single center: 
Erasmus Medical Center, Rotterdam, the Netherlands (226). The primary study objective 
was assessment of safety. The immunogenicity of the vaccines was assessed as a 
secondary objective. Our working hypothesis was that a recombinant MVA-based H5 
vaccine is safe and immunogenic in humans.
Both the healthy volunteers and the physicians who did the examinations and 
administered the vaccine were blinded for the vaccine. Eighty young adult volunteers 
were recruited (both male and female). When they met the inclusion and exclusion 
criteria (as described in the study protocol (226)) and provided written informed consent 
the healthy volunteers were randomly assigned to one of the eight study arms (n=10 per 
arm). The arms of the study were based on the number of immunizations (one or two), 
the immunization dose (107 or 108 pfu) and the vaccine (MVA-H5-sfMR or MVA-F6-sfMR) 
(see Table 1)(see Appendix for details on vaccine generation and characterization). 
Sample size was calculated based on the mean antibody titers obtained in the preclinical 
study with a prime and boost immunization with an MVA-H5 vaccine in macaques (221).
At the first visit (week 0) blood was drawn (max 34ml) and for pregnancy was excluded 
within 15-30 minutes prior to the vaccine administration among women who participated. 
Subsequently, the healthy volunteers received one immunization, administered as 
a solution of 0.5ml through intramuscular injection in the deltoid muscle. Healthy 
volunteers were observed for one hour at the trial unit and a blood sample was taken. 
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Then they were sent home with an ear thermometer and diary card for them to keep 
track of possible side-effects during seven subsequent days. In week 4 a blood sample 
was drawn from all healthy volunteers followed by a second immunization for the healthy 
volunteers in study arms 5-8. After an observation period of one hour a blood sample 
was taken again they were asked to complete a diary card for the next seven days. Eight 
and twenty weeks after their first immunization all healthy volunteers returned for their 
close-out visit at which the last blood sample was taken. The study design was reviewed 
and approved by the Central Committee on Research involving Human Subjects (CCMO) 
in the Netherlands. The trial is registered at the Dutch Trial Register (www.trialregister.
nl) (NTR registration number: NTR3401).
Safety Assessment
The safety of the vaccine candidates was assessed using multiple tests and scores. Each 
subject underwent a short physical examination prior to the immunization. Heart rate, 
blood pressure and body temperature were registered, the injection site was examined 
and questions were asked on possible pre-existing conditions. This physical examination 
was repeated 1 hour after immunization and an additional examination was performed 
if necessary upon indication during the 1 hour observation period post immunization. 
Before and 1 hour after immunization blood was drawn to measure clinical chemical 
and haematological parameters in order to detect acute effects that occurred upon 
immunization. four weeks after the first immunization all healthy volunteers again 
underwent the short physical examination and were asked by a trial physician if they had 
experienced any adverse reactions during and after the first week post immunization. 
Subsequently blood was drawn to measure the parameters as described above. Only the 
healthy volunteers that received a second immunization, determined by randomisation, 
had an additional examination and blood sampling 1 hour after immunization. 
To assess reactogenicity of the vaccine, the healthy volunteers received a diary card to 
be completed during the first seven days post immunization. In addition they received an 
earthermometer to measure their body temperature twice a day (morning and evening).
Booster immunization strategy
In order to assess the possibility to boost of the H5-specific immune response, healthy 
volunteers that received the MVA-H5-sfMR vaccine during the main study were 
approached for a follow-up study (if they approved of this by informed consent). Healthy 
volunteers that agreed to a booster immunization received a single shot of MVA-H5-
sfMR with the same dose that they received originally. Immunizations were performed 1 
year after the first MVA-H5-sfMR immunization. Prior to the booster blood was drawn to 
determine baseline influenza virus H5-specific and MVA-IgG specific antibody responses. 
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Healthy volunteers received a diary card to be completed during the first seven days post 
immunizations. four weeks after their visit the healthy volunteers returned and blood 
was drawn to determine the boost-effect of the MVA-H5-sfMR immunization.
Detection of influenza virus H5-specific antibodies
Serum was obtained from blood that was collected and centrifuged in coagulation tubes 
(Greiner Bio-one, Alphen a/d Rijn, the Netherlands). Sera were treated with a receptor-
destroying enzyme (cholera filtrate) and then heat-inactivated at 56°C. Subsequently 
the sera were pretreated with horse erythrocytes after which the sera were ready to be 
tested for the presence of anti-H5 antibodies. This was tested in the hemagglutination 
inhibition assay (HI) with an adapted protocol using 1% horse erythrocytes and four 
HA-units of either the homologous influenza H5N1 virus A/VN/1194/04 (clade 1) or the 
antigenically distinct strain: A/Indonesia5/05 (A/IND/5/05) (clade 2.1) (227). for serology, 
viruses were used from which the multi basic cleavage site in the HA, associated with 
high virulence, was deleted by reverse genetics. The use of these reverse genetics (RG) 
viruses in the HI assay was validated and the obtained antibody titers were comparable 
with those against the wild type strains (data not shown).
The sera were also tested for the presence of virus-neutralizing antibodies using a micro 
virus neutralization (VN) assay with the RG viruses described above. The VN assay was 
performed as described previously (228). Sera from MVA-H5-SfMR immunized New 
Zealand White Rabbits and Cynomolgus Macaques were used as a positive controls in 
both the HI and VN assays. for calculation purposes serum samples with an antibody 
titer of <10 were arbitrarily assigned a titer of 5. Seroconversion was arbitrarily defined 
as a post-vaccination titer of ≥20 or a fourfold rise in the antibody titer when the previous 
titer was >10. Antibody titers of ≥40 were arbitrarily considered to be seroprotective.
Detection of MVA-specific antibodies
Serum samples were tested for the presence of MVA-specific immunoglobulin G (IgG) 
antibodies. To this end, Baby Hamster Kidney-21 (BHK-21) cells (permissive for MVA 
virus infection) were infected with MVA-f6-sfMR at an MOI of 10 and incubated for 
6-8 hours. In parallel, serum samples were preincubated with uninfected BHK-21 cells. 
After the incubation period serum was added to either uninfected or infected BHK-21 
cells in triplicates. The cells were incubated for 16 hours at 4◦C and then washed and 
subsequently incubated with a fITC-labelled Rabbit anti-human IgG antibody preparation 
(DAKO, Glostrup, Denmark). Cells were analysed by flow cytometry using a fACS Canto 
(BD Biosciences, Breda, The Netherlands). The fold-increase in fITC-positive cells was 
calculated by dividing the values from the sera incubated with the infected cells by that 
from the corresponding sera incubated with the uninfected cells.
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Randomization and masking
Study subjects were assigned to one of the eight study groups based on a computer-
generated randomization list with 10 blocks of 8 randomized study arms. The 
randomization code was kept by the hospital pharmacist till the end of the study period. 
Based on the list a generic label was generated by the hospital pharmacy that masked 
the content of the vaccine vial and only indicated a reference to the respective recipient. 
A trial nurse would check the content of the vial and would fill the syringe from the vial 
and provide this with the masked label to the trial physician.
Statistics
To assess statistical significance of the differences between groups the Mann-Whitney 
U test was performed using IBM SPSS Statistics 22. for the analysis of the HI and VN 
antibody titers the log2 values of the titers were used.
Role of the funding source
The European Research Council (ERC) that provided funding for this study (project 
flUPlAN (250136)) had no role in the design of the study or data interpretation. AO 
designed the protocol together with JK, GS and GR and had final responsibility for the 
study.
RESULTS
Study demographics
Within 2 months after recruitment start (December 2012), eighty healthy young adults, 
18-28 years of age (mean= 21.9 ± 2.0), were enrolled in the study. Females comprised 
61% of these volunteers. All healthy volunteers were randomly assigned to one of the 
eight arms of the study. The male-females ratio’s per study arm are indicated in Table 
1. Study immunizations began in february 2013 and the last study visits took place in 
July 2013. Of the eighty healthy volunteers enrolled, 79 completed the study. Thirty-
nine of these healthy volunteers received one or two immunizations with the MVA-H5-
sfMR vaccine and thus were eligible for inclusion in a booster immunization study that 
was performed one year later (January 2014). Twenty-seven healthy volunteers were 
enrolled in this follow-up study and received a booster immunization.
Safety
No serious adverse events occurred during either the main or the follow-up study. 
Eleven adverse events were registered during the study period (indicated for the 
respective group and study period in Tables 2-4). One subject (group 6) experienced 
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severe headache and lightheadedness during the first hour after vaccination and 
received paracetamol. This event may have been related to the vaccination. No further 
acute effects were observed during the observation period nor during the subsequent 
physical examination. The ten other adverse events occurred in the four weeks after 
immunization. One subject in group 8 reported erythema nodosum, which was unlikely 
but possibly related to vaccination. five healthy volunteers (group 1, 8) reported 
respiratory illness and/or sore throat during the first week post immunization, which is 
most likely unrelated to vaccination. Their respiratory illness was accompanied by flu-
like symptoms. One subject in group 5 reported a local reaction at the injection site 
(evening post immunization) characterized by red spots (1-2 cm in diameter). The other 
three healthy volunteers (group 2, 6, 7) suffered from other conditions unlikely to have a 
causal relation to the vaccination. Blood samples of all healthy volunteers were analyzed 
for the before mentioned biochemical and hematological parameters. The majority of 
the values were within the standard ranges (specified per sex). The deviations that were 
observed were either pre-existing or isolated deviations that could be attributed to the 
healthy volunteer’s background and/or lifestyle. One subject had an elevated CK after 
vaccination which could have a causal relation to the vaccination, but this did not result 
in clinical symptoms and was not accompanied by any other biochemical deviation. 
Diary cards filled in for a period of seven days after each immunization recorded local 
and systemic reactions after the first immunization (Table 2), the second immunization 
(Table 3) and the booster immunization (Table 4). The majority of the healthy volunteers 
reported one or more local and systemic reactions, occurring within 72 hours post 
immunization and the majority of the reported reactions resolved within 6 days post 
immunization. focusing on the local reactions, pain at the injection site was reported 
most and was graded as mild-moderate by most healthy volunteers and only a minority 
reported the pain as severe. Itch, swelling and redness were only reported in a few 
cases distributed over the different groups. No difference in incidence and severity of 
the local reactions were experienced after the first, second or booster immunization. 
Most healthy volunteers experiencing systemic reactions reported them to be mild 
to moderate. There was no clear difference in incidence and severity of the systemic 
reactions after one, two or the booster immunization. There appeared however to be a 
dose-response effect, as the 107 pfu dose of either the MVA-H5-sfMR or MVA-F6-sfMR 
vaccines resulted in less reported systemic reactions than the108 pfu dose. Overall the 
MVA-H5-sfMR and MVA-F6-sfMR vaccines were well tolerated.
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Table 3. local and systemic reactions after the second immunisation
Group 5, MVA-
H5-sfMR 108 pfu 
(n=10)
Group 6, MVA-
H5-sfMR 107 pfu
(n=10)
Group 7, MVA-
F6-sfMR 108 pfu 
(n=10)
Group 8, MVA-
F6-sfMR 
107 pfu 
(n=10)
local reactions 8 (80%) 8 (80%) 4 (40%) 7 (70%)
Itch
 None
 Mild
 Moderate
 Severe
9 (90%)
-
-
-
7 (70%)
2 (20%)
-
-
9 (90%)
1 (10%)
-
-
9 (90%)
1 (10%)
-
-
Pain
 None
 Mild
 Moderate  
 Severe§
4 (40%)
-
3 (30%)
3 (30%), 1 days 
(1.0-3.0)
4 (40%)
3 (30%)
3 (30%)
-
6 (60%)
2 (20%)
2 (20%)
-
4 (40%)
6 (60%)
-
-
Redness
 None
 Mild
 Moderate
 Severe
 Diameter (mm)
7 (70%)
3 (30%)
-
-
2.0 (1.0-3.0)
9 (90%)
1 (10%)
-
-
2.0 (2.0-2.0)
7 (70%)
3 (30%)
-
-
3.0 (3.0-3.0)
8 (80%)
2 (20%)
-
-
2.0 (1.0-2.0)
Swelling
 None
 Mild
 Moderate
 Severe
5 (50%)
3 (30%)
2 (20%)
-
9 (90%)
1 (10%)
-
-
7 (70%)
3 (30%)
-
-
8 (80%)
2 (20%)
-
-
Systemic reactions 10 (100%) 9 (90%) 8 (80%)† 5 (50%)‡
Rise in body 
temperature (>37.5⁰C)
 Number
 Temperature range
 Days
4 (40%)
37.6-39.1
2.0
4 (40%)
37.6-38.3
2.3
3 (30%)
37.6-38.4
2.3
4 (40%)
37.6-37.9
2.5
Headache
 None
 Mild
 Moderate
 Severe§
-
6 (60%)
3 (30%)
1 (10%), 1 days 
(1.0-1.0)
6 (60%)
2 (20%)
1 (10%)
1 (10%), 1 days 
(1.0-1.0)
6 (60%)
2 (20%)
1 (10%)
1 (10%), 1 days 
(1.0-1.0)
8 (80%)
2 (20%)
-
-
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Table 3. Continued
Myalgia
 None
 Mild
 Moderate
 Severe§
3 (30%)
4 (40%)
1 (10%)
2 (20%), 1 days
2 (20%)
4 (40%)
4 (40%)
-
2 (20%)
4 (40%)
3 (30%)
1 (10%), 1 days
5 (50%)
4 (40%)
1 (10%)
-
Arthralgia
 None
 Mild
 Moderate
 Severe§
9 (90%)
-
-
1 (10%), 1 days 
(1.0-1.0)
10 (100%)
-
-
-
9 (90%)
1 (10%)
-
-
10 (100%)
-
-
-
Chills
 None
 Mild
 Moderate
 Severe§
7 (70%)
-
2 (20%)
1 (10%), 1 days 
(1.0-1.0)
10 (100%)
-
-
-
8 (80%)
1 (10%)
1 (10%)
-
10 (100%)
-
-
-
Malaise
 None
 Mild
 Moderate
 Severe§
6 (60%)
2 (20%)
1 (10%)
1 (10%), 1 days 
(1.0-1.0)
7 (70%)
1 (10%)
1 (10%)
1 (10%) 1 days 
(1.0-1.0)
8 (80%)
1 (10%)
-
1 (10%), 1 days 
(1.0-1.0)
9 (90%)
1 (10%)
-
-
fatigue
 None
 Mild
 Moderate
 Severe§
4 (40%)
2 (20%)
3 (30%)
1 (10%), 6 days 
(6.0-6.0)
5 (50%)
2 (20%)
1 (10%)
2 (20%), 1 days 
(1.0-1.0)
7 (70%)
1 (10%)
2 (20%)
-
9 (90%)
1 (10%)
-
-
Data are number (%) or mean (range), unless otherwise indicated. MVA=modified vaccinia 
virus Ankara. pfu=plaque-forming units. *One individual reported red spots (diameter 1-2 cm) 
around the injection site on the evening after immunisation.  †One individual reported having a 
sore throat for at least 1 day in the week after immunisation. ‡One individual reported 
sore throat and respiratory illness that started on day 1 after immunsation. §Mean number of 
days for which the reaction was reported as severe.
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Table 4. local and systemic reactions after booster immunisation
Group 1, MVA-
H5-sfMR 108 pfu 
(n=5)
Group 2, MVA-
H5-sfMR 107 pfu
(n=7)
Group 5, MVA-
H5-sfMR 108 pfu 
(n=6)
Group 6, MVA-
H5-sfMR 107 pfu 
(n=9)
local reactions 4 (80%) 5 (71%) 6 (100%) 8 (89%)
Itch
 None
 Mild
 Moderate
 Severe
5 (100%)
-
-
-
6 (86%)
1 (14%)
-
-
4 (67%)
2 (33%)
-
-
7 (78%)
1 (11%)
1 (11%)
-
Pain
 None
 Mild
 Moderate  
 Severe†
2 (40%)
2 (40%)
1 (20%)
-
3 (43%)
2 (29%)
1 (14%)
1 (14), 1 days 
(1.0-1.0
-
1 (17%)
2 (33%)
3 (50%), 1.3 days 
(1.0-2.0)
2 (22%)
4 (45%)
3 (33%)
-
Redness
 None
 Mild
 Moderate
 Severe
 Diameter (mm)
3 (60%)
2 (40%)
-
-
10.0 (10.0-10.0)
6 (86%)
1 (14%)
-
-
3.0 (3.0-3.0)
2 (33%)
4 (67%)
-
-
2.7 (1.0-3.0)
8 (89%)
9 (11%)
-
-
8.0 (2.0-8.0)
Swelling
 None
 Mild
 Moderate
 Severe
4 (80%)
1 (20%)
-
-
6 (86%)
1 (14%)
-
-
2 (33%)
4 (67%)
-
-
7 (78%)
2 (22%)
-
-
Systemic reactions
Rise in body 
temperature 
(>37.5⁰C)
 Number
 Temperature range
 Days
5 (100%)
37.7-38.5
1.6
5 (71%)
37.6-38.2
3.2
3 (50%)
37.6-38.2
2.7
4 (44%)
37.6-39
1.3
Headache
 None
 Mild
 Moderate
 Severe†
2 (40%)
2 (40%)
1 (20%)
-
5 (71%)
2 (29%)
-
-
-
1 (17%)
4 (67%)
1 (17%), 1 days 
(1.0-1.0)
2 (22%)
3 (33%)
3 (33%)
1 (11%), 1 days 
(1.0-1.0)
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Table 4. Continued
Myalgia
 None
 Mild
 Moderate
 Severe†
-
3 (60%)
2 (40%)
-
1 (14%)
1 (14%)
5 (72%)
-
1 (17%)
-
2 (33%)
3 (50%), 1 days 
(1.0-1.0)
3 (33%)
3 (33%)
2 (22%)
1 (11%), 1 days 
(1.0-1.0)
Arthralgia
 None
 Mild
 Moderate
 Severe†
3 (60%)
2 (40%)
-
-
6 (86%)
-
1 (14%)
-
4 (67%)
1 (17%)
1 (17%)
-
7 (78%)
1 (11%)
1 (11%)
-
Chills
 None
 Mild
 Moderate
 Severe†
1 (20%)
-
2 (40%)
2 (40%), 1 days 
(1.0-1.0)
5 (72%)
1 (14%)
1 (14%)
-
4 (67%)
-
2 (33%)
-
7 (78%)
-
2 (22%)
-
Malaise
 None
 Mild
 Moderate
 Severe†
1 (20%)
-
3 (60%)
1 (20%), 1 days 
(1.0-1.0)
3 (43%)
3 (43%)
1 (14%)
-
2 (33%)
-
3 (50%)
1 (17%), 1 days 
(1.0-1.0)
5 (56%)
2 (22%)
1 (11%)
1 (11%), 1 days 
(1.0-1.0)
fatigue
 None
 Mild
 Moderate
 Severe†
1 (20%)
1 (20%)
2 (40%)
1 (20%), 1 days 
(1.0-1.0)
5 (72%)
1 (14%)
1 (14%)
-
3 (50%)
2 (33%)
-
-
5 (56%)
4 (44%)
-
-
Data are number (%) or mean (range), unless otherwise indicated. MVA=modified vaccinia 
virus Ankara. MVA-H5-sfMR=vector encoding the haemagglutinin gene of influenza A/
Vietnam/1194/2004 virus H5N1 subtype. pfu=plaque-forming units. * One individual reported 
flu-like symptoms before the immunisation on the diary card. 
†Mean number of days which the reaction was reported as severe. 
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H5-specific immune responses
Pre- and post-immunization sera were tested for the presence of H5 specific antibodies 
in the HI and VN assay against homologous H5N1 influenza A/VN/1194/04 virus (Table 5) 
and heterologous H5N1 influenza A/IND/5/05 virus (Table 6). four weeks after the first 
immunization antibodies were detectable against both A/H5N1 viruses and titers were 
higher in healthy volunteers that received the 108 pfu dose of MVA-H5-sfMR, groups 1 
and 5 respectively. The A/VN/1194/04-specific HI GMT of the latter was significantly 
higher than that in groups 2 and 6, in which healthy volunteers had received the tenfold 
lower dose of the MVA-H5-sfMR vaccine. A second immunization (groups 5 and 6) further 
boosted the antibody response as measured at 8 weeks after the first immunization. 
HI GMT also rose for group 1, despite the lack of a second immunization, and were 
significantly higher than that of group 2. HI GMT of group 5 was significantly higher than 
that of groups 1, 2 and 6. Over time antibody titers waned as measured on time point 20 
weeks, however titers for group 5 remained significantly higher than those of groups 1, 2 
and 6. In the main study the maximal seroconversion rates (% of healthy volunteers with 
at least a four-fold increase in titer) and seroprotection rates (% of healthy volunteers 
with a titer of ≥40) were reached after two immunizations (at 8 weeks) in group 5, 100% 
and 80% respectively. The HI data were confirmed by those obtained with the VN assay 
though VN GMT generally were lower in the latter.
The extra immunization in the follow-up study resulted in a substantial boost of the antibody 
responses against the homologous A/VN/1194/04 (Figure 1) and heterologous A/IND/5/05 
strain (Figure 2). Highest GMTs were measured for group 1 with a 100% seroconversion 
and 100% seroprotection rate (Appendix 2). The titers in this group were significantly 
higher than in group 6 in the HI assay against the A/VN/1194/04 strain and significantly 
higher than group 2 in the VN assay against the A/IND/5/05 strain. Also for group 2 100% 
seroconversion and 100% seroprotection were reached with the extra immunization. 
Sera were not only tested against the homologous H5N1 influenza A/Vietnam/1194/04 
virus but also against viruses from antigenically distinct clades: H5N1 influenza A/Turkey/
Turkey/1/2005 virus (clade 2.2) and the transmissible variant of the H5N1 influenza A/
Indonesia/5/2005 virus (clade 2.1) as described recently (21,229). The boosting effect 
was also confirmed for the antibody responses against these viruses (see Appendix 3). 
Of the healthy volunteers immunized twice with MVA-f6-sfMR 10e8 pfu, three out of 
ten seroconverted in the HI assay (two had seroprotective antibodies titers) with a GMT 
of 10.1 (SD=2.8). One of ten healthy volunteers immunized twice with the 10-fold lower 
dose seroconverted (GMT 5.7 (SD=1.6)).
All subjects had antibody titers of <10 (arbitrarily assigned a value of 5 for calculation 
purposes) at the beginning of the study (0 weeks post immunization) in the 
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Figure 1. Mean HI (A) and VN (B) antibody titers against influenza A/Vietnam/1194/04 virus of the 
healthy volunteers that received a boost immunization after one year. 
To assess statistical significance of the differences between groups the Mann-Whitney U test was 
performed. for the analysis of the HI and VN antibody titers the log2 values were used of the titers 
of 0 weeks to 20 weeks for the complete groups (thus including the healthy volunteers that did not 
receive a booster immunization). for the 1 year and 4 weeks post boost immunization the statistics 
logically were performed with the boosted individuals only. *Antibody titers were significantly 
higher than in groups 2 and 6. ** Antibody titers were significantly higher than in group 6.  *** 
Antibody titers were significantly higher than in groups 1, 2 and 6. **** Antibody titers were 
significantly higher than in group 6.
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Figure 2. Mean HI (A) and VN (B) antibody titers against influenza A/Indonesia/5/05 virus of the 
healthy volunteers that received a boost immunization after one year. 
To assess statistical significance of the differences between groups the Mann-Whitney U test was 
performed. for the analysis of the HI and VN antibody titers the log2 values were used of the 
titers of 0 weeks to 20 weeks for the complete groups (thus including the healthy volunteers that 
did not receive a booster immunization). for the 1 year and 4 weeks post boost immunization 
the statistics logically were performed with the boosted individuals only. *Antibody titers were 
significantly higher than in group 2 (MVA-H5-sfMR 107).
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Hemagglutination Inhibition (HI) and Virus Neutralization (VN) assay. *Seroconversion 
was arbitrarily defined as a post-vaccination titer of  ≥20 or a fourfold rise in the antibody 
titer when the previous titer was >10. Seroconversion is cumulative to 20 weeks. A 
subject that was seroconverted on 4 weeks after the first immunization is accounted 
as seroconverted on 8 weeks and 20 weeks also. The numbers in parenthesis after the 
percentages are the absolute number of subjects for seroconversion and seroprotection. 
1Antibody titers were significantly higher than that in groups 2 and 6. 2Antibody titers 
were significantly higher than that in group 2. 3 Antibody titers were significantly higher 
than than in groups 1, 2 and 6.
All subjects had antibody titers of <10 (arbitrarily assigned a value of 5 for calculation 
purposes) at the beginning of the study (0 weeks post immunization) in the 
Hemagglutination Inhibition (HI) and Virus Neutralization (VN) assay. *Seroconversion 
was arbitrarily defined as a post-vaccination titer of  ≥20 or a fourfold rise in the antibody 
titer when the previous titer was >10. Seroconversion is cumulative to 20 weeks. A 
subject that was seroconverted on 4 weeks after the first immunization is accounted 
as seroconverted on 8 weeks and 20 weeks also. The numbers in parenthesis after the 
percentages are the absolute numbers of subjects for seroconversion and seroprotection. 
1Antibody titers were significantly higher than that in group 2.
Table 5. Cumulative seroconversion and seroprotection against homologous H5N1 virus influenza 
A/Vietnam/1194/2004 (clade 1)
Time after 1st immunization
4wks 8wks 20wks
Group HI VN HI VN HI VN
1
Single shot
MVA-H5-
sfMR
108 pfu
Seroconversion* 56% (5) 11% (1 78% (7) 11% (1) 78% (7) 33% (3)
Seroprotection 56% (5) 11% (1) 44% (4) 11% (1) 44% (4) 11% (1)
GMT (SD) 22.6 (4.6) 9.3 (6.3) 30.2 (3.8)2 9.3 (6.3) 12.2 (3.7) 12.6 (6.3)
2
Single shot
MVA-H5-
sfMR
107 pfu
Seroconversion 30% (3) 10% (1) 40% (4) 10% (1) 40% (4) 10% (1)
Seroprotection 10% (1) - - - - -
GMT (SD) 8.5 (2.4) 5.7 (1.6) 9.2 (2.3) 5.0 (1.0) 6.2 (1.6) 5.0 (1.0)
5
Two shot
MVA-H5-
sfMR
108 pfu
Seroconversion 80% (8) 10% (1) 100% (10) 50% (5) 100% (10) 40% (4)
Seroprotection 60% (6) - 80% (8) 30% (3) 70% (7) 20% (2)
GMT (SD) 39.3 (4.1)1 5.7 (1.6) 108.1 (2.4)3 14.1 (3.4) 43.9 (3.4)3 12.3 (3.7)
6
Two shot
MVA-H5-
sfMR
107 pfu
Seroconversion 20% (2) 10% (1) 50% (5) 10% (1) 50% (5) 20% (2)
Seroprotection 20% (2) - 30% (3) - - -
GMT (SD) 8.1 (2.4) 5.7 (1.6) 15.8 (3.2) 5.0 (1.0) 6.9 (2.0) 5.7 (1.6)
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MVA-specific IgG responses
MVA-specific IgG responses are expressed as fold increase in mean fluorescence (fIMf) 
(Figure 3). four weeks after the first immunization differences between the different 
groups were minimal and the mean responses ranged from 1.62 to 2.1 FIMF. The second 
immunization for groups 5-8 induced significantly higher (p values <0.05) MVA-specific IgG 
responses at time point 8 weeks when compared to groups 1-4 that did not receive a second 
immunization (exception: the difference between group 3 and 6 was not significant). The 
responses waned for all groups between 8 and 20 weeks and at the latter time point MVA-
specific IgG response in Groups 5, 7 and 8 were significantly higher (p values <0.05) than 
in Group 2. Group 7 also had a significantly higher response than Group 6 (p=0.04). The 
boost immunization for groups 1, 2, 5 and 6 resulted in a rise in MVA-specific IgG responses 
as measured four weeks after the booster. Differences between the groups were minimal.
DISCUSSION
An influenza A/H5N1 candidate vaccine based on the replication deficient viral vector 
MVA was safe and immunogenic in volunteers. The reactogenicity of MVA-H5-sfMR 
in young healthy adults was mild to moderate and apart from the limited number of 
adverse events, local and systemic reactions are acceptable and are in line with reports 
Table 6. Cumulative seroconversion and seroprotection against heterologous H5N1 virus influenza 
A/Indonesia/5/2005 (clade 2.1)
Time after 1st immunization
4 weeks 8 weeks 20 weeks
Group HI VN HI VN HI VN
1
Single shot
MVA-H5-sfMR
108 pfu
Seroconversion* 33% (3) 11% (1) 56% (5) 11% (1) 56% (5) 22% (2)
Seroprotection 22% (2) - 33% (3) 11% (1) 11% (1) 11% (1)
GMT (SD) 13.6 (3.2)1 5.8 (1.6) 18.5 (3.1) 9.3 (6.3) 7.3 (3.2) 9.3 (4.1)
2
Single shot
MVA-H5-sfMR
107 pfu
Seroconversion 10% (1) - 50% (5) - - -
Seroprotection - - 10% (1) - - -
GMT (SD) 5.7 (1.6) - 11.8 (2.7) - - -
5
Two shot
MVA-H5-sfMR
108 pfu
Seroconversion 40% (4) 10% (1) 50% (5) 20% (2) 50% (5) 20% (2)
Seroprotection 30% (3) 10% (1) 40% (4) 20% (2) 20% (2) 10% (1)
GMT (SD) 13.7 (3.6) 6.2 (1.9) 20.8 (3.7) 9.3 (4.1) 11.5 (3.4) 7.1 (2.1)
6
Two shot
MVA-H5-sfMR
107 pfu
Seroconversion 30% (3) - 50% (5) 10% (1) - 10% (1)
Seroprotection - - 20% (2) - - -
GMT (SD) 7.6 (2.0) - 11.5 (2.3) 5.7 (1.6) - 5.0 (1.0)
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of clinical evaluations of other MVA-based vaccines (for review see Gilbert) (230). The 
ten-fold lower dose of MVA-H5-sfMR was slightly less reactogenic than the 108 pfu 
dose, but its immunogenicity was lower. The latter induced significantly higher antibody 
responses, especially after two immunizations. One immunization with a dose of 108 pfu 
of MVA-H5-sfMR primed for the highest antibody responses upon boost immunization 
given after one year. Such a regimen would be of interest considering a pre-pandemic 
immunization scenario to establish priming for a H5N1-specific antibody response in a 
naïve population that could be boosted once a pandemic H5N1 virus would emerge.
Figure 3. MVA specific antibody responses after the first, second and booster immunization. 
MVA-specific IgG antibodies were measured in serum by incubating it with uninfected or MVA 
infected BHK-21 cells and subsequently analyzing these cells by labeling them with an anti-human 
IgG antibody and measuring the mean fluorescence of the cells on the fACS. MVA-specific IgG 
antibody responses are expressed as fold increase in mean fluorescence, calculated by dividing 
the values from the sera incubated with the infected cells by that from the corresponding sera 
incubated with the uninfected cells.
To assess statistical significance of the differences between groups the Mann-Whitney U test was 
performed. for the analysis of the MVA-specific IgG antibody responses values were used of 0 
weeks to 20 weeks for the complete groups (thus including the healthy volunteers that did not 
receive a booster immunization). for the 1 year and 4 weeks post boost immunization the statistics 
logically were performed with the boosted individuals only.
*The MVA-specific IgG response in groups 5, 6, 7 and 8 was significantly higher (p values <0.05) 
than in groups 1, 2, 3 and 4 (exception: the difference between group 3 and 6 was not significant).
**The MVA-specific IgG response in groups 5, 7 and 8 was significant higher (p values <0.05) than 
in group 2. Group 7 also had a significant higher response than Group 6 (p=0.04).
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Of interest, the antibodies induced after MVA-H5-sfMR immunization cross-reacted with 
influenza A/H5N1 viruses of antigenically distinct clades of H5N1 viruses, which suggests 
that this vaccine based on the clade 1 virus A/Vietnam/1194/04 would afford some level 
of protection to H5N1 viruses belonging to other clades as was demonstrated previously 
in mice and non-human primates (220–222).
Currently, circulating H5N1 viruses do not spread efficiently from human-to-human. 
A handful of mutations has been identified that are associated with gain-of-function 
and would allow these viruses to spread from human-to-human. Most of the mutations 
have been identified in avian influenza viruses currently circulating in birds and it has 
been shown that they may accumulate upon mammalian passage of these viruses (229). 
This possible scenario underscores the need for the development of effective vaccines. 
Therefore, numerous attempts have been made to develop such vaccines. Only with 
high doses of conventional vaccine preparations or the use of adjuvants appreciable 
H5N1 virus specific antibody responses could be induced (214). Here we demonstrate 
that the MVA-H5-sfMR replication-deficient vector vaccine candidate was immunogenic 
and that especially a booster vaccination given after one year, resulted in high antibody 
titers. The boosting effect observed here is reminiscent of the booster effect observed 
with an adjuvanted heterologous H5 vaccine (231).
To compare the immunogenicity of this vaccine with conventional H5N1 inactivated (un)
adjuvanted vaccine candidates head to head clinical trials are necessary.
A limitation of the use of vector-based influenza vaccines may be interference of vector-
specific immunity induced by natural infections or vaccination that could affect the 
immunogenicity of subsequent immunizations with vaccines based on the same vector 
(232). The MVA-based platform does apparently not suffer from this possible drawback 
as was shown previously (233). In the present study we also showed that the MVA-
H5-sfMR vaccine elicits strong anamnestic antibody responses to the influenza virus HA 
upon second and third immunizations despite the induction of anti-vector immunity 
upon the first immunization.
The boostability of the transgene encoded antigen-specific antibody response can 
probably be attributed to the administration of a relatively high dose of replication 
deficient MVA, resulting in an incomplete round of replication and co-incited expression 
of the transgene. The entry of MVA into the cells that eventually express and present the 
antigen, can apparently not be blocked by pre-existing MVA specific antibodies. This is 
not surprising, as antibody-mediated in vitro neutralization of poxviruses is notoriously 
inefficient and its mechanistic correlation to in vivo protection remains still unclear 
(234). T cell mediated anti-viral immunity requires at least one round of infection, gene 
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expression and antigen presentation before becoming active and efficient recombinant 
antigen synthesis is possible even in the presence of strong MVA-specific CD8+ T cell 
responses (235). This aspect favors the use of this vector over replication competent viral 
vectors, like adenoviruses, that may suffer from pre-existing immunity against naturally 
occurring adenoviruses or vaccination induced vector neutralizing antibodies. The use of 
such vectors may have to rely on multiple serotypes and/or genetically modified variants, 
which could complicate practical and regulatory acceptance of the vaccine. Thus, our 
data show that MVA vector-specific immunity cannot abrogate the ability of the MVA-H5 
vaccine to induce strong H5-specific booster responses. However, it is still unknown to 
what extent the priming of an H5-specific response could be modulated by anti-vaccinia 
immunity. This first-in-man study included only vaccinia naïve individuals and the capacity 
of MVA-H5 to elicit primary H5-specific immunity in healthy volunteers that were 
vaccinated against smallpox remains to be studied. Such follow-up studies would also 
inform about a potential influence of anti-vaccinia immunity on vaccine reactogenicity.
Although that this was only a single center trial, both the safety and immunogenicity data 
observed in humans with the MVA-H5-sfMR candidate vaccine are in accordance with 
previous results that we obtained with MVA-H5 candidate vaccines in mice and non-human 
primates (220–222). In addition, the MVA-influenza platform could be employed for the 
development of vaccines against emerging influenza viruses of subtypes other than H5N1. 
This way a library could be established consisting of recombinant MVA vaccines, each with 
a prototype HA gene (e.g. H5, H7, H9, H10) that can be used as a seed virus for fast up 
scaling of production on a suitable platform such as CEfs which are a well-established cell 
substrate that allows for large scale production of recombinant MVA viruses in a short time.
In conclusion, the present study demonstrates the favorable safety and immunogenicity 
profile of the MVA-based H5N1 vaccine and underlines that vaccine candidates arising 
from this platform hold great promise for the future.
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Appendix 1. MVA-H5-sfMR construction. 
A shows the pIIIred-PsynII-H5 plasmid that was a result of cloning of the PsynII promoter and codon-
optimized HA gene from influenza A/Vietnam/1194/04 virus in the pIIIred plasmid. B, MVA-f6-sfMR 
genome with the flank 2 region on the 5’end and the flank 1 region on the 3’end of the deletion III 
site. C, MVA-H5-sfMR-mCherry genome, the recombinant virus before the mCherry gene is looped 
out by homologous recombination. The picture shows a focus of red fluorescent cells as result of 
infection with MVA-H5-sfMR co-producing the marker protein mCherry.
D depicts the genome of the MVA-H5-sfMR recombinant virus that is evaluated as H5N1 vaccine 
candidate in the phase I/IIa clinical trial described here. The immunocytochemistry picture shows a 
plaque resulting of MVA-H5-sfMR infection in CEf cells. The staining shows H5 antigen expression, 
for this purpose an H5-specific mouse monoclonal antibody (IgG2a) was used. The Western blot lane 
depicts the influenza virus A/Vietnam/1194/04 HA0 protein (and cleavage products HA1 and HA2) 
in cell lysates of MVA-H5-sfMR infected baby hamster kidney cells (BHK-21 cells). The same mouse 
monoclonal antibody was used as for the immunocytochemistry staining.
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Appendix 3. Seroprotection rates against H5N1 viruses from antigenically distinct clades 
Seroprotection (antibody titers of >40 against: H5N1 influenza A/Turkey/Turkey/1/2005 virus 
(clade 2.2) and the transmissible variant of the H5N1 influenza A/Indonesia/5/2005 virus (clade 
2.1) are described here for the individuals in groups 1,2,5 and 6 after boost immunization.
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Appendix 2. Seroconversion and seroprotection against homologous and heterologous H5N1 virus 
influenza viruses after boost immunization
Time after 1st 
immunization
Time after Boost immunization
1 year 4 weeks
A/Vietnam/1194/04 A/Indonesia/5/05
Group Hi Vn Hi Vn
1
Single shot
MVA-H5-sfMR
108 pfu
Seroconversion*
Im
m
un
iz
ati
on N=
5 100% (5) 100% (5) 100% (5) 100% (5)
Seroprotection 100% (5) 100% (5) 100% (5) 100% (5)
2
Single shot
MVA-H5-sfMR
107 pfu
Seroconversion
N=
7 100% (7) 100% (7) 100% (7) 86% (6)
Seroprotection 100% (7) 86% (6) 100% (7) 86% (6)
5
Two shot
MVA-H5-sfMR
108 pfu
Seroconversion
Im
m
un
iz
ati
on N=
6 100% (6) 100% (6) 83% (5) 83% (5)
Seroprotection 100% (6) 100% (6) 83% (5) 67% (4)
6
Two shot
MVA-H5-sfMR
107 pfu
Seroconversion
N=
9 89% (8) 100% (9) 89% (8) 78% (7)
Seroprotection 89% (8) 100% (9) 89% (8) 67% (6)
* Seroconversion is cumulative to 20 weeks. A subject that was seroconverted on 4 weeks after the first 
immunization is accounted as seroconverted on 8 weeks and 20 weeks also. The numbers in parenthesis 
after the percentages are the absolute numbers of subjects for seroconversion and seroprotection.
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SUMMARIZING DISCUSSION 
The present thesis addresses the impact of acute viral infections in paediatric patients 
admitted to intensive care. Special attention is given to disease symptoms and signs, 
impact of underlying disease, and options for diagnosis and prevention of recently 
discovered respiratory virus infections, re-emerging dengue, and emerging avian 
influenza virus (H5N1). In this chapter the main findings are reviewed and discussed in 
the light of current clinical practice and future perspectives for improvement of clinical 
care.
Detection of previously unknown viruses has rapidly increased with the advent of 
random amplification and next-generation sequencing (NGS) technologies. Many 
recently discovered human respiratory viruses arose from the animal world and have, 
since crossing the species barrier to humans, adapted to the new species, eventually 
resulting in efficient human-to-human infection (62,236,237). Although new viruses 
are usually detected in individuals with clinical disease, upon detection, it is usually 
not clear to what extent the newly discovered virus is indeed associated with clinical 
manifestations in different age groups. The discovery of human metapneumovirus 
(HMPV, in 2001) was the first in a row to shed new light on new causes of bronchiolitis in 
paediatric patients, which until then was predominantly thought to be associated with 
the well-established viral pathogen RSV (4,27,47). Human coronavirus NL63 (HCoV-NL63) 
was discovered in 2004 and has since been related to acute respiratory tract infections 
(ARTI) (28,238,239). In 2005 human bocavirus (HBoV) was described in patients with 
respiratory complaints, while follow-up studies reported that HBoV was also associated 
with asymptomatic infections (113,240,241). Currently, four HBoV genotypes (HBoV 
1-4) have been identified in humans known to cause mostly mild respiratory or gastro-
intestinal disease (114).
In an attempt to assess the pathogenic potential of the recently discovered respiratory 
viruses in children, we studied paediatric patients with severe respiratory illness for the 
presence of these recently discovered respiratory viruses (Chapter 2 and Chapter 3). 
We first studied paediatric patients who had tested positive for HBoV by RT-PCR and 
had been  admitted to paediatric intensive care unit (PICU) excluding those with viral 
and bacterial co-infections. Pivotal to our approach was the addition of NGS data to the 
clinical and conventional laboratory data. NGS is a novel molecular method that among 
many other applications is currently also used to discover viruses. A major advantage 
of this method is that it bypasses the need to culture a virus, as not all viruses can be 
isolated in vitro. HBoV is a clear example of a virus that could not be isolated in vitro at 
the moment of discovery, and would probably not have been detected without NGS 
Processed on: 20-6-2016
503421-L-bw-Moesker
Summarizing Discussion 113
7
technologies (113). In addition, NGS assays may even be expected to eventually replace 
RT-PCR based diagnostic tools in the future, because of their ability to also detect 
modified known viruses (33,134). In our study we used NGS besides our routine RT-
PCR, since RT-PCR uses more or less fixed primer sets to detect viral pathogens. Thus 
the aim was to identify all viruses putatively present in the samples. We showed that 
HBoV without any detectable co-infection could cause severe acute respiratory tract 
infection (SARI) in paediatric patients requiring intensive care (Chapter 2). Moreover, we 
analysed the viral load of HBoV in these patients in which only HBoV could be detected 
and found significantly lower Ct-values (inversely related to viral loads) in these severely 
ill patients, compared to paediatric patients with viral co-infections. Therefore we 
concluded that HBoV in the absence of other detectable pathogens can cause SARI in 
children. Based on the abundant HBoV detection in children with either respiratory or 
gastro-intestinal complaints worldwide, the development of intervention strategies may 
have to be considered (118,241–247). Antiviral treatment of severely ill patients, with or 
without underlying disease, could reduce length of intensive care stay, hospital stay and 
improve patient outcome and would therefore be indicated if available. HBoV can now 
be cultured, which gives us the opportunity to start in vitro tests on possible antiviral 
treatment strategies (248–250).
The next step could be to consider vaccination against HBoV, although this should be 
subject to a thorough evaluation according to stringent scrutiny by industry and advisory 
bodies like Health Councils (251). The name HBoV (human bocavirus) is derived from 
bovine parvovirus and minute virus of canines, which are genetically closely related to 
HBoV and members of the parvovirus family: Parvoviridae (113). Bocaviruses can cause 
severe disease in different mammalian species, including humans and dogs (133,252). 
Dogs and cats are currently being vaccinated against another member of this family: 
canine parvovirus (CPV) and cats against feline parvovirus (FPV), which both may cause 
severe and even fatal disease in the respective species (253,254). The availability of 
registered safe and effective veterinary vaccines for members of this family, indicates 
that also the development of vaccines against HBoV might be feasible.
As a follow up to our HBoV study we also addressed the causative role of other recently 
discovered respiratory viruses, such as HMPV and HCoV-NL63 in children with severe 
respiratory disease admitted to PICU or medium care (MC), and compared their presence 
with those of longer known respiratory viruses such as RSV, human rhinovirus (HRV) and 
parainfluenza viruses (PIV) (Chapter 3 and Figure 1). Essential to our approach again was 
to the best of our possibilities; exclude known viral and bacterial co-infections. Virus 
infections were only considered to be associated with a single virus when other respiratory 
viruses tested negative with RT-PCR (fifteen viruses tested for). Bacterial co-infections 
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were considered absent or unlikely based on low C-reactive protein (CRP) levels (CRP ≤ 40 
mg/l), as CRP-levels are frequently used in clinical settings to help differentiate between 
viral infections and bacterial infections (137,173). In addition, we included bacterial test 
results performed on sputum, whenever available. These studies showed that the ‘big 
six’ of respiratory viruses in paediatric patients admitted to intensive care or medium 
care are RSV, HRV, influenza A virus, HBoV, PIV-3 and HMPV. However the longer known 
respiratory viruses (RSV and HRV) are still the leading causes of severe disease, although 
newly discovered viruses like HBoV and HMPV were also detected after exclusion of 
viral co-infections and bacterial co-infections, although numbers of HMPV detection 
were relatively low in our study compared to other studies (4,19,20,39). Overall, both 
our and other studies emphasize the importance of respiratory viruses in paediatric 
patients. In the pneumococci vaccination era, it is becoming clear that respiratory 
viruses appear to be at least as important as bacterial pathogens as causes of severe 
disease of previously healthy children and children with underlying medical conditions 
(2,4,39,47,127,128,187). In Chapter 3 we reported on 68 patients with underlying 
disorders admitted to PICU and MC. Current guidelines advice to vaccinate children with 
underlying disorders against influenza and to passively immunize premature infants 
(gestational age < 32 weeks) against RSV (46,255). When new intervention strategies 
become available for other respiratory viruses, these patients should be considered for 
prevention or therapy with priority.
This thesis also deals with the possible role of emerging and re-emerging viruses as a 
cause of severe disease in paediatric patients with underlying disorders. Therefore we 
studied the clinical impact of dengue virus (DENV) infection in patients with underlying 
disorders during the dengue outbreak in Curaçao that took place during the rainy season 
from 2010 to 2011. In total 1822 serologically confirmed cases were reported and four 
deaths. In these studies we identified two patients with DENV infection and underlying 
Figure 1. Single respiratory virus infections in paediatric patients admitted to intensive care and 
medium care at the Erasmus MC-Sophia over a 5-year period (2007-2012).
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sickle cell disease or sickle cell anaemia. Chapter 4 describes the case histories of these 
patients. Both patients died, despite intensive treatment, which led us to hypothesize 
that extensive endothelial cell damage caused by DENV infection and sickled erythrocytes 
characteristic of sickle cell disease is a fatal combination. Although DENV prevention and 
control today solely depends on effective vector control measures (11), patients with 
underlying sickle cell disease or sickle cell anaemia should probably be considered in the 
future among the high-risk groups for vaccination or specific treatment.
Controlling paediatric respiratory viral infections from primary through tertiary care is 
dependent on currently available intervention strategies, which include prevention, early 
detection and treatment. Although the most cost-effective way to prevent respiratory 
viral infections would be the implementation of vaccination strategies, currently only 
for influenza preventive vaccines are available and their universal paediatric use beyond 
well-defined risk groups is still a matter of debate (256–258). In spite of decades of major 
research efforts, no effective vaccines against RSV and HRV are available, whereas vaccine 
research into the newly discovered viruses is still in its infancy (59,80,259). Therefore to 
prevent nosocomial infections in the respective hospital settings, intervention strategies 
for respiratory viral infections are largely limited to targeted hygienic and epidemiological 
measures. As recently reported by Kulkarni et al. spontaneously breathing and ventilated 
infants infected with RSV spread large amounts of RSV in aerosols, which remain airborne 
and infectious over significant periods of time and could be inhaled into the lower 
respiratory airways by other patients admitted to the ward and cause infection (260). 
This is a serious risk especially for immune-compromised and other high-risk paediatric 
patients.
The number of immune-compromised patients and patients with other underlying 
disorders tends to increase due to advances in medical treatment options. Therefore 
rapid and reliable diagnostic facilities are of utmost importance to identify respiratory 
viral infections as soon as they emerge in the hospital setting. Currently, several 
diagnostic methods are available for this purpose, including: RT-PCR, viral culture, 
direct immunofluorescence (D-If), and rapid antigen detection tests (RADTs). In this 
thesis we focused on the evaluation of the value for the tertiary hospital care setting of 
commercially available RADTs for influenza A virus and RSV as an alternative to the gold 
standard RT-PCR based methods (Chapter 5). We studied the diagnostic performance 
of a influenza A virus rapid test in our tertiary care paediatric hospital over a period 
of almost 8-years that included the influenza H1N1 pandemic that started in 2009. 
However the test results were rather disappointing as we showed that sensitivity and 
positive predictive value (PPV) of the assay evaluated were relatively low (69% and 55% 
respectively), when compared with the gold standard RT-PCR. Therefore we would not 
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encourage the use of such first generation RADTs in a tertiary care setting, and either 
use newer generations RADTs with better performances or only gold standard RT-PCR 
methods. In contrast, the higher sensitivity and PPV of a RADT for RSV rendered this 
rapid test more useful, albeit still less sensitive than RT-PCR in our tertiary care setting. 
The downside of gold standard RT-PCR is the relatively long time (6-24 hours) between 
sample collection and availability of test results (200). This makes current RT-PCR formats 
less useful for admission decision-making and calls for the availability of faster methods. 
Indeed, currently new rapid point-of-care PCRs are being developed and implemented 
with a shorter turnaround time (201–206).
Although respiratory viruses can be detected with advanced diagnostic methods, 
clinicians are still largely empty-handed when it comes to specific antiviral treatment 
options. Treatment of respiratory virus infections in the paediatric setting is largely 
limited to symptomatic treatment as -with the exception of influenza viruses- for these 
virus infections limited or no antiviral treatment options are available (46,59,261). 
Currently, several antivirals are being tested for RSV and other respiratory virus 
infections, including: immunoglobulins, siRNA-interference, fusion inhibitors and small 
molecules (46).
finally, an important aspect of respiratory virus infections is the threat by, as well as 
preparedness for a newly emerging pandemic influenza virus. Considering the paediatric 
population not only as a potential high-risk group, but also a reservoir for viral spread, it 
is highly recommended to pay special attention to this group in pandemic preparedness 
programs, as was practised e.g. in The Netherlands during the last influenza pandemic 
that started in 2009 (262,263). In the context of pandemic preparedness a clinical trial 
phase 1/2A study was successfully conducted to test a vaccine-candidate based on 
the Modified Vaccinia virus Ankara (MVA) vector platform expressing the HA of avian 
influenza virus (H5N1), in young adult volunteers as a proof of principle (Chapter 6). The 
data clearly highlighted that priming the population with a MVA that expresses the HA 
of the influenza virus (H5N1) from Vietnam (VN/1194/04) not only provides protective 
antibody responses against the homologous virus strain, but upon booster immunization 
also against a distant influenza virus (H5N1) from Indonesia (IND/5/05). This illustrates 
that this vaccination strategy may be useful to heterologously prime the human 
population with a vaccine derived from a distantly related virus of the same subtype, at 
times of an influenza pandemic threat.
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Future perspectives & concluding remarks
Viruses are here to stay and will continue to cause disease in paediatric patients. Despite 
advanced diagnostic methods, about 10-20% of patients with acute respiratory disease 
remain undiagnosed, even when using state-of-the-art technology. This probably leaves 
the door open for the discovery of new pathogens (4). 
Moreover, although the complex interplay between viral and bacterial co-infections has 
been studied widely, the exact basis of their mutual interactions within the host is still 
far from understood (264,265). Using state-of-the-art technologies, new insights into 
the bacterome and virome as well as their interplay with the host will surface and help 
us better understand this interaction between both groups of pathogens within and 
with the human host. Antibiotic resistance is a worldwide problem, and better studying 
and managing the interplay between bacterial infections and viral infections in the host 
could probably reduce antibiotic administration considerably. The need for antibiotics 
may therefore be expected to further be reduced with the future development and use 
of novel generations of antivirals and antiviral vaccines.
Virus infections may also be involved in the development of certain forms of chronic 
disease, causing activation or altering of host immunity. The role of previous virus 
infections in the pathogenesis of complex diseases such as type 1 diabetes, asthma and 
inflammatory bowel disease will further have to be elucidated and may lead to a better 
understanding of their pathogeneses and therefore to novel interventions for these 
diseases.
Worldwide eradication programs encouraged by WHO that target vaccine preventable 
diseases have been applauded but also raise new concerns. With our current knowledge 
of the human-animal interface, it is not unlikely that animal viruses related to the 
eradicated viruses, have a tendency to cross the animal-human interface when cross-
reactive immunity is waning in the population. Perhaps the most significant example 
is the re-emergence of monkey- and cowpox virus infections in humans after smallpox 
eradication and subsequent abolishment of smallpox vaccination (266). A similar threat 
may come from animal morbilliviruses after the envisaged eradication of measles from 
humans (267,268). Therefore active surveillance programs in animals and humans alike, 
as well as the development of vaccination strategies for such post-eradication events 
should be considered essential elements of future virus eradication strategies.
finally, intervention programmes for respiratory and other viral threats should be 
developed in ‘peace-time’, based on the development of more efficient, and most 
importantly, more rapid vaccine development and production platforms for rapid ‘war-
time’ response to future influenza and other epidemic and pandemic viral threats (269).
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ENGlISH SUMMARY
The present thesis describes studies on different aspects of acute respiratory tract 
infections (ARTIs) caused by viruses in paediatric patients admitted to intensive care. 
Special attention is given to disease symptoms and signs, impact of underlying disease, 
and options for diagnosis and prevention of recently discovered respiratory virus 
infections, re-emerging dengue, and emerging avian influenza virus (H5N1). In this 
chapter the main findings are summarized.
Chapter 1 gives an overview of virus infections in paediatric patients, starting by giving an 
overview of ARTIs caused by respiratory viruses and proceeding to discuss the diagnostic 
and prevention methods of these viruses. In addition newly discovered viruses, emerging 
and re-emerging virus infections are described in more detail.
Virus discovery
Detection of previously unknown viruses has rapidly increased with the advent of 
random amplification and next-generation sequencing (NGS) technologies (62,236,237). 
Although new viruses are usually detected in individuals with clinical disease upon 
detection, as described for avian influenza virus (H5N1), severe acute respiratory 
syndrome coronavirus (SARS-CoV) and Middle-East respiratory syndrome coronavirus 
(MERS-CoV) for example, it is usually not clear to what extent the newly discovered 
virus is indeed associated with clinical manifestations in different age groups (30,31). 
The discovery of human metapneumovirus (HMPV) in 2001 was the first in a row to 
shed new light on new causes of bronchiolitis in paediatric patients, which until then 
was predominantly thought to be associated with the well-established viral pathogen 
respiratory syncytial virus (RSV) (4,27,47). Human coronavirus Nl63 (HCoV-Nl63) was 
discovered in 2004 and since has been related to ARTI (28,238,239). In 2005 human 
bocavirus (HBoV) was described in patients with respiratory complaints, while follow-up 
studies reported that HBoV was also associated with other disease manifestations and 
asymptomatic infections (113,240,241).
Respiratory viruses
The present thesis describes studies on different aspects of ARTIs caused by respiratory 
viruses in paediatric patients. It is not uncommon for a child under the age of five to 
suffer up to six febrile ARTI episodes per year (12–14). Moreover, ARTIs are the most 
important reason for emergency department visits and hospitalization of young children 
and are often caused by respiratory viruses (15–18).
In an attempt to assess the pathogenic potential of the recently discovered respiratory 
viruses in children, we studied paediatric patients with severe respiratory illness for the 
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presence of these recently discovered respiratory viruses (Chapter 2 and Chapter 3). 
We first studied HBoV real-time reverse transcriptase polymerase chain reactions (RT-
PCR) positive samples from paediatric patients admitted to paediatric intensive care unit 
(PICU) excluding those with viral and bacterial co-infections. Pivotal to our approach was 
the addition of next-generation sequencing (NGS) data to the clinical and conventional 
laboratory data. NGS is a novel molecular method that among many other applications 
is currently also used to discover viruses. In our study we used NGS besides our routine 
RT-PCR, since RT-PCR uses more or less fixed primer sets to detect viral pathogens. Thus 
the aim was to identify all viruses putatively present in the samples. We showed that 
HBoV without any detectable co-infection could cause severe acute respiratory tract 
infection (SARI) in paediatric patients requiring intensive care (Chapter 2). Therefore we 
concluded that HBoV in the absence of other detectable pathogens could cause severe 
respiratory disease in children.
As a follow up to our HBoV study we also addressed the causative role of other recently 
discovered respiratory viruses, such as HMPV and HCoV-NL63 in children with severe 
respiratory disease admitted to PICU or medium care (MC). We compared their presence 
with those of longer known respiratory viruses such as RSV, human rhinovirus (HRV), and 
parainfluenza viruses (PIVs) (Chapter 3). Essential to our approach again was to the best 
of our possibilities, exclude known viral and bacterial co-infections. Severe respiratory 
tract infection was only considered to be associated with a single virus when other 
respiratory viruses tested negative with RT-PCR (fifteen viruses tested for). Bacterial 
co-infections were considered absent or unlikely based on low C-reactive protein (CRP) 
levels (CRP ≤ 40 mg/l), as CRP-levels are frequently used in clinical settings to help 
differentiate between viral infections and bacterial infections (137,173). In addition, we 
included bacterial test results performed on sputum, whenever available. Finally, we 
identified 40 patients admitted to MC and 44 patients admitted to PICU with a single 
respiratory virus infection. This study showed that the ‘big six’ of respiratory viruses in 
paediatric patients admitted to PICU or MC are RSV, HRV, influenza A virus, HBoV, PIV-3 
and HMPV. Overall, our studies emphasize the importance of these respiratory viruses 
as sole causative agents of SARIs in children.
Controlling paediatric respiratory viral infections from primary through tertiary care 
is dependent on currently available intervention strategies, which include prevention, 
early detection and treatment. Although the most cost-effective way to prevent 
respiratory viral infections would be the implementation of vaccination strategies, 
currently only preventive vaccines are available for influenza and their universal 
paediatric use beyond well-defined risk groups remains a matter of debate (256–258). 
Moreover, passive immunisation against RSV is currently being used for high-risk infants 
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only. In spite of decades of major research efforts, no effective vaccines against RSV and 
HRV are available, whereas vaccine research into the newly discovered viruses is still 
in its infancy (59,80,259). Epidemiological studies, such as presented in Chapter 2 and 
Chapter 3, describing the prevalence of different respiratory viruses in specific patients 
groups provide valuable information for when specific vaccines and antiviral treatments 
become available.
Emerging and re-emerging viruses
This thesis also deals with the possible role of emerging and re-emerging viruses as a 
cause of severe disease in paediatric patients with underlying disorders. Dengue virus 
(DENV) is a re-emerging virus that circulates in tropical and subtropical areas around the 
world and is transmitted by the bite of infected mosquitoes of the Aedes species. There 
are four DENV serotypes (1-4). Yearly, 390 million people are at risk to become infected 
with DENV, many of them are children. Seventy-five per cent do not develop clinical signs 
or symptoms, 25% do develop symptoms, of which a small percentage develop severe 
DENV infection. Several risk factors have been determined for patients to develop severe 
DENV infection, such as a previous infection with a different DENV serotype or underlying 
disorders. We studied the clinical impact of DENV infection in patients with underlying 
disorders during the dengue outbreak in Curaçao that took place during the rainy season 
from 2010 to 2011. In total 1822 serologically confirmed cases were reported and four 
deaths. In these studies we identified two patients with DENV infection and underlying 
sickle cell disease or sickle cell anaemia. Chapter 4 describes the case histories of these 
patients. Both patients died, despite intensive treatment, which has not been described 
before in Curaçao. Recently, the first dengue vaccine, Dengvaxia (CYD-TDV) by Sanofi 
Pasteur, was registered in several countries for use in individuals between 9-45 years of 
age living in endemic areas (11,106,109). Soon recommendations of the WHO will follow 
concerning immunization with this new dengue vaccine. Patients with underlying sickle 
cell disease or sickle cell anaemia should probably be considered among the high-risk 
groups for vaccination or specific treatment when these become available.
Virus diagnostics
Currently, several diagnostic methods are available to detect respiratory viruses, 
including: RT-PCR, viral culture, direct immunofluorescence (D-If), and rapid antigen 
detection tests (RADTs). Identification of respiratory viruses is important for disease 
management, as the presence of these infections may require specific treatment (i.e. 
oseltamivir) and hospital containment measures. Gold standard RT-PCR is not performed 
in all hospitals, as it requires a molecular diagnostic laboratory with specialized 
personnel and equipment. Instead, RADTs are often used as these assays are easier and 
cheaper to perform and less time-consuming (15-30 minutes vs 6-24 hours) (43–45). In 
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the present thesis we evaluated the diagnostic performance of commercially available 
RADTs BinaxNOW® for influenza A&B viruses and RSV in our tertiary care paediatric 
hospital over a period of almost 8-years (Chapter 5). We analysed the results obtained 
with fresh nasal washings from children between 0-5 years who visited our emergency 
department or were admitted to our hospital. The test results for influenza A virus were 
rather disappointing with a sensitivity and positive predictive value (PPV) of 69% and 
55% respectively, when compared with RT-PCR. In contrast, the higher sensitivity and 
PPV of a RADT for RSV rendered this rapid test more useful, albeit still less sensitive than 
RT-PCR in our tertiary care setting (79% and 97% respectively). Based on our results we 
stopped using both rapid tests and currently use rapid PCR-based tests for detection of 
influenza virus and RSV.
Prevention
An important aspect of respiratory virus infections is the threat by, as well as preparedness 
for newly emerging pandemic influenza viruses. In Chapter 6 we describe a clinical 
trial phase 1/2A study in 79 young adult volunteers, that was successfully conducted 
to test a vaccine-candidate based on the Modified Vaccinia virus Ankara (MVA) vector 
platform expressing the haemagglutinin (HA) gene of avian influenza virus (H5N1). The 
safety of the use of an MVA-vector was shown, and the data clearly highlighted that 
priming the population with a MVA that expresses the HA of the influenza virus (H5N1) 
from Vietnam (VN/1194/04) not only provides protective antibody responses against 
the homologous virus strain, but upon booster immunization of 27 volunteers, also 
against a distant influenza virus (H5N1) from Indonesia (IND/5/05). This illustrates that 
this vaccination strategy may be useful to heterologously prime the human population 
with a vaccine derived from a distantly related virus of the same subtype, at times of an 
influenza pandemic threat.
The last chapter of this thesis (Chapter 7) comprises an overview of its findings, together 
with a general discussion and future perspectives.
In conclusion this thesis addresses the disease burden of more recently discovered 
respiratory viruses and their role in severe disease in paediatric patients. Moreover, 
the re-emerging DENV is described in relation to patients with underlying disease. In 
addition, we describe the diagnostic performance of rapid antigen detection tests for 
RSV and influenza viruses in our hospital. finally, a study with a new prevention method 
against the emerging avian influenza virus (H5N1), making use of a vectored candidate 
vaccine, is described.
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NEDERlANDSE SAMENVATTING
Dit proefschrift beschrijft studies naar verschillende aspecten van ernstige virale 
luchtweginfecties in kinderen. Het voorkomen van reeds langer bekende respiratoire 
virussen zoals respiratory syncytial virus (RSV) en influenza virus (griepvirus) wordt 
vergeleken met dat van meer recent ontdekte virussen zoals human metapneumovirus 
(HMPV) en humaan bocavirus (HBoV). Er wordt vooral aandacht besteed aan klachten 
die geassocieerd kunnen zijn met deze respiratoire virusinfecties, het eventuele 
onderliggend lijden van deze patiënten en naar de mogelijkheden van diagnostiek 
om deze respiratoire virussen aan te tonen. Daarnaast worden twee fatale gevallen 
van dengue beschreven in patiënten met onderliggend lijden. Het proefschrift sluit af 
met een studie naar een preventiemethode voor het opkomende aviair influenza virus 
(H5N1) (vogelgriep).
De introductie, beschreven in hoofdstuk 1, geeft een overzicht van virale infectieziekten 
bij kinderen. Er wordt ingegaan op acute bovenste en onderste luchtweginfecties 
veroorzaakt door respiratoire virussen. Daarnaast worden de huidige diagnostiek en 
preventiemethoden voor respiratoire virussen beschreven. Tevens is er in dit hoofdstuk 
aandacht voor opkomende virusinfecties zoals coronavirussen (o.a. SARS- en MERS 
coronavirussen) en virussen overgedragen door muggen zoals denguevirus, Chikungunya 
virus en Zika virus.
Recent ontdekte virussen
Met de opkomst van geavanceerde detectiemethoden voor virussen op basis van 
het genetisch materiaal van het virus, is recent een aantal nieuwe virussen ontdekt 
(62,236,237). Vaak worden deze nieuwe virussen gevonden bij patiënten met ernstige 
klachten, zoals patiënten met aviaire influenza, SARS en MERS, maar voor sommige 
virussen is het niet altijd direct duidelijk of deze klachten ook daadwerkelijk veroorzaakt 
worden door het nieuw ontdekte virus en wat de rol van deze virussen in de gehele 
populatie is (30,31). In 2001 werd HMPV ontdekt bij jonge kinderen met een ernstige 
bronchiolitis (27). Dit ziektebeeld wordt meestal veroorzaakt door RSV, maar bleek nu 
ook door HMPV te kunnen worden veroorzaakt (4,27,47). In 2004 werd het human 
coronavirus NL63 (HCoV-NL63) ontdekt. Dit virus wordt sindsdien vaak gevonden bij 
patiënten met luchtweginfecties (28,238,239). HBoV werd voor het eerst beschreven 
in 2005 (113). Dit virus werd gevonden in patiënten met respiratoire klachten, maar 
vervolgstudies beschreven ook HBoV geïnfecteerde patiënten met andere, of zelfs in het 
geheel geen klachten (113,240,241).
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Respiratoire virussen
In dit proefschrift wordt aandacht besteed aan ziektebeelden veroorzaakt door 
respiratoire virussen. Kinderen jonger dan vijf jaar kunnen tot wel zes keer per jaar 
last hebben van een acute luchtweginfectie (12–14). Mede daardoor zijn acute 
luchtwegproblemen bij kinderen jonger dan 1 jaar de meest voorkomende reden van 
huisarts-consultatie en ziekenhuis- opname (15–18). Virussen zijn meestal de oorzaak 
van acute luchtwegproblemen, maar welke van de recent ontdekte virussen al dan niet 
ernstige klachten kunnen veroorzaken bij paediatrische patiënten is op dit moment nog 
niet duidelijk. In een groot deel van dit proefschrift ligt de nadruk op onderzoek naar de 
rol van deze recent ontdekte respiratoire virussen.
Een voorbeeld van een recent ontdekt virus waarvan nog niet duidelijk is of het 
daadwerkelijk ernstige ziekte kan veroorzaken is HBoV. Onderzoek naar dit virus 
wordt beschreven in hoofdstuk 2. Wij identificeerden ernstig zieke patiënten over een 
periode van vijf jaar die positieve testresultaten te zien gaven in de HBoV RT-PCR. RT-
PCR is momenteel de gouden standaard om respiratoire virussen aan te tonen met 
specifieke primers om een bepaald gedeelte van het genetische materiaal van het virus 
te amplificeren. Deze methode wordt meer en meer gebruikt voor virusdiagnostiek. De 
geselecteerde patiënten waren opgenomen op de Intensive Care unit (IC) met ernstige 
luchtweginfecties omdat zij respiratoir-insufficiënt waren en beademd moesten worden. 
Wij ontwikkelden een algoritme waarmee bacteriële en virale co-infecties zoveel mogelijk 
werden uitgesloten. Op basis hiervan bleek dat HBoV kinderen inderdaad ernstig ziek 
kan maken in afwezigheid van bacteriële en virale co-infecties. Wij gebruikten hiervoor 
onder andere next-generation sequencing, een methode om bekende, onbekende en 
veranderde virussen op basis van hun genetische materiaal aan te tonen. Dit deden we 
als aanvulling op de reeds uitgevoerde RT-PCR testen om vijftien bekende virussen op 
te sporen.
Als een vervolg op deze studie hebben we ook de rol bestudeerd van andere recent 
ontdekte virussen zoals HMPV en HCoV-Nl63 bij het ontstaan van ernstige ziekte bij 
kinderen in afwezigheid van bacteriële en virale co-infecties (hoofdstuk 3). Hierbij 
vergeleken wij het voorkomen van deze virussen met die van de reeds langer bekende 
virussen zoals RSV, humaan rhinovirus (HRV) en parainfluenza virussen (PIV). We hebben 
twee patiëntengroepen met elkaar vergeleken, de eerste groep was opgenomen op 
de medium care (MC) en de tweede groep patiënten op de IC. Door middel van het 
nauwkeurig bestuderen van de medische dossiers, virologische, bacteriologische en 
andere laboratoriumuitslagen, vonden wij uiteindelijk 40 patiënten opgenomen op 
de MC en 44 patiënten opgenomen op de IC met als enige verwekker één respiratoir 
virus. Een bacteriële co-infectie als additionele reden van de ernstige ziekte was 
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onwaarschijnlijk op basis van een laag C-reactief proteïne (CRP ≤ 40 mg/l) en, voor zover 
getest, een negatieve bacteriologische uitslag. CRP is een veel gebruikte bloedwaarde 
om de aanwezigheid van een bacteriële infectie aan te tonen (137,173). Deze studie 
laat zien dat RSV, HRV, influenza A virus, HBoV, PIV-3 en HMPV de meest voorkomende 
respiratoire virussen zijn bij kinderen opgenomen op de MC en IC. Samenvattend laten 
beide studies zien dat naast de reeds langer bekende respiratoire virussen, recent 
ontdekte virussen zoals HBoV, HMPV en HCoV-Nl63 ook ernstige respiratoire ziekte 
kunnen veroorzaken bij kinderen.
Ondanks vele jaren onderzoek naar geschikte preventiemethoden en antivirale 
therapieën zijn deze tot dusver niet beschikbaar voor de meeste respiratoire virussen. 
Hoewel vaccineren de meest kostenefficiënte manier is om virale luchtweginfecties te 
voorkomen is er momenteel alleen een effectief vaccin beschikbaar tegen influenza. Het 
gebruik van dit vaccin wordt momenteel in Nederland alleen geadviseerd voor kinderen 
in bepaalde risicogroepen en het universele gebruik van dit vaccin voor alle kinderen is 
nog onderwerp van discussie (256–258). Daarnaast is er passieve immunisatie tegen RSV 
beschikbaar voor zuigelingen in bepaalde risicogroepen. De ontwikkeling van andere 
respiratoire virusvaccins en antivirale middelen staat helaas nog in de kinderschoenen 
(59,80,259). Epidemiologische studies, zoals beschreven in hoofdstuk 2 en 3, naar het 
voorkomen van de verschillende respiratoire virussen in patiëntengroepen met ernstige 
respiratoire klachten zijn daarom van groot belang om wanneer deze vaccins of antivirale 
middelen beschikbaar komen, de te vaccineren risicogroepen te identificeren.
Opkomende virussen
Het proefschrift besteedt verder aandacht aan opkomende virussen zoals denguevirus 
(DENV) en aviaire influenza virus (H5N1). DENV infecties komen wereldwijd voor in 
tropische en subtropische gebieden en DENV wordt overgedragen door Aedes muggen. 
Er zijn vier serotypes van het DENV (DENV 1-4). Jaarlijks lopen ongeveer 390 miljoen 
mensen het risico om geïnfecteerd te worden met het DENV, een groot aantal hiervan 
zijn kinderen. De meeste mensen die geïnfecteerd worden met het DENV ontwikkelen 
geen of nauwelijks klachten. Een kwart van hen ontwikkelt wel klinische symptomen 
en daar weer een klein deel van ernstige symptomen. Welke patiënten uiteindelijk 
ernstige ziekte ontwikkelen kan gerelateerd zijn aan verschillende oorzaken. Bekende 
risicofactoren voor een ernstige DENV infectie zijn o.a. een eerdere infectie met een 
ander DENV serotype of onderliggend lijden. Tijdens een dengue-uitbraak in 2010-2011 
op Curaçao hebben wij de impact van DENV bestudeerd in patiënten met onderliggend 
lijden. Tijdens deze uitbraak werden 1822 serologisch bevestigde dengue patiënten 
en vier sterfgevallen gerapporteerd. In hoofdstuk 4 beschrijven wij twee patiënten 
met sikkelcelziekte en een ernstige DENV infectie. Ondanks intensieve behandeling 
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overleden beide patiënten. Het voorkomen van gevallen van sikkelcelziekte en DENV 
infectie was nog niet eerder beschreven op Curaçao. Recente studies met een kandidaat 
dengue vaccin hebben laten zien dat het vaccin Dengvaxia (CYD-TDV) van Sanofi Pasteur 
effectief en veilig is (106,109). Dit vaccin is momenteel in een aantal landen waar DENV 
endemisch voorkomt geregistreerd voor gebruik bij kinderen en volwassenen tussen 
de 9-45 jaar (11). Verdere aanbevelingen van de WHO over het gebruik van dit vaccin 
voor bepaalde risicogroepen zullen snel volgen. Zoals beschreven in onze studie vormen 
patiënten met sikkelcelziekte zeker een risicogroep waarvoor mogelijk dit vaccin of 
andere vaccins beschikbaar zouden moeten komen.
Virusdiagnostiek
In de laatste jaren zijn veel nieuwe detectiemethoden ontwikkeld om virusinfecties aan 
te tonen dan wel uit te sluiten. Het belang van het juist diagnosticeren van een virale 
infectie heeft invloed op het beleid voor de patiënt en het ziekenhuis. Zo kan er worden 
besloten om een patiënt met een positieve uitslag voor RSV of influenza geen antibiotica 
te geven en eventueel te starten met oseltamivir indien influenza virus is aangetoond. 
Daarnaast is het belangrijk om virusverspreiding te voorkomen door patiënten te 
isoleren en strikte hygiënische maatregelen te treffen voor het verzorgend personeel en 
andere patiënten.
Er zijn momenteel verschillende diagnostische methoden voor virusdetectie beschikbaar 
zoals de reeds eerder beschreven RT-PCR, maar ook virusisolatie in vitro, en methoden 
om snel een virus-antigeen aan te tonen zoals met directe immunofuorescentie 
(D-If) en antigeendetectie doormiddel van de zogenoemde sneltesten. RT-PCR (de 
goudenstandaard voor virusdiagnostiek) wordt niet in elk ziekenhuis uitgevoerd omdat 
met de huidig tests een moleculair diagnostisch laboratorium met gespecialiseerd 
personeel beschikbaar moeten zijn. In plaats hiervan worden veelal sneltesten gebruikt, 
deze hebben als voordeel dat ze makkelijk te gebruiken zijn (geen moleculair diagnostisch 
laboratorium nodig) en veel sneller een uitslag geven dan bijvoorbeeld RT-PCR (15-30 
minuten vs 6-24 uur) (43–45).
In dit proefschrift hebben we de diagnostische waarde en beperkingen van zulke 
sneltesten die in ons ziekenhuis (een tertiar centrum) werden gebruikt voor de detectie 
van RSV en influenza virus geanalyseerd (hoofdstuk 5). We hebben de uitkomsten van 
vier virus-diagnostische methodes namelijk: RT-PCR, virus kweek, D-If en de sneltesten 
van BinaxNOW® RSV en influenza A&B, over een periode van bijna acht jaar met elkaar 
vergeleken. Hierbij hebben we alleen de uitslagen geanalyseerd van testen gedaan op 
verse neusspoelsels van kinderen jonger dan vijf jaar. Uit deze analyses kwam duidelijk 
naar voren dat de sensitiviteit en positief voorspellende waarde van BinaxNOW® influenza 
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beduidend lager was dan die van de gouden standaard RT-PCR (respectievelijk 69% en 
55%). Hoewel de BinaxNOW® RSV beter presteerde dan de BinaxNOW® influenza, waren 
ook deze uitkomsten minder betrouwbaar dan die van de gouden standaard RT-PCR 
(respectievelijk 79% en 97%). Deze resultaten hebben ertoe geleid dat beide sneltesten 
niet meer routinematig worden gebruikt voor diagnostiek bij kinderen in het Erasmus 
MC-Sophia. Er worden momenteel nieuwe methodes ontwikkeld en gebruikt zoals 
snellere RT-PCR voor het aantonen van RSV en influenza virusantigenen.
Preventie
Het proefschrift eindigt met een hoofdstuk gericht op de preventie van een nieuw 
opkomende virusinfectie middels vaccinatie. In hoofdstuk 6 worden veiligheid en 
effectiviteit van een kandidaat-vaccin tegen het opkomende aviaire influenza virus 
(H5N1) beschreven. In deze studie werd gebruik gemaakt van een gemodificeerd 
pokkenvirus (MVA) als vector, dat het heamaglutinine (HA) van het aviaire influenza virus 
(H5N1) tot expressie brengt. In totaal werden 79 vrijwilligers geïncludeerd waarna een 
gerandomiseerde studie met de relevante controles werd uitgevoerd gebruik makend 
van een kandidaat-vaccin gebaseerd op MVA-H5 dat in een escalerende dosis werd 
toegediend. Na een jaar werden 27 vrijwilligers die eerder gevaccineerd waren met 
het MVA-H5 vaccin nogmaals gevaccineerd (booster). Geen van de vrijwilligers bleek 
ernstige bijwerkingen te vertonen en vrijwilligers die met het MVA-H5 vaccin waren 
gevaccineerd ontwikkelden niet alleen beschermend geachte antistoffen tegen de 
homologe H5 virusstam uit Vietnam (VN/1194/04), maar na booster-vaccinatie een jaar 
later ook tegen de minder verwante H5 virusstam uit Indonesië (IND/5/05). Het veilig 
kunnen gebruiken van de MVA-vector en het boosten van een heterologe antistofrespons 
biedt nieuwe perspectieven voor de ontwikkeling van vaccins tegen andere potentieel 
pandemische influenza-virussen.
Het laatste hoofdstuk van dit proefschrift (hoofdstuk 7) geeft een overzicht van 
alle bevindingen die in het proefschrift zijn beschreven. Deze bevindingen worden 
samengevat en geïnterpreteerd in het licht van de huidige kennis over virusinfecties. Dit 
hoofdstuk eindigt met een overzicht van de laatste ontwikkelingen en aanbevelingen 
voor de toekomst.
Concluderend kan gesteld worden dat dit proefschrift niet alleen aandacht heeft besteed 
aan de rol die recent ontdekte respiratoire virussen spelen bij kinderen, maar ook aan 
bepaalde aspecten van opkomende virussen zoals DENV en aviaire influenza virus 
(H5N1). Tevens is de waarde onderzocht van diagnostische methoden die thans gebruikt 
worden voor het aantonen van respiratoire virussen. Daarnaast is de veiligheid en de 
beschermende waarde van een nieuwe methode van vaccinatie tegen aviaire influenza 
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virus (H5N1) bestudeerd. Het onderzoek beschreven in dit proefschrift heeft derhalve 
bijgedragen aan de kennis over recent ontdekte en opkomende virusinfecties, hun 
bijdrage aan het doen ontstaan van ernstige ziekte bij kinderen en het ontwikkelen van 
nieuwe interventiestrategieën tegen deze infecties. Deze inzichten kunnen een bijdrage 
leveren aan toekomstig onderzoek naar en het doelgericht inzetten van vaccins en 
antivirale middelen gericht op het voorkomen en genezen van deze virusinfecties.
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DANKWOORD
Yes, het is zover, tijd voor het dankwoord! Dit is toch wel het leukste stuk om te schrijven, 
want zonder iedereen die hier genoemd zal gaan worden was dit proefschrift er niet 
gekomen. Natuurlijk zal ik proberen iedereen persoonlijk te bedanken, maar mocht dit 
niet het geval zijn dan doe ik dit graag alsnog via deze weg, heel erg bedankt!
Allereerst, dit proefschrift was er niet geweest zonder de patiënten en hun ouders die 
het mogelijk hebben gemaakt om onderzoek te kunnen doen naar de virus infecties van 
hun kinderen, heel erg bedankt hiervoor.
Ik ga graag verder met het bedanken van mijn promotor: prof.dr. A.D.M.E. Osterhaus. 
Beste Ab, ik weet nog goed dat ik voor het eerst een presentatie van jou bijwoonde in 
2006. Tijdens de Anatomische Les in het Concertgebouw van Amsterdam, georganiseerd 
door het AMC en de Volkskrant, gaf jij een prachtig overzicht over, hoe kan het ook 
anders, mogelijk pandemische griepvirussen. Ik was direct geïntrigeerd en toen ik de 
mogelijkheid kreeg om bij jou te komen werken heb ik deze kans met beide handen 
aangegrepen. Jouw eindeloze interesse en fascinatie voor virussen zijn voor mij een 
enorme bron van inspiratie. Tijdens mijn promotie heb ik echt ontzettend veel van jou 
geleerd. De grote diversiteit van medewerkers bij het Viroscience Lab (dierenartsen, 
artsen, biomedische wetenschappers, epidemiologen, farmacologen, statistici, 
modelleurs, analisten, secretaresses, etc.) die jij bij elkaar hebt gebracht en die uitstekend 
met elkaar samenwerken vind ik bewonderingswaardig en ik vond het geweldig om daar 
deel van uit te mogen maken. Ik heb je verder leren kennen als niet alleen de viroloog 
die ontzettend veel weet over alle virussen, maar ook over Amsterdam, voetbal, wijn, 
wielrennen, nou eigenlijk alles. Je hebt gewoon overal enorm veel verstand van en 
gelukkig wilde je die kennis graag met mij delen!
Natuurlijk ben ik je enorm dankbaar voor het vertrouwen dat jij in mij hebt gehad. Hoewel 
je je kritiek niet onder stoelen of banken stak was deze altijd opbouwend en wist je mij 
ook altijd te enthousiasmeren om het anders en vooral beter te doen. Jouw laudatio 
tijdens het behalen van mijn research master was bijna ontroerend (volgens mij zei je 
iets over ‘de perfecte schoondochter’?!?) en natuurlijk waren er ook de broodnodige 
opmerkingen over het ‘roze’ doktertje.
Tijdens mijn promotie heb ik gelukkig de mogelijkheid gekregen om verschillende landen 
te bezoeken en tijdens ESPID congressen was jij ook altijd van de partij. Hoewel we elkaar 
dan meestal spraken tijdens de borrel of een diner, kan ik mij nog goed herinneren dat jij 
op het laatste moment mijn zorgvuldig voorbereide presentatie in Milaan omgooide, dit 
was even stressen, maar pakte uiteindelijk erg goed uit gelukkig. Ook met het afronden 
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van dit proefschrift was jij de drijvende kracht en ik zal nu het klaar is onze mails en 
telefoontjes gaan missen. Ik wens jou als onderzoeker, buitengewoon bijzonder mens 
en al je fantastische projecten heel veel goeds en ik hoop dat ik nog heel lang veel van 
je mag leren.
Dan was dit proefschrift er ook nooit gekomen zonder de niet aflatende steun van mijn 
copromotor dr. P.L.A. Fraaij. Beste Pieter, wat ben ik blij dat jij mijn copromotor wilde 
zijn! Ik heb enorme waardering voor jouw onuitputtelijke energie, ideeën en kritische 
blik. Ik heb echt heel veel van jou geleerd over het doen van onderzoek, over virussen 
en over de Kindergeneeskunde. Onze dinsdagochtend sessies brachten structuur in mijn 
promotie en waren altijd een perfect moment voor mij om alles te bespreken. Ik weet 
niet goed hoe je altijd tijd voor mij wist vrij te maken ondanks diensten, besprekingen en 
deadlines, maar ik vond het geweldig hoe jij altijd voor mij klaar stond. Natuurlijk wil ik 
Kristel hier ook heel erg voor bedanken, die jou in staat stelde dit te kunnen doen. Jouw 
continue drive om virussen beter op de kaart te zetten voor clinici is een groot voorbeeld 
voor mij. Naast alle noeste arbeid was het ook altijd erg gezellig om tijdens één van de 
vele Viro-borrels of congressen bij te praten. Heel erg bedankt dat jij de afgelopen jaren 
mijn mentor, steun en toeverlaat wilde zijn en ik hoop dat we de nog lopende projecten 
met succes zullen afronden en dat we nog lang met elkaar zullen gaan samenwerken.
Daarnaast gaat mijn dank uit naar de leescommissie prof.dr. R. de Groot, prof.dr. E.C.M. 
van Gorp en dr. A.M.C. van Rossum. Heel erg bedankt dat jullie tijd wisten vrij te maken 
in jullie overvolle agenda’s om dit proefschrift te lezen en te beoordelen. Beste prof.dr. 
R. de Groot, ik ben vereerd dat de voormalig president van de ESPID en de promotor van 
mijn copromotor, plaats heeft willen nemen in mijn leescommissie.
Beste dr. A.M.C. van Rossum, beste Annemarie, ik heb erg veel bewondering voor de 
manier waarop jij werkt, je bent daarin voor mij echt een rolmodel. Ik ben je ontzettend 
dankbaar voor de opbouwende manier waarmee je naar onze papers keek en de gezellige 
tijd die we hebben gehad tijdens de ESPID congressen.
Beste prof.dr. E.C.M. van Gorp, beste Eric, heel erg bedankt voor al het vertrouwen dat jij 
altijd in mij hebt gehad. Na mijn coschap bij de Interne Geneeskunde van het Slotervaart 
ziekenhuis zijn wij elkaar niet meer uit het oog verloren en daarom is het nu zo mooi dat 
jij plaats hebt genomen in mijn leescommissie. Mijn dank voor alle mogelijkheden die jij 
mij hebt geboden is groot.
Ook de overige leden van de commissie wil ik heel erg bedanken, prof.dr. C.A.B. Boucher, 
prof.dr. H.A.W.M. Tiddens en prof.dr. D. Tibboel. Ik heb enorme waardering voor al jullie 
kennis over virussen, longziekten en Intensive Care geneeskunde en ik ben vereerd dat 
jullie in mijn grote commissie wilden plaatsnemen.
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Het was altijd een plezier om naar de Virusdiagnostiek afdeling te gaan, heel erg bedankt 
voor de altijd warme ontvangst (in het bijzonder van Darina en Soeranie) en de fijne 
samenwerking.
Stiekem heb ik eigenlijk ook een tweede copromotor gehad, dr. J.J.A. van Kampen, beste 
Jeroen. Wat was het fijn dat ook jij mij wilde begeleiden tijdens mijn promotie. Jouw 
oprechte vragen en kritische blik hielden mij scherp en waren zeer nuttig tijdens het 
afronden van de manuscripten, dankjewel hiervoor!
Beste Annemiek, onze gezellige tijd in Madeira schiep direct een band. Heel erg bedankt 
voor al jouw steun en wetenschappelijke- en levensadviezen, jouw enthousiasme voor 
de virologie is besmettelijk! Beste Martin, heel erg bedankt voor de nodige kritische 
noten toen het nodig was, de goede meetings en de gezellige borrels. Ik hoop dat we 
de lopende projecten met succes zullen afronden! Beste Suzan, heel erg bedankt voor 
het altijd klaar staan en regelen als ik plots iets moest uitzoeken of nodig had. Beste 
Georgina, bedankt voor het delen van al jouw kennis over virusdiagnostiek, jij bent voor 
mij een wandelende encyclopedie en ik ben blij dat jij mij daar iets van hebt willen leren. 
Beste Jean-Luc, heel erg bedankt voor het mij op weg helpen bij het begin van mijn 
promotieonderzoek, jouw adviezen waren zeer waardevol.
Beste Sandra en Janine, heel erg bedankt voor al jullie hulp met de ElISAs! Ik vond het 
erg leuk om met jullie samen te werken. Beste Hans, je staat al vermeld bij bijna elk 
artikel in het dankwoord, maar natuurlijk wil ik ook jou heel graag bedanken voor al je 
hulp bij het leveren en uitzoeken van de data.
Mijn lieve kamergenootjes, Rob, Patrick en Rachel en de nieuwe leden Chantal, Nathalie 
en Erwin, wat was het fijn om met jullie te werken en vergeet niet om elke dag even te 
genieten van het prachtig uitzicht op de Maas. Beste Rob, heel erg bedankt voor je steun 
en zeer nuttige adviezen. Vooral in het begin van mijn promotieonderzoek was het erg 
prettig om alles met jou te kunnen overleggen. Beste Patrick, wat was het fijn om vier 
jaar lang lief en leed met jou te delen, heel erg bedankt voor je luisterend oor, motivatie 
en zeer nuttige tips!
Dan natuurlijk mijn lieve collega’s van de vaccinatiepoli en de flu-plan studie: Marco, 
Lennert, cox, esther, Joost en Simone. Wat een geweldig team waren wij, niet alleen 
voor de poli, maar zeker ook tijdens de flu-plan studie. Ik heb echt met heel veel plezier 
met jullie samengewerkt! De opvolgers Wesley en Laura wil ik ook graag van harte 
bedanken voor jullie nieuwe energie, interesse en vooral gezelligheid!
Lieve Marco, wie had gedacht dat toen wij samen coschappen liepen wij uiteindelijk 
allebei bij het Erasmus MC zouden promoveren? Jouw enthousiasme voor het onderzoek 
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is aanstekelijk en jouw onuitputtelijke energie om leuke dingen te doen is geweldig! 
Vooral de Viro-borrels waren altijd enorm geslaagd dankzij jou. Ik ben benieuwd naar 
de teaser over mij in jouw proefschrift! lieve Lennert, wat een topkerel ben jij! Jij stond 
altijd voor mij klaar en ik vond het geweldig om met jou samen te werken. Ik kijk uit naar 
jouw verdediging. Lieve cox, wat was het fijn om virolief en viroleed met elkaar te delen 
en om daarna nog harder te werken aan onze onderzoeken.
De Exotics, Byron, Penelope, Fasha, Jeroen, Stephanie en Petra wat een warm onthaal 
kreeg ik van jullie! Jullie maakten de borrels altijd tot een feest, bedankt voor al jullie 
steun en hulp met mijn promotie! 
Natuurlijk was dit proefschrift er nooit gekomen zonder de steun van de statistici! lieve 
David, heel erg bedankt dat jij mijn rots in de branding wilde zijn. Ik vond het heel fijn 
dat ik altijd alles met jou kon overleggen en dat jij mij de positieve energie en moed gaf 
om het nog beter te doen! Dear Brooke, you are a true inspiration for me in the way you 
perform your research and in creating your perfect family! Thank you so much for all 
your support and fun at the Viro!
Graag wil ik dr. F.L. van Vliet, dr. J.L. Nouwen, alle hoogleraren en docenten ontzettend 
bedanken voor alle kennis die ik dankzij jullie heb op kunnen doen tijdens de research 
master Infection & Immunity! En natuurlijk mijn masterstudievrienden, in het bijzonder 
Jurre en Fane, jullie maakten de master tot een feest!
Beste Jurre, wie had gedacht dat toen wij elkaar voor het eerst ontmoetten tijdens de 
introductie van de master, jij vers uit Australië en ik uit Curaçao, dat jij mijn paranimf zou 
worden? Heel erg bedankt voor al jouw hulp bij het maken en bewerken van figuren die 
natuurlijk niet konden ontbreken in dit proefschrift! Ik ben ontzettend blij dat ik jou heb 
leren kennen en ik vond het altijd super om met jou mijn onderzoek te bespreken, maar 
vooral ook om veel lol met je te hebben! Je bent een geboren onderzoeker en ik kijk uit 
naar jouw proefschrift!
Ook wil ik graag echt alle collega’s van de toch wel meest geweldige onderzoeksafdeling 
van Nederland/de wereld bedanken voor alle gezelligheid en hulp wanneer dit nodig 
was! Ik vond het fantastisch hoe iedereen mij altijd wilde helpen en mij wilde voorzien 
van de broodnodige adviezen door zowel de hoogleraren, werkgroep leiders, postdocs, 
mede PhD-ers, analisten, secretaresses, etc., echt gewoon iedereen. Ik wil in het 
bijzonder nog de Sinterkerst-commissies bedanken voor de altijd weer spectaculaire 
Sinterkerst feesten! Ik keek altijd reikhalzend uit naar het thema om vervolgens weer 
helemaal los te kunnen gaan met de meest vreemde verkleedcreaties, die dan weer 
door jullie werden bekroond als ‘Best Dressed’. Dankzij jullie allemaal was mijn tijd bij 
de Viro onvergetelijk!
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Mijn dank is groot naar mijn coauteurs, naast de reeds bovengenoemde wil ik in het 
bijzonder ook graag prof.dr. M.P.G. Koopmans en prof.dr. M. de Hoog bedanken voor 
jullie expertise, zeer nuttige correcties en aanvullingen.
Natuurlijk wil ik ook graag het altijd even behulpzame en gezellige secretariaat met 
verspreid over het Erasmus MC Simone, Loubna, Maria, Anouk, Carola en Darina heel 
erg bedanken voor het altijd willen regelen van vliegtickets, hotels, vergaderruimtes, 
handtekeningen, etc. Jullie maakten het wachten op Ab of Pieter altijd erg gezellig voor 
mij!
Beste Rob van Herwijnen, heel erg bedankt dat ik mee mocht draaien op jouw 
laboratorium. Ik ben blij dat je al jouw kennis over ELISAs met mij hebt willen delen. Dat 
brengt me ook bij dr. A. de Mol, beste Amerik, heel erg bedankt dat jij mee wilde werken 
aan het speeksel-onderzoek en dat ik mee mocht lopen met jouw poli’s. Ik heb er erg 
veel van geleerd!
Dear REVIEW-study collaborators from abroad, dr. T. Heikkinen, dr. F. Martinon-Torres 
and drs. A. Justicia-Grande, it was a pleasure working with you and I am looking forward 
to the final results.
Het Curaçao-team, wat een geweldige tijd heb ik daar gehad. Beste Izzy, zoals jij mij 
onder je hoede nam toen ik op Curaçao kwam was geweldig, jouw continue drive om de 
gezondheidszorg op alle vlakken te bestuderen en te verbeteren is bewonderenswaardig.
Graag bedank ik ook de huisartsen, patiënten en het ADC die allemaal belangeloos wilden 
mee werken aan het onderzoek. Beste prof.dr. A. Duits, heel erg bedankt voor de kansen 
en mogelijkheden die jij mij hebt geboden op Curaçao. Ik vond het ontzettend leuk en 
leerzaam om te werken op de Bloedbank en ik wil al mijn collega’s van toen hartelijk 
bedanken. Beste dr. F. Muskiet, wat was ik blij dat ik u leerde kennen op Curaçao. Ik 
vond onze meetings buitengewoon interessant en ik heb ontzettend veel van u geleerd, 
heel erg bedankt hiervoor. Lieve Gonneke, wat heb ik een geweldige tijd met jou gehad! 
Bedankt voor het delen van al jouw onderzoekers kennis en het tweede thuis dat jij 
voor mij was. Beste Maarten Limper, dankjewel voor het begeleiden van mij tijdens 
mijn eerste stappen als arts-onderzoeker. lieve Imke, wat was ik blij dat jij naar Curaçao 
kwam, jouw positieve energie en drive zijn een voorbeeld voor mij! lieve Lizzy, ik vond 
het heel leuk om jou als student te mogen begeleiden, ik had mij geen betere student 
kunnen wensen, dankjewel! lieve Nicky, wat was het ontzettend gezellig met jou op het 
werk en daarbuiten!
Mijn treinmaatje, lieve Janneke, wat was het toch altijd leuk om samen met jou te 
reizen, naast heel veel gezellig kletsen kon ik ook altijd met vragen over mijn onderzoek 
uitstekend bij jou terecht!
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Mijn ESPID maatje, lieve Lilly, wat ben ik blij dat wij elkaar hebben leren kennen tijdens 
de ESPID. Door jou was het allemaal nog leuker en jouw carrière is voor mij zeker een 
voorbeeld!
Mijn hartsvriendinnen, Hannah, Marianne, eeke, Karlijn, Jennilee, Sepideh en Sarah 
beter bekend als de ‘Medicinas’, bedankt voor jullie onvoorwaardelijke steun en 
gezelligheid! Wat hebben we na de start van onze studie al veel met elkaar meegemaakt. 
Ik vind jullie allemaal powerladies en ik ben heel trots dat jullie mijn vriendinnen zijn! 
Wie had gedacht bij onze eerste ontmoeting op de snijzaal dat we huisgenootjes, 
ceremoniemeesters en elkaars paranimfen zouden zijn? lieve Hannah, ik heb het al vaak 
tegen je gezegd, maar zonder jouw steun, adviezen en jouw uitstekende voorbeeld was 
dit proefschrift er nooit geweest. Ik vind het geweldig dat jij nu ook mijn paranimf zult 
zijn en ik waardeer het echt enorm hoe zeer jij mij altijd echt met alles helpt! lieve 
Marianne, wat was ik blij dat jij ook gezellig naar Rotterdam kwam! We hebben samen 
heel wat uurtjes in de fyra gezeten waarbij we dan heerlijk konden kletsen, maar ook 
onze onderzoeken met elkaar konden bespreken. Met jouw gigantische motivatie, 
energie en enthousiasme ben ik ervan overtuigd dat je een geweldig proefschrift zult 
gaan afleveren en binnenkort al een prachtig huwelijk zult gaan hebben!
Lieve Hester en Manouk, ook jullie wil ik bedanken voor de geweldige vriendschap die 
we al zolang hebben en jullie steun voor het afmaken van dit proefschrift.
Lieve Ruben en Raphaëla, wat ben ik blij dat wij elkaar ook al zo lang kennen, bedankt 
voor jullie support van deze ‘eeuwige’ student!
Lieve Jacqueline, heel erg bedankt voor het nog leuker maken van Rotterdam!
Met zo’n sterke thuisbasis kon ik de studie Geneeskunde, een tweede master en mijn 
promotie zeker aan. lieve Pap en Mam, heel erg bedankt voor de vrijheid die jullie 
mij hebben gegeven om te worden wie ik nu ben en jullie onvoorwaardelijke liefde en 
interesse in alles wat ik doe. Ook wil ik mijn lieve zus Sanna, broer Tijmen, zwager nick 
en schoonzusje Marijn heel erg bedanken voor alle hulp, steun en positieve energie. Dit 
geldt natuurlijk ook voor de rest van mijn familie, heel erg bedankt!
Als laatste wil ik natuurlijk jou bedanken, lieve Matthijs, mijn avontuur bij de Viro heeft 
niet alleen dit proefschrift opgeleverd, maar vooral ook mijn leven met jou! Dankzij het 
dengue-onderzoek zijn wij elkaar tegen gekomen op Curaçao en was het meteen raak. 
Een tandarts en dokter gaan perfect samen! Ik vond het geweldig om met jou, tussen 
onze onderzoeken door, van het prachtige eiland te genieten. Al waren we maar wat blij 
dat ik werd toegelaten tot de research master en weer terugkwam naar Amsterdam, 
hoewel de afstand naar Groningen soms net zover voelde als naar Curaçao. Gelukkig 
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wonen we nu al meer dan 3 jaar samen in het heerlijke Amsterdam en geniet ik van elke 
dag die we samen zijn. Door jou heb ik er ook nog eens een geweldige schoonfamilie 
bij gekregen, lieve Sander, José, Maarten en JP, heel erg bedankt voor het warme nest 
waarin ik ben gekomen en al jullie steun tijdens mijn promotieonderzoek.
Lieve Matthijs, ik kijk ontzettend uit naar de hopelijk eveneens geweldige toekomst die 
we met elkaar gaan delen. Jouw kopjes thee in de ochtend hielpen mij door de laatste 
stukken van mijn promotie heen en jouw onvoorwaardelijke steun en vertrouwen 
zorgden ervoor dat dit proefschrift nu dan echt klaar is.
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